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3PART I
4Objectives and outline of the thesis
Prologue
Mitochondriocytopathies, defined as structurally or numerically abnormal mitochondria, are 
genetically and biochemically a complex group of diseases with a very wide range of clinical 
phenotypes. Frequently, they are due to defects in the oxidative phosphorylation (OXPHOS) 
system. This system consists of four multi-subunit enzyme complexes (I-IV) of the 
mitochondrial respiratory chain (RC) and complex V. The RC, located in the inner 
mitochondrial membrane, transfers electrons from NADH and FADH2 to the final electron 
acceptor, oxygen. Simultaneously with this electron transfer, protons are translocated from 
the mitochondrial matrix, across the inner mitochondrial membrane, to the intermembrane 
space. Subsequently, protons are returned to the mitochondrial matrix by complex V, resulting 
in the generation of adenosine triphosphate (ATP), the main carrier of free energy. The 
estimated incidence of mitochondriocytopathies is 1:10,000 living births. There is an 
enormously wide variety of documented symptoms in OXPHOS deficiencies [9]. Age at onset 
ranges from neonatal to adult life. The severity of the disease in this group of disorders varies 
from fatal neonatal multi-system disorder to mild myopathy. The pediatric population usually 
presents with non-specific clinical symptoms common to many other pediatric disorders. 
Neurological presentations, frequently seen in children, often become manifest with 
psychomotor delay. The wide range of presenting symptoms in mitochondrial disorders means 
that the clinician needs useful clues from other investigations (e.g. laboratory) to suspect a 
mitochondriocytopathy. If the suspicion is strong enough, morphological and biochemical 
investigations in skeletal muscle have to be performed. To obtain enough material for the 
extensive investigations which are necessary to assess the diagnosis, pediatric patients 
undergo a surgical muscle biopsy. This is an invasive procedure, and the clinician needs a 
reliable screening procedure to select those patients who indeed should undergo a muscle 
biopsy. If the selection criteria are too narrow patients remain undiagnosed. If they are too 
wide, unnecessary muscle biopsies are performed.
Biochemical investigations in muscle tissue are done stepwise. First, mitochondrial substrates 
oxidation rates and ATP plus creatine phosphate production rate are measured, resulting in 11 
different parameters. If these investigations point to a defect, enzymatic studies are performed.
5Single and combined deficiencies of the different OXPHOS complexes are found. In some 
cases, the localization of the defect is not (yet) possible.
Genetically, the components of the OXPHOS system (except complex II) are encoded by the 
nuclear and mitochondrial genome. Human mitochondrial DNA (mtDNA) is maternally 
transmitted and encodes 13 structural subunits of the complexes I, III, IV and V [1]. The 
knowledge of human nuclear genes encoding RC complexes has exponentially increased 
during the last years and the first nuclear mutations causing RC defects have been elucidated 
[2-8,10]. Due to the different characteristics of inheritance of nuclear and mitochondrial DNA, 
genotype-phenotype differences in these genetically different groups of defects could be 
expected. Establishment of these differences is relevant for parental counseling and molecular 
genetic studies.
Objectives
1) To assess selection criteria to perform a muscle biopsy in children, suspected to be 
suffering from a mitochondriocytopathy on clinical grounds.
2) To develop a method to summarize biochemistry parameters of a muscle biopsy in order to 
facilitate and standardize the interpretation of mainly difficult cases.
3) To study clinical differences in patients with OXPHOS defects due to nuclear versus 
mitochondrial DNA mutations.
4) To illustrate several clinical aspects of mitochondriocytopathies with case histories.
6Outline of the thesis
Part I
Chapter 1, the general introduction, gives a general survey on mitochondrial disorders.
Part II
Chapter 2, is dedicated to assess the best selection criteria to perform a muscle biopsy in 
patients suspected of a mitochondriocytopathy.
A prospective study of 45 patients suspected of mitochondriocytopathy who underwent a 
standard screening protocol was conducted. Five parameters with evidence of a statistical 
relationship with the result in muscle, normal or deficient, could be selected: age < 4 years, 
elevated fasting lactate to pyruvate ratio, an elevated thrombocyte count, elevated lactate in 
blood (fasting or after oral glucose loading) or CSF or urine, and elevated alanine in blood or 
CSF or urine. Each parameter was scored 0 (not present) or 1 (present). A prognostic index 
was then constructed with these parameters, so that, the chance of a normal or abnormal 
biopsy by a given value of this index could be calculated. This prognostic index is a valuable 
instrument for the clinician in deciding whether or not to perform a muscle biopsy.
Chapter 3, presents a method to summarize the results of biochemical investigations in 
muscle. These investigations are done stepwise. First, mitochondrial substrates oxidation rates 
and ATP plus creatine phosphate production rate are measured, resulting in 11 different 
parameters. If these investigations point to a defect, enzymatic studies are performed. In some 
cases it is difficult to conclude from these 11 parameters whether the patient has a disturbed 
mitochondrial energy metabolism or not, because the different parameters do not unanimously 
point to normal or deficient. This chapter describes a statistical method to summarize these 11 
parameters in a score. This score discriminates between patients with normal or defective 
mitochondrial energy metabolism. It facilitates and standardizes the interpretation of mainly 
difficult cases.
Chapter 4, focuses on the clinical differences in patients with a mitochondriocytopathy due 
to nuclear versus mitochondrial DNA mutations. The different enzyme complexes of the 
oxidative phosphorylation (OXPHOS) system, with the exception of complex II, are
7genetically encoded by the nuclear and the mitochondrial genomes with a different mode of 
inheritance. We hypothesized that there might be clinical differences in patients with 
OXPHOS defects due to nuclear versus mtDNA mutations. To test this hypothesis a study was 
conducted in 16 families with 2 or more siblings affected of a mitochondrial disorder with an 
established genetic mutation in nuclear or mitochondrial DNA, 4 families from our center and 
12 families from the literature. The study was performed in families with at least two affected 
offspring to be able to assess the intrafamilial variability in both groups.
PART III
Chapter 5 describes a new phenotype in mitochondrial disorders and adds to the ever 
increasing list of presenting signs and symptoms in this group of disorders.
Chapter 6 illustrates how proton MR spectroscopy of the brain can be used as non-invasive 
diagnostic tool in patients affected of a mitochondrial disorder to investigate whether 
metabolites such as alanine and lactate in brain tissue are elevated, and so contribute to the 
decision whether to perform a muscle biopsy or not.
Chapter 7 reports on a child with a severe deficiency of complex III and less severe 
deficiencies of complex I, II and IV of the respiratory chain with a favourable clinical course 
despite the persistence of severe biochemical abnormalities in skeletal muscle. This report 
reveals another puzzling feature of mitochondrial disorders: the discrepancy between clinical 
and biochemical findings.
Chapter 8 reports on 2 siblings with a complex I deficiency with identical clinical picture, 
who later were found to have a mutation in one of the nuclear encoded subunits of complex I.
PART IV
Chapter 9 General discussion and future perspectives 
Chapter 10 Summary
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Chapter 1 
General Introduction
Mitochondriocytopathies in pediatric patients
M.E. Rubio-Gozalbo, J.A.M. Smeitink, R.C.A. Sengers
In Mitochondrial Ubiquinone (Coenzyme Q10): Biochemical, Functional, Medical, and 
Therapeutic aspects in human health and diseases (Ebadi M., Marwah J.,Chopra R.K. eds) 
Prominent Press, Scottsdale in press
Abstract
Mitochondriocytopathies are frequently due to defects in the oxidative phosphorylation 
system. Although no single manifestation is specific, several circumscript syndromes due to 
mitochondrial DNA (mtDNA) mutations are recognized. Pediatric patients rarely fit into one 
of these syndromes and mtDNA mutations are rarely found. There are, however, some clinical 
entities which are frequently encountered in pediatric patients with a mitochondrial cytopathy: 
fatal infantile lactic acidosis, Leigh syndrome, unspecified encephalopathy, cardiomyopathy, 
and myopathy. Because the clinical presentation and physical examination is common to 
many other pediatric diseases, the clinician needs useful clues from other investigations (e.g. 
laboratory) to suspect a mitochondrial disorder. Detection of a high concentration of lactate in 
body fluids, especially if associated with increased pyruvate and alanine concentrations, 
usually leads the clinician in the correct diagnostic direction. When a mitochondrial cytopathy 
is suspected, histopathological, biochemical and genetic investigations in tissue are necessary 
to obtain the diagnosis. Skeletal muscle is the preferred tissue because it expresses the defect 
in the majority of patients. While there is no curative therapy for this group of disorders, 
various therapeutic interventions have been tried and found beneficial in selected cases.
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1. Introduction
Mitochondria were first described in 1897 [3] as cytoplasmic organelles (Greek: mito-, thread; 
chondrion, granule). They consist of an inner and an outer membrane, with the inner 
membrane highly folded (cristae), surrounding a matrix. Two spaces can therefore be 
distinguished inside the mitochondrion: the intermembrane space and the matrix. This 
compartmentalization is of importance for the different enzymatic functions. Outside the 
mitochondrion, glucose is converted into pyruvate via glycolysis. Under anaerobic conditions, 
pyruvate is converted into lactate by the enzyme lactate dehydrogenase. Under aerobic 
conditions pyruvate is transported into the mitochondrion, after which it is converted into 
acetyl-CoA by the enzyme complex pyruvate dehydrogenase. Acetyl-CoA is also the product 
of fatty acid P-oxidation. Acetyl-coA can enter the citric acid cycle where electrons 
accumulated into carbon compounds are transferred to the electron carriers nicotinamide 
adenine dinucleotide (NAD+) and FAD (flavin adenine dinucleotide). The reduced 
coenzymes, NADH and FADH2, are the substrates for the subsequent process of oxidative 
phosphorylation by the respiratory chain (complexes I-IV) and complex V. The electrons are 
funneled into the respiratory chain at the level of complex I in case of NADH or complex II in 
case of FADH2. The transfer of two electrons from NADH to the lipid-soluble redox-carrier 
coenzyme Q is mediated by complex I. Complex III mediates the subsequent transfer of the 
electron pair from reduced coenzyme Q to the electron carrier cytochrome c. In the final step, 
cytochrome c is re-oxidized by complex IV, reducing molecular oxygen to water. The energy 
released during these electron transfer reactions is conserved in the form of an electrochemical 
proton gradient by means of a vectorial transport of protons across the mitochondrial inner 
membrane. Due to this proton transport, a trans-membrane potential is built up, which is used 
by complex V for the synthesis of the high-energy compound ATP from ADP plus inorganic 
phosphate (Figure 1).
Pyruvate conversion to acetyl-CoA and the enzymatic reactions of the citric acid cycle take 
place in the matrix, while oxidative phosphorylation is membrane bound.
Several other pathways also (partly) take place in the mitochondria such as the urea cycle, 
biosynthesis of heme, cardiolipin and lipid metabolism, and biosynthesis of ubiquinol 
(coenzyme Q).
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Figure 1. The respiratory chain. I -  IV represent complex I -  IV, U = ubiquinone, C = 
cytochrome c, e= electron.
Mitochondria have their own DNA and are believed to have originated from a symbiotic 
relationship between a protoeukaryotic cell and a primitive prokaryote capable of oxidative 
phosphorylation, the endosymbiont hypothesis [16]. The distinction between the two cells in 
the simplest view is that the protoeukaryote already had its DNA compartmentalized in a 
nucleus with a nuclear membrane, while the protomitochondrion resembled a bacterium 
without a nucleus. The initial association between these two cells must have led to a 
considerable amount of redundancy of genetic information. The redundant genes in the 
mitochondrion could simply be lost, others were transferred to the nucleus, and only a very 
small number remained in the mitochondrion. However, recent studies of unicellular 
eukaryotes indicate that the mitochondrion arose in a common ancestor of all extant 
eukaryotes and raise the possibility that this organelle originated at essentially the same time 
as the nuclear component of the eukaryotic cell rather than in a separate, subsequent event 
[17]. The human mitochondrial DNA (mtDNA), maternally transmitted, encodes 13 subunits 
of the respiratory chain enzyme complexes I, III, IV, and complex V [1]. In addition to 
structural genes, mtDNA also codes for 22 transfer RNAs and two ribosomal RNAs.
This makes the oxidative phosphorylation (OXPHOS) system, which includes the respiratory 
chain (complexes I-IV) and complex V, unique as the different components are encoded by 
nuclear DNA (Mendelian inheritance) and mtDNA (maternal inheritance) with the exception 
of complex II which is entirely nuclear encoded.
Mitochondriocytopathies are a group of disorders caused by defects of mitochondrial energy
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metabolism. The term mitochondrial cytopathy is usually applied to diseases caused by 
disturbances in the OXPHOS system. In this chapter we also include disturbances in the 
pyruvate dehydrogenase complex (PDHC), citric acid cycle, and transporters (voltage 
dependent anion channel -VDAC- and adenine nucleotide translocator -ANT-), clinically 
indistinguishable from OXPHOS defects, for a complete overview.
Clinically, mitochondriocytopathies are a heterogeneous group of disorders that can affect 
multiple systems, in a mono- or multi-system pattern. Central nervous system (CNS), skeletal 
muscle and heart muscle are often involved. Moreover, the same biochemical defect may 
cause diverse clinical phenotypes and, conversely, symptoms may be similar in patients with 
different biochemical defects. Patients may become symptomatic at any age and show variable 
symptoms and outcome. Genetically, mitochondriocytopathies can be due to mutations of 
either nuclear or mitochondrial genome which will be transmitted by Mendelian or maternal 
inheritance, respectively. The mutations can also be sporadic.
Despite this heterogeneity, several circumscript clinical presentations which are associated 
with mtDNA mutations, such as Leber's hereditary optic neuropathy (LHON) can be 
recognized. LHON, presenting as acute or subacute central vision blindness in young adults, 
was the first disease in which a mtDNA mutation was documented [28]. Other clinical 
syndromes associated with mtDNA mutations are e.g. MELAS (Mitochondrial myopathy, 
Encephalopathy, Lactic Acidosis and Stroke-like episodes), MERRF (Myoclonic Epilepsy 
and Ragged-Red Fibers), Pearson's syndrome (refractory sideroblastic anemia and exocrine 
pancreas dysfunction) and Kearns-Sayre syndrome (progressive external ophthalmoplegia plus 
retinitis pigmentosa and/or heart block, cerebellar syndrome and high CSF protein content). In 
most pediatric patients suffering from a mitochondriocytopathy, the clinical picture does not 
fit into one of these distinct presentations and no mutation in the mtDNA is found [41].
Clinical recognition of pediatric patients with a mitochondriocytopathy is rarely possible and 
clues from additional investigations (e.g. laboratory) are needed. There are, however, several 
signs and symptoms in children which can be due to a mitochondriocytopathy and urge the 
clinician to perform metabolic screening.
2. Clinical findings
Virtually all organ systems are dependent on mitochondrial energy supply and a disorder of 
OXPHOS, PDHC, citric acid cycle, or transporters can theoretically cause any sign or 
symptom. Table 1 lists the spectrum of clinical symptoms associated with
15
mitochondriocytopathies.
Mono- and multi-systemic involvement occurs in these patients. Younger children very often 
have a multi-systemic presentation. CNS, skeletal muscle and heart muscle are frequently 
involved. Cardiac involvement can dominate the clinical picture but it is more often part of a 
multisystem disorder in which cardiac involvement is a major component.
2.1 Age-related presenting symptoms
As a guide for clinicians, several age categories with age-related presenting symptoms can be 
distinguished (Table 2). There is a continuous spectrum of symptoms and the age categories 
thus show a big overlap. This table is meant only as a practical guide. The clinicians using it 
need to keep this in mind.
2.2 Clinical entities
There are several clinical phenotypes which are more frequently observed in pediatric 
patients: 1- fatal infantile lactic acidosis, 2- Leigh disease, 3- unspecified 
encephalo(myo)pathy, 4- cardiomyopathy, and 5- myopathy.
1- Fatal infantile lactic acidosis
These children usually present shortly after birth with tachypnea, hypotonia and occasionally 
seizures. They rapidly deteriorate and die of cardiorespiratory arrest due to uncontrollable 
lactic acidosis. Exceptionally, a benign course has also been reported [11,32,43,45]. These 
reports describe a severe neonatal or immediate postnatal onset, caused by a complex IV 
deficiency, followed by spontaneous improvement with increasing activity of complex IV. It 
is speculated that switching from a fetal to an adult isoform of complex IV in infancy is the 
basis for improvement. The existence of these benign forms makes it very difficult for 
clinicians to decide how long supportive treatment should be continued in these patients. 
Because of the non-specificity of the presenting symptoms, which are common to other 
neonatal problems, the recognition of this entity may be difficult.
2- Leigh disease (subacute necrotizing encephalomyelopathy)
This neurological entity was first described by Leigh in 1951 [22]. The age of onset is 
variable, but is most often within the first years of life. The first symptoms are aspecific and 
consist of feeding problems (dysphagia, anorexia, vomiting), respiratory difficulties (irregular
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respiration, hyperventilation, apnea and frequent sighing), motor disturbances, eye symptoms 
(blindness, optic atrophy, strabismus, nystagmus, ophthalmoplegia) and cerebellar and 
extrapyramidal signs. The course of the disease can be chronic with gradual deterioration or 
characterized by exacerbations often triggered by infections with suboptimal recovery. Death, 
often due to respiratory insufficiency, usually follows within a few years after onset of 
symptoms.
Despite the fact that the clinical course is very variable, the neuropathological findings are 
characteristic. Post-mortem brain studies in these patients reveal diencephalic and 
mesencephalic spongiform lesions with degeneration, demyelinisation, capillary proliferation, 
endothelial swelling and relative sparing of neurons, which partly occur bilaterally and 
symmetrically in the periaqueductal region and tegmentum. Definitive diagnosis depends on 
this distinctive neuropathology, although modern imaging techniques can give strong 
diagnostic support.
3- Unspecified encephalo(myo)pathy
This is a patient group with CNS involvement and in some cases skeletal muscle involvement 
that cannot be classified into one of the more specific encephalopathies such as Leigh 
syndrome, Alpers’ disease (progressive infantile poliodystrophy) and MELAS, among others. 
Age of onset varies from several days after birth to late infancy. Psychomotor retardation or 
regression, hypotonia, hypertonia, blindness, sensorineural deafness, and seizures are 
frequently seen. Several of these patients also have cardiac and/or skeletal muscle 
involvement. Diagnosis is often delayed because of the non-specificity of symptoms.
4- Cardiomyopathy
Both dilated and hypertrophic cardiomyopathy are well-known manifestations of 
mitochondriocytopathies [24]. Age at onset ranges from neonatal to older childhood. Severity 
of cardiac involvement varies from end-stage dilated cardiomyopathy to asymptomatic 
hypertrophic cardiomyopathy. The heart may be the only organ involved dominating the 
clinical picture or be part of a multi-organ involvement.
5- Myopathy
These patients have pure skeletal muscle involvement. They usually become symptomatic in 
childhood with exercise intolerance, easy fatigability and/or myalgia. This pure myopathic
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form is usually seen in older children (> 4 years) with a stationary or slowly progressive 
clinical course. In our experience, this pure myopathic form is rare and often there is 
asymptomatic involvement of other organs.
2.3 Clinical course
The clinical course also varies enormously. Three main categories can be distinguished: 1- 
rapidly progressive with fatal outcome, 2-slowly progressive and 3-benign. Usually, the 
younger the age at presentation, the more rapid and severe the clinical course.
Neonates can rapidly worsen and die days or weeks after birth of cardiorespiratory arrest. 
Exceptionally, they may improve and survive the neonatal period, becoming asymptomatic or 
showing any of the signs and symptoms constellation described above.
Well-known in mitochondriocytopathies are the neurological deteriorations triggered by an 
infection with suboptimal recovery (often seen in the Leigh phenotype).
2.4 Prognosis
Obviously, this is a difficult question for the clinician to answer for the individual patient 
affected by a mitochondriocytopathy. The child may show severe deterioration and early 
death, or exceptionally completely recover. Between these two extremes, there is a continuous 
spectrum of intermediate forms.
Neonatal or early infantile manifestations usually predict a severe clinical course. Our group 
described a benign complex I encephalopathy [40], but without data regarding enzyme activity 
after clinical improvement. We also described a favourable clinical course in an infant with 
neonatal presentation and severe deficiency of complex III combined with less severe 
deficiencies of complexes I, II and IV despite persistent biochemical abnormalities (chapter
7).
Table 1. Clinical symptoms associated with mitochondriocytopathies
Brain
Skeletal muscle 
Heart
Eyes
Liver 
Kidney 
Endocrine 
Gastrointestinal 
Other
Seizures
Hypotonia / hypertonia 
Spasticity
Transient paraparesis 
Lethargy / Coma
Psychomotor retardation / regression 
Extrapyramidal signs 
Ataxia (episodic)
Dyspraxia
Central hypoventilation
Deceleration / acceleration of head growth
Blindness (cortical)
Deafness (perceptive)
Exercise intolerance / easy fatigability 
Muscle weakness
Cardiomyopathy (hyperthrophic or dilated) 
Conduction abnormalities
Ptosis
Restricted eye movements
Strabismus
Cataract
Pigmentary retinopathy 
Optic atrophy
Hepatic failure
Tubular dysfunction
Diabetes insipidus 
Delayed puberty 
Hypothyroidism 
Hypoparathyroidism 
Diabetes mellitus 
Exocrine pancreas dysfunction 
Primary ovarian failure
Diarrhea (villous atrophy)
Intestinal pseudo-obstruction
Failure to thrive 
Short stature
Pancytopenia________________________
Table 2. Age-related presenting symptoms
neonates - 3 mo 3 mo-1 yr 1-4 yrs >4 yrs
Small for gestational age y n n n n
Dysmorphic features* y n n n n
Respiratory and / or cardiac symptoms
episodic apnea, tachypnea, dyspnea, y y y y y
episodic deep respiration, cyanosis y y y y y
heart conduction defects y y y y y
Neurological symptoms
weak suck, floppiness y n n n n
hypotonia y y y y y
hypertonia, spasticity n n y y y
lethargy, coma, convulsions y y y y y
psychomotor retardation/regression n n y y y
deceleration/acceleration of head growth n y y y y
extrapyramidal signs n n y y y
(episodic) ataxia n n y y y
transient paraparesis n n y y y
Myopathic symptoms**
post-exercise fatigue, exercise intolerance n n n n y
limb weakness n n n n y
Feeding difficulties, dysphagia y y y y y
Failure to thrive y y y y y
Short stature y y y y y
Eye symptoms
ptosis, strabismus, cataract, nystagmus y y y y y
visual inattention y y y y y
restricted eye movements n n n n y
Hearing symptoms
no response to sound y y y y y
* Frontal bossing, broad nasal bridge, upturned nose, micrognathia, low set and posteriorly rotated ears, 
short fingers, short arms, simian creases, thin upper lip and wide fontanel, are described in PDHC 
deficiency. **Myopathic symptoms are not usually seen before age 4 years; y = yes, n = no
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3. Laboratory investigations
The clinician facing a child with any of the signs and symptoms mentioned above should 
consider a mitochondriocytopathy and consequently perform metabolic investigations. A 
disturbance in the PDHC, citric acid cycle or OXPHOS results in accumulation of pyruvate. 
The accumulated pyruvate is mostly converted to lactate by the cytosolic lactate 
dehydrogenase, or transaminated to alanine. In the case of a PDHC deficiency the lactate to 
pyruvate ratio is theoretically normal whereas it is often elevated in OXPHOS defects. The 
elevated lactate to pyruvate ratio in OXPHOS defects is the consequence of an increased 
NADH/NAD+ ratio, resulting in a shifting of the cytoplasmatic lactate/pyruvate equilibrium in 
favour of lactate.
Laboratory screening should include measurement of lactate and pyruvate in blood, amino- 
acids in blood and urine, lactate and amino-acids in CSF (if neurological manifestations are 
present), and urine organic acids. Lactate, pyruvate and alanine concentrations vary depending 
on the feeding state of the individual. An increased concentration of these metabolites might 
only be present after feeding. The urine portion for aminoacid and organic acid analysis is 
preferably collected in the fed state.
If no lactate increase is found in body fluids, a loading test with glucose can be carried out to 
increase the pressure on the biochemical pathway. Our greatest experience is with an oral 
glucose loading test (2 g/kg). Glucose and lactate are determined at baseline and 15, 30, 45, 
60, 90, 120, 180 and 240 minutes after glucose loading. Glucose and lactate concentrations 
reach their maximum values at 30 and 60 minutes respectively. At the moment, based on 
unpublished results, we consider this test abnormal if peak lactate concentrations are greater 
than 2 mM at two or more point determinations after glucose loading. Ruitenbeek et al. [30], 
considered the test pathological if the peak increase in blood lactate surpassed 1 mM or 
double the value of the baseline concentration.
Exercise tests with simultaneous measurement of lactate concentrations can also be helpful 
but cannot be used for very young children. For accurate lactate determination in blood, it is 
very important that stress factors are avoided. Resistance to venepuncture in children can 
result in a five-fold increase in the blood lactate level [21].
Aminoacid determination can reveal hyperalaninemia in blood and/or urine pointing to a lactic 
acidemia. Generalized amino aciduria, or even Fanconi syndrome [44,27] can be observed in 
mitochondriocytopathies. Renal tubular reabsorption is a highly energy-dependent process, 
consequently defects of mitochondrial energy metabolism can alter this process.
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Urinary organic acid determination can reveal lactic aciduria, increased excretion of citric acid 
cycle intermediates and/or ethylmalonic aciduria. The association of ethylmalonic aciduria 
with mitochondriocytopathies is based on practical experience, the mechanism underlying this 
phenomenon not yet being clear.
Despite the fact that increased lactate levels in body fluids are frequently seen in 
mitochondriocytopathies, normal lactate values do not exclude them [39]. 
Mitochondriocytopathies with normal lactate levels might be underestimated since increased 
lactate levels are an important determinant to refer patients to a metabolic disease center.
4. Additional investigations
4.1 Cardiac evaluation
Dilated and hypertrophic cardiomyopathy are frequently found in OXPHOS defects [24]. 
Conduction heart defects are also encountered, for instance in Kearns-Sayre syndrome [10]. 
Mitochondrial cardiomyopathy can be asymptomatic and routine cardiac screening of patients 
suspected of an OXPHOS defect is urged.
Chest X-ray and ECG can be used for routine screening. If an increased cardiothoracic ratio in 
the chest X-ray and/or ECG abnormalities such as heart conduction defects, or signs of 
ventricular hypertrophy/dilatation are found, an echocardiography should be performed for 
further assessment of the problem.
4.2 Imaging of the brain
Neuroradiological abnormalities in patients with CNS pathology, assessed by CT-scan or 
MRI, can also orient the clinician towards the correct diagnosis. Multiple symmetric lesions in 
the basal ganglia, mesencephalon and brainstem, as seen in Leigh disease [25], brain 
infarction, mostly in the occipital cortex, symmetric calcifications of deep structures, brain 
and cerebellar atrophy, and hypoplasia or absence of the corpus callosum are frequent in 
patients with neuromitochondrial disorders [46], but are also seen in other entities affecting 
the CNS.
Proton MR Spectroscopy (1H MRS) of the brain makes the in vivo monitoring of brain 
metabolites such as lactate possible and can be used in the diagnostic work-up of 
mitochondriocytopathies [15].
31Phosphorus MR Spectroscopy ( P MRS) permits in vivo investigation of energy metabolism
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by measurement of concentrations of phosphocreatine, inorganic phosphate and ATP in 
muscle [20] or in brain [12].
4.3 Electromyography
Evidence of myopathy in electromyography (EMG) studies is an important indicator of 
muscle involvement of any origin. In our experience, it can be a helpful investigation when 
the clinician doubts whether there is muscle involvement or not.
5. Diagnosis
When the clinical features and metabolic screening findings suggest a defect in the 
mitochondrial energy metabolism, morphological and biochemical investigations in tissue 
are necessary to obtain the correct diagnosis. Mitochondriocytopathies are tissue-specific, 
the defect possibly being present in only one or a restricted number of tissues, or affecting 
all tissues. Skeletal muscle is the preferred tissue because it expresses the defect in the 
majority of patients [13].
5.1 Morphological studies
Light microscopy, histochemical and enzyme-histochemical staining and ultrastructural 
studies are usually performed. Light microscopy often reveals non-specific findings. On 
histochemical staining lipid deposits may be seen. Enzyme-histochemical staining (succinate 
dehydrogenase, cytochrome oxidase (COX) staining) may yield abnormal staining patterns 
such as increased cytoplasmic basophilia and the presence of COX-negative fibers pointing to 
a complex IV deficiency.
Ultrastructural studies may reveal changes including increased number or size of 
mitochondria, disoriented or rarefied cristae, and paracrystalline inclusions.
The classical hallmark of mitochondriocytopathies in skeletal muscle is the finding of ragged 
red fibers (RRF), muscle fibers with abnormal subsarcolemmal clustering of mitochondria, or 
ultrastructural mitochondrial abnormalities. However, RRF and/or ultrastructural abnormal 
mitochondria are non-specific and can be seen in disorders of non-mitochondrial etiology such 
as myositis and muscular dystrophies, probably representing secondary changes. RRF also 
occur with increasing age. Conversely, these findings are rarely seen in neonatal or early 
infantile mitochondriocytopathies.
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5.2 Biochemical studies
5.2.1. Skeletal muscle
Biochemical investigations of skeletal muscle specimens at our center are performed 
according to a stepwise procedure. First, oxidation rates of mitochondrial substrates [5] and 
ATP plus creatine phosphate (CrP) production rate [29] are measured in the intact 
mitochondria of a fresh muscle specimen.
If these investigations yield normal results, no further enzymatic studies are performed. If the 
outcome of these investigations points to a defect in the mitochondrial energy metabolism, 
depending on the abnormalities established, the activities of PDHC [36], RC complexes [14] 
and complex V [9] are measured, and the content of VDAC and ANT are determined 
immunochemically [19], To cope with differences in mitochondrial distribution and recovery, 
the results are normalized by expressing them to citrate synthase activity, a mitochondrial 
matrix reference enzyme, except for complex V which is measured in isolated mitochondrial 
fraction and therefore is expressed to cytochrome c oxidase activity.
Single and combined deficiencies of the different functional complexes can be found. In our 
experience, in 40% of the skeletal muscle specimens, there is a disturbed mitochondrial 
energy metabolism without a localized defect.
5.2.2. Skin fibroblasts
Biochemical studies can also be performed in cultured skin fibroblasts. At our center we 
additionally measure the activity of the different enzyme complexes in cultured skin 
fibroblasts if the parents are intending to have more children. The enzyme assays performed 
on mitochondrial enriched fractions from cultured skin fibroblasts are done according to 
Bentlage et al. [4] with slight modifications.
5.2.3 Prenatal diagnosis
If the defect is expressed in cultured skin fibroblasts, enzyme studies in chorionic villi, or 
amniotic cells for prenatal diagnosis, can be performed at our center. However, the relatively 
limited experience in this field makes it difficult in many cases to give conclusive results. In 
the few cases where the mutation is known in the index patient, prenatal diagnosis at the 
molecular basis can be offered.
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5.3 Molecular biology studies
The majority of patients with a deficiency of PDHC activity have a mutation in the PDH-E1a 
gene, located on the X chromosome [8] and encoding for the E1a subunit. Consequently, 
patients with or suspected of PDHC deficiency can be tested for mutations in this gene.
Citric acid cycle enzyme deficiencies, although rare diseases (less than 25 cases reported in 
the literature) are clinically indistinguishable from defects in PDHC or the OXPHOS system 
[31]. Several mutations causing deficiency of fumarase have been reported [18,6].
Defects in the OXPHOS system (except complex II) can be due to nuclear or mtDNA 
mutations. In our experience, screening for common mtDNA mutations in pediatric patients is 
unsatisfactory (in less than 5% of the patients, common mtDNA mutations are encountered). 
Family data concerning pediatric patients with OXPHOS defects usually point to autosomal- 
recessive traits. The knowledge of human nuclear genes encoding RC enzyme complexes has 
increased exponentially during the last few years [2,26,34,35,38]. Along with this, the first 
nuclear mutations causing RC defects have been elucidated [7,23,33,38,39,42,47]. OXPHOS 
defects in children are probably due in the majority to mutations in the nuclear DNA.
6. Therapeutic strategies
No curative treatment is currently available for mitochondriocytopathies. Some treatment 
strategies have been reported to be beneficial, many reports being anecdotal. These include 
coenzyme Q10, and other quinone derivatives, vitamins and others.
Quinone derivatives can become reversibly reduced to hydroxyquinones, allowing electrons to 
bypass defective RC complexes, or act as pure electron acceptors.
Thiamine (vitamin B1) is a cofactor of PDHC, and its supplementation may therefore lower 
lactate and pyruvate levels in PDHC deficiency. Riboflavin (vitamin B2) acts as a precursor to 
flavin monophosphate and flavin adenine dinucleotide, cofactors for complex I and complex II 
respectively. Vitamin E has also been tried as a radical scavenger, to protect the mitochondria 
from secondary damage inflicted by free radicals.
Hopefully, gene therapy may offer help to future patients. Taivassalo et al. [37] have described 
an encouraging method to increase the ratio of wild-type to mutant mtDNAs in a patient with 
a mtDNA myopathy.
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Abstract
The aim of this study was to assess an optimal screening for pediatric patients suspected of a 
mitochondriocytopathy to justify a muscle biopsy. Forty-five patients were included. Medical 
history, physical examination, cardiac and ophthalmologic evaluation, biochemical 
investigations, in vivo function tests, neuroimaging and a skeletal muscle biopsy were 
performed. The results of the biochemical muscle studies were compared with the results of 
the other investigations. First, parameters with a statistical relationship with the result in 
muscle, normal or deficient, were selected. Secondly, a prognostic index was constructed 
using these parameters. Five parameters were selected: age<4 years, elevated fasting lactate to 
pyruvate ratio, elevated thrombocyte count, elevated lactate, and elevated alanine. Each 
parameter was scored 0 (not present) or 1 (present). The chance of a normal biopsy with a 
given value of this index (sum of the scores) was calculated: logit (Pr) = a  + P x index; a: -
0.8167 and P: 0.8331. (Pr: probability of normal biopsy). The chance of a normal biopsy with 
an index value of 5 is 0.03, 4 is 0.07, 3 is 0.16, 2 is 0.30, 1 is 0.50 and 0 is 0.69. This 
prognostic index is a valuable instrument in deciding whether the suspicion of 
mitochondriocytopathy is strong enough to merit a muscle biopsy.
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Introduction
Mitochondriocytopathies, can be defined as structurally or numerically abnormal 
mitochondria and/or abnormally functioning mitochondria [14]. Despite the fact that 
mitochondrial energy metabolism includes pyruvate oxidation as well as fatty acid oxidation, 
the term mitochondriocytopathy is applied mainly to defects of the oxidative phosphorylation 
system. These include deficiencies of the respiratory chain enzyme complexes (complex I-IV) 
and complex V. Among these, respiratory chain disorders are the most frequent. Genetically, 
the respiratory chain is unique, as it is encoded by nuclear and mitochondrial genomes, with 
the exception of complex II. Human mtDNA, maternally transmitted, encodes 13 subunits of 
the respiratory chain enzyme complexes I, III, IV, and complex V [1].
Mitochondriocytopathies are genetically and biochemically a complex group of diseases with 
a very wide range of clinical phenotypes [11,21]. Age at onset ranges from neonatal to adult 
life. The severity of the disease varies from fatal neonatal multi-system disorder to mild 
myopathy. The pediatric population usually presents with non-specific clinical symptoms 
common to many other paediatric disorders. Neurological presentations, frequently seen in 
children, often become manifest with psychomotor delay. Because the clinical presentation 
and physical examination are often not orientative, the clinician needs useful clues from other 
investigations (e.g. laboratory, neuroimaging) to suspect a mitochondrial disorder. Detection 
of a high concentration of lactate in body fluids, especially if associated with increased 
pyruvate and alanine concentrations, usually leads the clinician to the correct diagnostic 
consideration. High lactate concentration in CSF, in patients with neurological symptoms is 
believed to be the most reliable screening procedure [18,20]. However, an elevated lactate 
concentration in body fluids is not invariably present, not even after an oral glucose loading 
test (2 gram/kg) in otherwise biochemically proven or furthermore genetically elucidated 
mitochondrial disorders [17]. Neuroradiologi cal abnormalities in patients with CNS 
pathology, assessed by CT-scan or MRI, can also be useful. Multiple symmetric lesions in the 
basal ganglia, mesencephalon and brainstem, as seen in Leigh disease [9], brain infarction, 
mostly in the occipital cortex, symmetric calcifications of deep structures, brain and cerebellar 
atrophy, and hypoplasia or absence of the corpus callosum are frequent in patients with 
neuromitochondrial disorders [20], but also seen in other entities affecting the CNS.
When a mitochondriocytopathy is suspected, histopathological and biochemical investigations 
in tissue are necessary to obtain the correct diagnosis. Skeletal muscle is the preferred tissue 
because it expresses the defect in the majority of patients. A muscle biopsy is an invasive
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procedure; accordingly a reliable screening procedure is an absolute requirement to select the 
patients who should undergo a muscle biopsy. If the selection criteria are too narrow patients 
remain undiagnosed. If they are too wide, unnecessary muscle biopsies are performed.
We reviewed our series of patients to see which additional investigations prior to biopsy were 
indicative of a mitochondrial disorder and had resulted in a justified muscle biopsy. This 
review led us to the conclusion that it was not possible to get accurate results in a 
retrospective setting mainly because patients being referred from different centres having 
distinct screening protocols. Additionally blood and urine sample collection had been done 
randomly, under various feeding conditions in the different patients. Lactate, pyruvate and 
alanine concentrations vary depending on the feeding state of the individual. An increased 
concentration of these metabolites might only be present after feeding.
Therefore, we designed a prospective study with a standardized investigation protocol to 
assess an optimal screening procedure in pediatric patients in order to select those who should 
undergo a muscle biopsy.
Materials and Methods
Patients. All 45 patients, suspected of a mitochondriocytopathy referred to our centre for a 
muscle biopsy during the period Jan. 1997 to Dec. 1998 were included in the study after 
informed parental consent. Age at inclusion in the study ranged from 0 - 18 years with the 
exception of one patient who was 21.5 years. Medical history and physical examination was 
assessed by one investigator (patient characteristics are listed in Table 1). Thereafter each 
patient was submitted to a standard screening protocol (see Table 2) followed by a surgical 
muscle biopsy for histopathological and biochemical investigations.
Cardiac evaluation. Chest X-ray and ECG were performed following routine procedures and 
evaluated. If one or both of them showed abnormalities an echocardiogram was performed.
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Table 1. Patient characteristics and results of skeletal muscle biopsy
pat sex age
onset
Presenting symptoms clinical course biopsy
1 m neonatal FD, axial hypotonia, 
limb hypertonia
severe PR, FTT at 2 yr deficient
2 m 16 mo. generalized convulsions deterioration, died at 2.5 yr deficient
3 m first yr hypotonia fatigue, EI at 11 yr normal
4 m 17 yr fatigue, EI stationary at 18 yr deficient
5 f neonatal hypotonia moderate PM, EI at 2 yr deficient
6 m first mo. developmental delay severe PR at 9 yr deficient
7 m first mo. microcephaly, PR moderate PR, EI, HCM, WPW, 
hypokinetic at 18 yr
normal
8 m first mo. hypertonia severe PR, epilepsy, progressive 
spastic tetraplegia
deficient
9 m first mo. FD, hypotonia severe PR, epilepsy, stationary 
at 3 yr
deficient
10 f neonatal hypotonia fatigue, EI, stationary at 5 yr deficient
11 m neonatal FD, hypotonia PR, absences, at 1 yr deficient
12 m first mo. convulsions West syndrome, severe PR at 6 yr deficient
13 m 3 yr fatigue, EI stationary at 6 yr normal
14 f 2.5 yr walking difficulties, 
chorea arms
PR, spasticity left > right, ataxia, 
epilepsy, deterioration
deficient
15 m 14 yr severe headache, altered 
behaviour
generalized convulsions at 15 yr deficient
16 f 2 yr ataxia, delayed speech 
development
moderate PR, non-progressive 
ataxia at 3 yr
borderline
17 m first mo. hypotonia motor developmental delay, EI, 
stationary at 13 yr
normal
18 f 8 yr renal insufficiency peripheral neuropathy, HCM, 
stationary at 15 yr
normal
19 f 2 yr hypotonia, ataxia stationary at 10 yr normal
20 m 4 yr stiff walking pattern hypokinetic rigid syndrome, 
stationary at 16 yr
normal
21 f first mo. motor retardation, 
hypertonia
spastic tetraplegia, mentally 
normal at age 5 yr
deficient
22 m first mo. no development, axial 
hypotonia,
convulsions, no development 
at age ca. 3 yr
deficient
23 m neonatal dysmorphia, hypotonia ectopic (tongue base) thyroid, 
partial trisomy 17, severe PR
normal
24 m first mo. motor retardation cataract, HCM, motor retardation deficient
25 m first mo. FD, hypotonia HCM, progressive deterioration, 
died at 4 mo
deficient
26 m first mo. FTT, hypotonia FTT, motor retardation at 2.5 yr deficient
27 f first mo. PR developmental arrest after infection 
severe PR at 3 yr
normal
28 m neonatal generalized hypotonia, severe PR at 1.5 yr deficient
convulsions
37
Table 1. Patient characteristics and results of skeletal muscle biopsy (continued)
pat sex age
onset
presenting symptoms clinical course biopsy
29 m 2 year fatigue EI, stationary at 6 yr deficient
30 f neonatal dysmorphia, 
convulsions, hypotonia
FD, structural heart disease, 
epilepsy, severe PR at 1.5 yr
normal
31 f neonatal FD, thoracal scoliosis, 
hip dysplasia
progressive thoracal scoliosis, 
mentally normal at 1 yr
deficient
32 f first mo. PR mild PM, tremor, stationary at 15 yr normal
33 f first mo. PR mild PR, epilepsy, EI at 3 yr normal
34 f first mo. convulsions, hypertonia FTT, PR at 1 yr deficient
35 m first mo. hypotonia PR, deafness, fatigue, absences, 
at 7 yr
normal
36 f neonatal microcephaly, FD, 
hypotonia
severe PR, died at 15 mo. of age 
of infection
deficient
37 f neonatal FD, convulsions no development, hypotonia, 
hemiballistic movements arms at 4
deficient
38 m 14 yr. EI
mo
stationary at 16 yr deficient
39 m 2 year chorea, dyspraxia, 
dysarthria
stationary at 9 yr normal
40 m 14yr EI stationary at 16 yr normal
41 f first mo. developmental
stagnation
moderate PR, ataxia, no speech 
development at 3 yr
deficient
42 f first mo. cyanotic attacks epilepsy-like cyanotic attacks, 
stationary at 5 yr
normal
43 m first mo. PR, convulsions severe PR, myoclonic epilepsy at 4 yr deficient
44 f neonatal FD, hypotonia severe PR at 8 mo deficient
45 m neonatal respiratory distress HCM, uneventful otherwise at 3 mo deficient
Abbreviations: FD: feeding difficulties; PR: psychomotor retardation; FTT: failure 
to thrive; EI: exercise intolerance; HCM: hypertrophic cardiomyopathy, WPW: 
Wolff-Parkinson-White syndrome
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Ophthalmological examination. Eye lenses and fundi in all patients were examined by the 
ophthalmologist.
Laboratory investigations. Haemoglobin, leukocytes, thrombocytes, cell indices, ASAT, 
ALAT, y-GT, AF, LDH, urea, creatinine, CK, glucose, total and free carnitine in blood were 
measured following the routine procedures. Blood samples for the measurement of the 
concentrations of lactate, pyruvate and ketone bodies were collected in perchloric acid and 
analyzed following standard procedures. These measurements were performed after an 
overnight fasting period, preprandial and 1 hour postprandial.
If no lactate elevation was observed, an oral glucose tolerance test (2 gram glucose/kg) was 
performed. Glucose and lactate concentrations were measured at 0, 15, 30, 60, 90, 120, 180 
and 240 min. Pyruvate and ketone bodies concentrations were also measured at 0, 60 and 90 
min.
Blood samples for quantitative analysis of aminoacids were collected postprandially. CSF 
samples (in patients with neurological manifestations) were collected in the fasting state. 
Urine samples for quantitative analysis of aminoacids and organic acids were collected from
8.00 am to 2.00 p.m. The quantitative analysis of aminoacids in blood, urine and CSF and the 
quantitative analysis of organic acids in urine were done by ion-exchange and gas 
chromatography respectively, following standard procedures. Cells, glucose and protein in 
CSF were measured following routine procedures.
Imaging. CT-scan or MRI of the brain was performed following the routine procedures if the 
patients had neurological manifestations affecting the CNS.
Skeletal muscle investigations. Skeletal muscle specimens were obtained from the right 
vastus lateralis under general anesthesia. The oxidation rates of mitochondrial substrates [2], 
and ATP production rates [12] were immediately measured in the fresh skeletal muscle 
specimen. If the outcome of these investigations pointed to a defect, the enzyme activities of 
the PDHC, and the RC complexes and complex V and the content of ANT (adenine 
nucleotide translocator) and VDAC (voltage dependent anion channel) were measured, 
depending on the pattern of abnormalities (see Table 3). The enzyme activities were measured 
according to Sperl et al. [15] in frozen muscle homogenate (PDHC) and according to Fischer 
et al. [5] in 600g supernatant (RC enzymes). Complex V was measured in isolated
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mitochondria as previously described with minor modifications [3]. To cope with differences 
of mitochondrial distribution and recovery, the results were normalized by expressing them to 
citrate synthase activity, a mitochondrial matrix reference enzyme, except for complex V 
which was measured in isolated mitochondrial fraction and therefore was expressed to 
cytochrome c oxidase. The ANT and VDAC contents were determined immunochemically 
using specific antibodies as previously described [6]. The measured biochemical parameters in 
skeletal muscle specimens and their reference values (range, mean, SD), are listed in Table 3.
Statistics. Based on the results of biochemical investigations of muscle tissue, the patients 
were classified in 2 groups: group I (normal mitochondrial energy metabolism), group II 
(decreased mitochondrial energy metabolism). A deficiency of the mitochondrial energy 
metabolism was defined by 1) identified deficiency: substrate oxidation rates, ATP production 
rate and activity of one or more of the functional complexes below the lowest value of 
reference range, or 2) non-identified deficiency: substrate oxidation rates and ATP production 
rate below the lowest value of reference range and normal activity of the measured functional 
complexes. As there was a large number of variables measured prior to biopsy, compared with 
the number of patients, their statistical relationship (prognostic value) to the result of the 
biopsy (normal, deficient) was analyzed in 2 steps.
First step: selection of variables. The parameters measured prior to biopsy were grouped under 
6 different headings: clinical, blood parameters, in vivo function tests, CSF parameters, urine 
parameters and imaging parameters. For the CSF parameters and imaging, only the patients 
with neurological manifestations were considered.
Within each heading it was tested for each parameter whether there was some evidence of a 
statistical relationship with the result of the biopsy (normal or deficient). In order to account 
for the sex and age dependency of the clinical parameters (height, weight and head 
circumference) we transformed them to standard z-scores by means of age and sex related 
summary statistics (mean, sd) taken from the ‘Dutch Reference Population 1997’. The 
distributions of these z-scores and those of age were compared between the groups ‘normal’ 
and ‘deficient’ by means of the Wilcoxon 2-sample test. In order to account for the sex and 
age dependency as well as for the occurrence of extreme values the outcomes of the 
haematological and biochemical variables were transformed to dichotomous or trichotomous 
categories by use of their reference ranges used in our clinic. The resulting distributions were 
compared between both groups by means of the exact test for the 2x2 or 2x3 table. All the
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parameters for the headings in vivo function tests and neuroimaging had dichotomous 
outcomes and these were also compared between both groups by the exact test for the 2x2 
table. In the case of variables with hardly any variation in their outcomes or too many missing 
values, statistical testing was not done and these variables were omitted from the analysis. At 
the end of this first step all those parameters for which the statistical test had resulted in a p- 
value < 0.15 were selected for the second step.
Second step: prognostic index. In the second step we intended to construct a prognostic index 
from the selected parameters at the first step, and added the variables ‘lact4=lactate increased 
in at least 1 of the 3 body fluid samples (blood -fasting or after glucose loading test-, CSF, or 
urine) and ‘alan3=alanine increased in at least 1 of the 3 body fluids (blood, CSF, urine). To 
be helpful in selecting those patients who should undergo a muscle biopsy, such an index 
should reliably reflect to which group the patient probably belongs (normal or deficient). It 
was decided, for the ease of construction of a simple index, to dichotomize all selected 
variables. For trichotomous variables the 2 lower categories (below or within reference range) 
were combined to 1 category (below upper limit of reference range). Age was dichotomized as
0 = 4 years or older and 1 = 0-4 years. The value for a prognostic index could then simply be 
calculated as the sum of a certain set of selected dichotomous variables (i.e. counting the 
number of variables with score 1). The corresponding probability (Pr) of a ‘normal’ biopsy 
outcome was estimated, for each index value, by means of a logistic regression model: 
logit(Pr) = a  + P x Index.
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Table 2. Screening protocol
Blood haemoglobin, leukocytes, thrombocytes, cell indices 
urea, creatinine, ASAT, ALAT, y-GT, AF, LDH 
CK, glucose, total and free carnitine
fasting lactate, fasting pyruvate, fasting lactate to pyruvate ratio 
aminoacids
In vivo pre and postprandial (1 hour after meal): glucose, lactate, pyruvate,
function ketone bodies
tests oral glucose loading test* (2 gr/kg): glucose, lactate, pyruvate,
ketone bodies
* if no lactate increase otherwise
CSF only in patients with neurological manifestations
glucose, cells, protein
lactate, pyruvate, lactate to pyruvate ratio
aminoacids
Urine organic acids and aminoacids in a urine portion collected from
8.00 am to 2.00 pm
Cardiac Chest X-ray, ECG, if one or both abnormal echocardiogram
evaluation
Ophthalmologic examination eye lens, fundus
Neuroimaging CT-scan or MRI brain (only in patients with 
neurological manifestations)
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Table 3. Biochemical parameters measured in skeletal muscle specimens
I. Oxidation rates and ATP + CrP production rates reference
Oxidation ratesa for n mean SD range
1. [1 - 14C] Pyruvate + malate 20 5.52 0.99 3.61-7.48
2. [1 - C] Pyruvate + carnitine 20 5.73 1.38 2.84-8.24
3. [1 - 14C] Pyruvate + malate - ADP 19 1.20 0.29 0.77-1.83
4. [1 - 14C] Pyruvate + malate - ADP + CCCP 21 5.07 1.38 2.40-8.05
5. [U - 14C] Malate + pyruvate + malonate 20 7.18 1.28 4.68-9.62
6. [U - 14C] Malate + acetylcarnitine + malonate 20 5.51 1.16 3.43-7.30
7. [U - C] Malate + acetylcarnitine + arsenite 19 2.74 0.63 2.05-3.85
8. [1,4-14C] Succinate + acetylcarnitine 19 4.64 1.12 2.54-6.39
9. ATP + CrP production rateb from pyruvate and malate 16 63.9 10.1 42.1-81.2
10. ATP/pyruvate ratio 20 11.1 1.8 8.0-15.0
11. ADP stimulation 25 4.7 1.2 2.9-7.9
II. Mitochondrial enzyme activities
Pyruvate dehydrogenase complexd 25 0.08 0.024 0.034-0.122
NADHiQj oxidoreductase (C I)d 20 0.14 0.03 0.07-0.25
Succinate dehydrogenase (C II)d 11 0.13 0.04 0.06-0.17
Succinate:cytochrome c oxidoreductase (C II + CoQ + C III)d 38 0.59 0.17 0.30-0.97
Decylubiquinol:cytochrome c oxidoreductase (C III)d 21 4.30 0.93 2.50-6.61
Cytochrome c oxidase (C IV)d 21 1.75 0.67 0.81-3.12
ATPase (C V)e 17 0.44 0.13 0.22-0.68
Citrate synthasec (CS, reference enzyme) 43 88.0 32.6 37-162
III. Mitochondrial transmembrane carrier
Voltage-dependent anion channel (VDAC) immunochemistry studies
Adenine nucleotide translocator (ANT) immunochemistry studies
a nanomoles substrate oxidized/hour- mU CS b nanomoles product formed /hour- mU CS 
c milliunits per milligram protein mU/mU CS e mU/mU cytochrome c oxidase
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Results
There were 18 females and 27 males (male to female ratio 1.5:1). Mean age at biopsy was 1.2 
years, range 3 months - 21 years. Sixteen patients had a normal biopsy result and 28 patients 
had a deficient biopsy result. One patient had borderline biopsy results and therefore was not 
included in the analysis (for the specified deficiency per patient see Table 4).
1) Selection of variables: 8 parameters could be selected: age at biopsy, fasting lactate, fasting 
L/P ratio, thrombocytes, urine alanine, urine lactate, lact4 and alan3 (see Table 5).
2) Prognostic index: for several combinations, out of the 8 fore-mentioned dichotomous 
variables, a prognostic index was simply calculated as the number of variables with score 1. 
We present the results for the index calculated from the following 5 selected variables: age at 
biopsy, fasting L/P ratio, thrombocytes, lact4 and alan3. Incidentally, in patients with a 
missing value in one of these parameters, the sum of the 4 known parameters was multiplied 
by 5/4. The corresponding probability (Pr) of a ‘normal’ biopsy outcome was estimated, for 
each index value (0-5), by means of the logistic regression model: logit (Pr) = a  + P x Index; 
a  : -0.8167 and P: 0.8331. In summary, the calculation of the prognostic index is done as 
follows: each of the selected parameters is scored 0 if not present, and 1 if present. The sum of 
these scores is the index value. The chance of a normal biopsy for a given index value can be 
calculated as mentioned above (see Table 6).
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Table 4. Patients with deficient mitochondrial energy metabolisme________________
pat deficiency*______________________________________________________
Single deficiencies
4 c 1:0.059(84%)
8 c III:2.3(92%)
10 c 1:0.05(71%)
14 c III:1.66(66%)
26 c III:1.50(60%)
28 c III:2.36(94%)/VDAC 
31 c III:2.23(90%)
36 c II:0.028(42%)
37 c III:1.75(70%)
41 c III:2.38(95%)
Combined deficiencies
2 c I:0.06(86%)+c III:1.59(56%)
6 c I:0.06(86%)+c II(58%)+c III(84%)+c IV(94%)
11 c I:0.005(7%)+c III:2.0(70%)+c IV:0.5(62%)
15 c I:0.02(29%)+c III:2.03(71%)+c IV:0.61(75%) (MELAS A3243G)
22 PDHC:0.028(82%)+c III:2.04(82%)+c IV:(96%)
24 PDHC:0.009(26%)+c I:0.02(29%)+c III:0.59(21%)+c IV:0.20(25%)+ANT
25 PDHC:0.038(82%)+c I:0.05(71%)+c III:1.79(63%)+c IV:0.47(58%)
38 c I:0.033(47%)+c III:2.11(74%)+c IV:0.21(26%)
43 c I:0.06(86%)+c III:2.11(74%)+c IV:0.75(93%)
44 c I:0.02(29%)+c III:0.55(19%)+c IV:0.18(22%)
45 c I:0.01Q4%)+c III:2.12(74%)
Non-identfied
1
5
9
12 
21
29 
34
* measured values, (mU/mU CS) and percentage of lowest value of reference 
range in parentheses
Table 5. Selected parameters
parameter normal
n=16
deficient
n=28
p-value
age at biopsy < 4 years 3 17 0.011
= 4 years 13 11
fasting lactate normal 15 17 0.032
elevated 1 11
fasting L/P ratio normal 14 18 0.065
elevated 1 10
thrombocytes normal 13 12 0.025
elevated 1 10
urine alanine normal 12 15 0.090
elevated 2 11
urine lactate normal 14 22 0.083
elevated 0 6
lactate4
(fasting or after GLT * normal 12 10 0.027
or CSF or urine) elevated 4 18
alanine3
(blood or CSF normal 12 11 0.056
or urine) elevated 4 16
* glucose loading test
Age at biopsy = 4 years scores 0, age < 4 years scores 1, for the other parameters 
normal scores 0 and elevated scores 1.
Reference values for different parameters: 
thrombocytes: 120 - 350 x 109/l
fasting lactate < 2000 |imol/l; fasting lactate to pyruvate ratio: 10-15 
serum alanine < 450 |imol/l
urine lactate (^mol/mmol creatinine): 0 - 1 year < 200; > 1 year < 100 
urine alanine (^mol/mmol creatinine):
0 - 1 month 75 - 244 1 - 6 months 72 - 206
6 months - 2 years 36 - 266 2 - 4 years 33 - 115
4 - 7 years 27 - 92 7 - 10 years 17 - 65
10 - 13 years 21 - 62 > 13 years 16 - 68
CSF lactate < 2000 |imol/l
CSF alanine (^mol/l) - 1 year 17 - 41 1 - 3 years 14 - 34
3 - 18 years 13 - 31 > 18 years 19 - 54
Table 6. Distribution of Index (age, fasting lactate to pyruvate ratio, 
thrombocytes, lact4 and alan3) over groups normal and deficient.
Index normal
n=16
deficient
n=28
chance of normal biopsy
0 10 3 0.69
1 2 5 0.50
2 2 4 0.30
3 1 6 0.16
4 1 5 0.07
5 0 5 0.03
Comparison index normal and deficient: Wilcoxon test: p=0.0004
logit (Pr) = a + ß x Index; a: -0.8167 and ß : 0.8331 
Pr stands for probability of having a normal biopsy.
Abbreviations: GLT = glucose loading test; lact4 = fasting lactate or 
after GLT or CSF or urine; alanine3 = alanine in blood or CSF 
or urine
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Discussion
The known biochemical defects of the oxidative phosphorylation system have a very variable 
phenotypic expression [21,10]. Some phenotypic manifestations frequently encountered in 
paediatric patients are encephalopathy, especially Leigh phenotype, myopathy, and 
cardiomyopathy (hypertrophic or dilated [7,8]). The clinician who considers a mitochondrial 
disorder in an individual patient can use the prognostic index constructed in this study as an 
additional instrument to decide whether the suspicion of mitochondriocytopathy is so strong 
that a muscle biopsy is indicated.
The selected parameters (see methods) in this study with a prognostic value are: age at biopsy 
under four years, an elevated fasting serum lactate to pyruvate ratio, an elevated lactate in 
blood (fasting or after oral glucose loading) or CSF or urine, an elevated alanine in blood or 
CSF or urine, and an elevated thrombocyte count.
The only non-laboratory parameter with a prognostic value is age at biopsy under 4 years. The 
lower the age at diagnosis, the more severe the clinical course and the poorer the prognosis, in 
accordance with our own experience. The fact that other clinical parameters do not have a 
prognostic value is not surprising because of the wide range of clinical presentations and the 
non-specificity of symptoms in mitochondriocytopathies.
The other selected parameters -  elevated serum fasting lactate to pyruvate ratio, elevated 
lactate and elevated alanine in body fluids -  are frequently found in oxidative phosphorylation 
defects. A disturbance in the oxidative phosphorylation system results in accumulation of 
pyruvate. The accumulated pyruvate is mostly converted to lactate by the cytosolic lactate 
dehydrogenase, or transaminated to alanine. The elevated lactate to pyruvate ratio is the 
consequence of an increased NADH/NAD+ ratio, resulting in a shifting of the cytoplasmatic 
lactate/pyruvate equilibrium in favour of lactate. For those patients who have a normal lactate 
in urine but elevated excretion of citric acid cycle intermediates (e.g. succinic acid in complex
II deficiency), the parameter lactate in urine is scored 1. Oxidative phosphorylation defects 
can be associated with a postprandial lactate increase and abnormal ketone body ratio after 
meals due to the respectively abnormal cytoplasmic and mitochondrial redox status [13]. 
Postprandial lactate increase and abnormal ketone body ratio after a regular meal were not of 
prognostic value in this group. In contrast, lactate increase after a glucose loading test (2 
gr/kg) was probably due to the more standardized glucose load in this test.
Laboratory investigations of routine clinical chemistry showed surprisingly that a slightly 
elevated thrombocyte count (> 350 x 109/l but never exceeding 950 x 109/l) had a prognostic
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value. This increment could not be explained by other causes known to be associated with an 
elevated thrombocyte count such as infections, exercise [4], surgery, iron-deficiency, or other 
chronic anaemias [16,19]. This finding needs to be investigated in future studies.
Other clinical chemical investigations such as total and free carnitine and CK determination, 
usually performed in patients suspected of an oxidative phosphorylation defect, were found to 
be superfluous. Total and free carnitine concentrations in blood were normal in all patients in 
this study, illustrating that this is an unnecessary measurement when a patient is suspected of a 
mitochondriocytopathy caused by an oxidative phosphorylation defect. The CK was normal or 
only slightly elevated in all patients with a deficiency in the mitochondrial energy metabolism. 
A severe elevation of CK does not suggest a defect in oxidative phosphorylation. If other 
causes of muscle injury such as intramuscular injections, the muscle biopsy itself, or other 
surgeries can be excluded, a severe elevated CK urges other diagnostic considerations such as 
mitochondrial fatty acid oxidation disorders.
Imaging of the brain in this group of patients was also non-discriminative, which is in 
agreement with the non-specificity of the encountered abnormalities in neuromitochondrial 
disorders.
The clinician willing to calculate the chance of a normal biopsy result in an individual patient 
can use as laboratory screening: lactate and pyruvate in blood, aminoacids in blood and urine, 
lactate and amino-acids in CSF (if neurological manifestations are present), urine organic 
acids and thrombocytes. The urine portion for aminoacid and organic acid analysis should be 
collected in the fed state. If no lactate increase is found in body fluids, an oral glucose loading 
test should be performed. Postprandial determinations of lactate and ketone bodies were non­
discriminative for this group and therefore we advise the use of the oral glucose loading test in 
its place.
Those patients with a low prognostic index (0-1) and an abnormal mitochondrial energy 
metabolism (in this study 8 of 28), or a high prognostic index (3-5) and a normal 
mitochondrial energy metabolism (in this study 2 of 16) form a difficult group. In the patients 
with a low prognostic index, additional findings which do not have a prognostic value but are 
known to be associated with mitochondrial disorders (such as ptosis, cataract, 
cardiomyopathy, aminoaciduria) can help to decide whether or not to perform the muscle 
biopsy. The patients with a high prognostic index are the ones who will more often undergo a 
muscle biopsy with a low risk of finding a normal mitochondrial energy metabolism. It is very
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important to bear in mind that a mitochondriocytopathy may still be present even if all the 
screening parameters are normal.
Mitochondrial DNA studies in blood and/or skeletal muscle (data not shown) revealed a 
mutation (MELAS A3245G) in only one patient who became symptomatic at 14 years of age. 
In our experience, patients with oxidative phosphorylation defects caused by mtDNA 
mutations usually become symptomatic at an older age than patients with a nuclear mutation. 
Due to the relatively low age of this group (median age 4.5 years), this is not an unexpected 
result.
In conclusion, because of the non-specificity of symptoms, patients should be widely screened 
for mitochondriocytopathies. This prognostic index can help the clinician to decide in which 
patients a muscle biopsy should be performed in order to rule out or prove a 
mitochondriocytopathy. Further studies are needed to make the prognostic index more 
accurate. The association of a slightly elevated thrombocyte count with oxidative 
phosphorylation defects has not previously been reported and requires further study.
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A summary score for skeletal muscle biochemical results in 
mitochondriocytopathies
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Abstract
The diagnostic approach of patients suspected of a mitochondriocytopathy includes 
biochemical investigation of skeletal muscle. First oxidation rates of mitochondrial substrates 
and ATP plus CrP production rate are measured which brings up eleven different parameters. 
If these parameters are abnormal, enzymatic studies (pyruvate dehydrogenase complex, 
complex I-V) are performed. In some cases it is difficult to conclude whether the patient has a 
disturbed mitochondrial energy metabolism or not. This, because the different parameters do 
not unanimously point to normal or deficient. To facilitate and standardize the interpretation 
of mainly these cases, we searched for a method to summarize these 11 parameters in one. 
Here, a scoring method based upon linear discriminant analysis to summarize in a 
discriminant score (DS) the skeletal muscle biochemical results is presented. This DS 
discriminates between patients with normal and defective mitochondrial energy metabolism. 
DS > 0 points to a normal mitochondrial energy metabolism and based on the skeletal muscle 
biochemistry results no further investigations are necessary. Conversely, a DS < 0 points to a 
decreased mitochondrial energy metabolism and warrants further investigations.
Furthermore, the use of a summary score simplifies correlation studies between oxidation 
rates and ATP production rate in skeletal muscle and other parameters (e.g. clinical, 
biochemical, radiological, morphological).
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Introduction
Mitochondriocytopathies are characterized by structurally or numerically abnormal 
mitochondria and/or abnormally functioning mitochondria [12]. This group of diseases have a 
very wide spectrum of clinical manifestations [4,5,18]. They are caused by defects in the 
mitochondrial energy generating system. The adequate functioning of this system requires at 
least normal activity of the pyruvate dehydrogenase complex (PDHC), citric acid cycle (CAC) 
enzymes, respiratory chain (RC) complexes, complex V and a proper functioning of the 
mitochondrial transport proteins, such as the adenine nucleotide translocator (ANT) 
[11,15,16]. RC defects are a main cause of mitochondriocytopathies.
When the clinical presentation and course of a disease in a patient combined with metabolic 
screening findings suggest a defect in the mitochondrial energy metabolism, histochemical 
and biochemical investigations in tissue are necessary to obtain the correct diagnosis. Skeletal 
muscle is the preferred tissue because it expresses the defect in the majority of patients [6]. To 
obtain enough muscle tissue for extensive investigations to optimally assess the diagnosis, a 
surgical biopsy is necessary in pediatric patients. The skeletal muscle specimen is directly 
investigated so that the function of intact mitochondria -substrate oxidations and ATP plus 
creatine phosphate (CrP) production rate- can be examined.
If these are decreased enzymatic studies (PDHC, complex I-V) are performed depending on 
the pattern of abnormalities. Exceptionally, further studies are performed if clinical, clinical 
chemical and morphological findings are strongly suggestive of a defect in the mitochondrial 
energy metabolism, despite normal oxidation rates and ATP production rate. The assessment 
of the substrate oxidation rates of several mitochondrial substrates and ATP plus CrP 
production rate (described in detail in the addendum) brings up eleven different parameters. In 
some cases it is difficult to conclude whether the patient has a disturbed mitochondrial energy 
metabolism or not because the different parameters do not unanimously point to normal or 
deficient.
To facilitate and standardize the interpretation of mainly these cases, we searched for a 
method to summarise these eleven different results in one. A scoring method based upon 
linear discriminant analysis, resulting in a discriminant score (DS) was tested for this purpose. 
Furthermore, the use of a summary score simplifies correlation studies between oxidation 
rates and ATP production rate in skeletal muscle and other parameters (e.g. clinical, 
biochemical, radiological, morphological).
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Methods
The scoring method was applied to the biochemical results of skeletal muscle investigations 
of patients who had undergone a muscle biopsy because of suspicion of 
mitochondriocytopathy based on clinical and metabolic screening findings.
The traditional method of interpretation (normal or decreased mitochondrial energy 
metabolism) was compared with the developed scoring method.
1- Study group
Sixty-six consecutive pediatric patients who had undergone a muscle biopsy in the period 
December 94 to January 97.
2- Biochemical investigations in skeletal muscle
Skeletal muscle specimens had been obtained from the right vastus lateralis muscle under 
general anaesthesia after informed parental consent. Subsequently, the oxidation rates of 
mitochondrial substrates [2], and ATP production rate [10] had been measured in the fresh 
skeletal muscle specimen. The mitochondrial enzyme activities had been measured according 
to Sperl et al. [14] in frozen muscle homogenate (PDHC) and according to Fischer et al. [7] in 
600g supernatant (RC enzymes). Complex V had been measured in isolated mitochondria as 
previously described with minor modifications [3]. To cope with differences of mitochondrial 
distribution and recovery, the results are expressed to citrate synthase activity, a mitochondrial 
matrix reference enzyme, except for complex V which was measured in isolated 
mitochondrial fraction and therefore was expressed to cytochrome c oxidase. The measured 
biochemical parameters in skeletal muscle specimens and their reference values (range, mean 
and SD), are listed in Table 1.
3- Traditional method of interpretation of results of biochemical investigations in skeletal 
muscle specimens
A disturbed mitochondrial energy metabolism results in decreased oxidation rates and ATP 
plus CrP production rate ( Table 1). The results of some parameters depend on the localization 
of the defect (see interpretation Table 1). We consider a parameter decreased if the result is 
below the lowest value of the reference range.
The results of all patients were reviewed by the same biochemist and technical assistant.
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4- Discriminant analysis
Linear Discriminant Analysis [1] is one of the methods that can be applied, in comparing two 
groups, (group I: normal and group II: decreased mitochondrial energy metabolism), to reduce 
the multiple number of results in one summary result (Discriminant Score, DS). The result of 
the maximally separating linear combination of results is termed the DS. The lower the DS of 
a patient, the further this patient is from the normal group. (For the calculation of DS, see 
Table 1).
Table 1. Biochemical parameters measured in skeletal muscle specimens
I. Oxidation rates and ATP + CrP production rate reference values interpretation DS##
Oxidation rates3 for n mean SD range decreased in deficiencies of multiplier
1. [1 - 14C] Pyruvate + malate 20 5,52 0.99 3.61-7.48 PDHC,CAC,RC 2,97
2. [1 - 14C] Pyruvate + carnitine 20 5,73 1,38 2.84-8.24 PDHC, RC, * -3,95
3. [1 - 14C] Pyruvate + malate - ADP 19 1,20 0,29 0.77-1.83 ** 1,24
4. [1 - 14C] Pyruvate + malate - ADP + CCCP 21 5,07 1,38 2.40-8.05 *** -0,61
5. [U - 14C] Malate + pyruvate + malonate 20 7,18 1.28 4.68-9.62 PDHC, CAC, RC 0,86
6. [U - 14C] Malate + acetylcarnitine + malonate 20 5,51 1,16 3.43-7.30 **** 2,12
7. [U - 14C] Malate + acetylcarnitine + arsenite 19 2,74 0,63 2.05-3.85 ***** 2,67
8. [1,4-14C] Succinate + acetylcarnitine 19 4,64 1,12 2.54-6.39 -0,50
9. ATP + CrP production ratesb from pyruvate and malate 16 63,9 10.1 42.1-81.2 0,34
10. ATP/pyruvate ratio 20 11,1 1,8 8.0-15.0 -0,44
11. ADP stimulation 25 4,7 1,2 2.9-7.9 -0,26
II. Mitochondrial enzyme activities
Pyruvate dehydrogenase complexd 25 0,08 0,024 0.034-0.122
NADH:Q1 oxidoreductase (C I)d 20 0,14 0,03 0.07-0.25
Succinate dehydrogenase (C II)d 11 0,13 0,04 0.06-0.17
Succinate:cytochrome c oxidoreductase (C II + CoQ + C III)d 38 0,59 0.17 0.30-0.97
Decylubiquinol:cytochrome c oxidoreductase (C III)d 21 4.3 0.93 2.50-6.61
Cytochrome c oxidase (C IV)d 21 1,75 0.67 0.81-3.12
ATPase (C V)e 17 0,44 0,13 0.22-0.68
Citrate synthasec (reference enzyme) 43 88,0 32.6 37-162
a nanomoles substrate oxidized per hour per mU CS b nanomoles product formed per hour per mU CS c mU per mg protein d mU per mU CS
e mU per mU cytochrome c oxidase * In case of RC deficiency 14C02 production is less decreased as compared to 1.
** Comparision of 1 and 3 yields the ADP-stimulation (in all experiments except 3 ADP is included); if decreased, 
points to a disturbance in the coupling of mitochondria.
*** If normal compared to 1: coupling defect, discriminates between PDHC,CAC,RC and cV **** If normal compared to 5: PDHC deficiency
***** if the same as 6: alpha ketoglutaric acid dehydrogenase deficiency
## Calculation of DS: result of parameter x multiplier, add these results, add constant (-14.50); result = DS value
Table 2. Results biochemical investigations in skeletal muscle of study group
pat *p+m c+p* *p+m *p+m *m+p *m+ac *m+ac *su+ac ATPap
PmTA ADP
ADP- ADP-
CCCP+
ma + ma + ar + ratio stim
1 1.52 2,71 0,64 1,37 0.89 1,71 1,49 1,46 12,0 7,9 2,4
2 2.76 3,55 0,58 3,10 2.82 2,29 1,25 1,67 19,2 6,9 4,8
3 2.29 3,24 0,95 2,74 2.43 2,03 1,24 1,49 25,0 10,9 2,4
5 3.28 4,28 1,12 3,45 3.73 2,02 1,28 2,00 35,6 10,9 2,9
6 0.49 1,81 0,62 1,56 1.53 1,15 0,73 0,72 3,5 7,2 0,8
7 1.50 1,55 0,80 1,39 2.01 1,85 1,01 1,39 5,8 3,9 1,8
8 3.39 3,91 0,57 3,55 3.91 3,32 2,02 2,59 30,7 9,1 6,0
9 1.11 1,75 0,40 1,13 0.98 1,05 0,60 0,67 11,7 10,5 2,8
10 1.10 1,38 0,47 1,02 1.16 0,96 0,83 0,57 12,8 11,7 2,3
12 2.23 3,13 0,77 1,96 3.20 1,68 1,11 2,75 32,9 14,3 3,0
13 3.50 4,62 1,26 4,64 4.70 2,24 1,24 1,93 48,2 13,8 2,8
14 0.74 0,94 0,27 0,57 0.75 0,81 0,69 0,35 6,5 8,9 2,7
15 1.62 2,26 0,49 1,83 2.36 2,51 1,50 1,61 26,6 16,4 3,3
16 2.77 4.28 0.51 2.44 2.80 3.21 1.51 2,06 32,1 12.2 5.4
18 2.71 3.25 0.81 3.27 2.48 1.88 0.96 1,26 27,4 10.2 3.3
19 4.27 5.30 0.97 5.25 4.54 4.20 1.75 2,97 45,4 10.6 4.4
20 2.43 2.52 0.79 2.70 2.75 3.02 1.66 1,96 22,4 9.2 3.1
21 1.21 2.98 0.65 0.54 2.98 1.94 1.49 1,81 37,4 31,0 1.9
22 1.66 2.40 0.63 2.19 1.50 1.83 1.14 1,30 15,5 9.4 2.7
23 1.95 3.17 0.32 2.37 2.00 1.54 0.93 1,39 22,3 11.5 6.2
24 7.52 8.21 0.90 7.36 7.05 6.64 3.17 4,95 83,0 11,0 8.1
25 1.10 1.46 0.33 1.66 2.45 2.05 1.29 1,33 30,3 27,0 3.4
26 1.59 2.51 0.46 2.17 1.02 1.64 0.80 1,18 29,7 18,0 3.5
27 2.54 3.80 0.72 1.97 2.27 2.13 1.48 1,62 31,5 12.4 3.6
28 1.46 1.58 0.44 1.32 1.54 1.09 0.61 0,83 18,3 12.6 3.3
29 1.66 2.36 0.35 0.65 1.64 1.43 0.94 1,98 19,0 11.6 9.7
30 0.82 0.87 0.48 0.85 1.43 2.32 1.32 1,77 4,5 5.5 1.7
32 0.69 1.52 2.85 0.46 0.70 0.97 0.87 0,69 8,0 11.6 2.4
33 0.27 0.67 0.15 0.39 0.24 0.28 0.25 0,16 0,9 3.5 1.7
34 3.89 4.97 0.91 4.02 4.19 3.82 2.15 2,93 37,2 9.6 4.3
35 2.78 3.49 0.47 2.59 3.59 2.67 1.43 0,32 24,8 8.9 5.8
36 4.40 5.32 0.69 3.14 4.06 3.35 1.93 2,75 29,0 6.6 6.3
38 3.57 3.49 0.65 4.84 4.42 3.04 1.39 2,67 31,8 8.9 5.5
39 2.90 3.95 0.69 3.65 3.78 3.20 1.78 1,87 41,6 14.3 4.2
41 1.42 1,77 0,59 1,34 1.52 0,95 0,48 0,73 18.6 13,1 2,4
42 5.76 5.88 0.76 5,29 5.18 4.94 2.65 3,82 51,8 9.0 7.6
44 1.34 1.71 0.53 1.26 1.83 1,40 0.89 1,12 26,4 20,0 2.5
47 1.10 1.28 0.43 0.94 1.26 1.29 0.79 0,87 6,9 6.2 2.6
48 3.58 4.46 0.99 4.19 4.36 2.84 1.4 1,92 36,0 10,0 3.6
49 2.10 2.64 0.85 2.79 2.22 1.77 1.02 1,29 23,1 11,0 2.5
*oxidation rate in nanomoles substrate oxidized per hour per mU CS 
a nanomoles product formed per hour per mU CS
In some patients the ATP/p ratio is > 15, this is due to analytical errors in both assays; 
Abbreviations: p:pyruvate; m:malate; c:carnitine; ma:malonate; ac:acetylcarnitine; 
ar:arsenite; su:succi nate
Table 2. Results biochemical investigations in skeletal muscle of study group (continued)
pat *p+m c+p* *p+m
ADP-
*p+m
ADP-
CCCP+
*m+p 
ma +
*m+ac 
ma +
*m+ac 
ar +
*su+ac ATPap ATP/p
ratio
ADP
stim
50 2.12 2.66 0.47 1.91 1.73 1.79 1.06 1,19 37,2 17.6 4.5
52 2.87 3.16 0.91 3.06 2.84 2.45 1.5 1,48 17,8 6.2 3.2
53 1.27 1.82 0.33 1.24 1.23 0.86 0.49 0,67 12,3 9.7 3.9
54 0.84 0.93 0.18 0.74 1.05 0.80 0.49 0,57 24,2 20,0 4.8
55 4.25 5.09 1.12 4.69 4.65 4.10 2.33 2,70 10,2 2.4 3.8
56 2.28 2,70 0.71 2,50 2.17 1.48 0.89 1,28 17,5 7.7 3.2
57 2.61 2.78 0.33 2.99 2.44 2.11 1.03 1,57 34,8 13.3 7.9
58 1.96 3.13 0.53 1.71 1.30 1.50 1.18 1,32 12,7 6.5 3.7
59 1.59 2.87 0.48 1.89 0.95 1.34 0.95 1,07 16,4 10.3 3.4
60 5.22 4.99 0.85 5.89 6.31 5.35 2.38 4.75 55,3 9.8 6.1
61 5.14 5.32 0.98 4.89 6.29 3.43 2.11 2.95 61,5 11.9 5.2
62 6.03 6.6 0.99 6.05 6.13 4.74 2.77 3.19 50,4 8.4 6.1
63 5.25 5.01 0.79 4.81 6,20 5.39 2.84 3.55 42.2 8.2 6.6
64 4.38 4.98 0.79 4,70 5.08 4.22 2.37 3.01 44.3 10.1 5.5
65 5.22 4.67 0.67 5.85 6.57 4.63 2.49 3.12 46.8 9.0 7.9
66 9.37 10.47 1.35 10,30 9.30 5.96 3.05 6.30 93.1 9.9 6.9
*oxidation rate in nanomoles substrate oxidized per hour per mU CS 
a nanomoles product formed per hour per mU CS
In some patients the ATP/p ratio is > 15, this is due to analytical errors in both assays; 
Abbreviations: p:pyruvate; m:malate; c:carnitine; ma:malonate; ac:acetylcarnitine; 
ar:arsenite; su:succinate
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Results
1- Biochemical investigations in skeletal muscle of patients in study group
There were 37 males and 29 females. Mean age at biopsy was 5.0 years (range 0.1-18 years). 
Six patients had incomplete measurements due to technical problems or not enough muscle 
specimen was available (pat. 11,17,31,37,40,43). In four patients, the recovery of 
mitochondria from the muscle specimen was too low to be able to perform reliable 
measurements (pat. 4,45,46,51). The outcome of the biochemical investigations in fresh 
skeletal muscle specimens of the 56 remaining patients is listed in Table 2.
2- Classification of patients according to the traditional method
These 56 patients were classified by the biochemist and technical assistant in group I (normal 
mitochondrial energy metabolism) and group II (deficient mitochondrial energy metabolism). 
The patients with doubtful results were classified as group III (borderline mitochondrial 
energy metabolism) (see Table 3).
On behalf of this study, PDHC, C I, SCC, C III and C IV was also measured in the patients 
classified as normal. These results were all in the reference range except C III in patient 
number 65, (data not shown). This patient had a C III activity of 2.30 milliunits per milliunit 
citrate synthase (reference 2.50-6.61). In patients classified as deficient (n=46), routine 
subsequent investigations had been performed depending on the pattern of abnormalities. 
Sixteen patients were found to have a deficiency in one of the measured enzyme complexes,
11 patients had a deficiency in > 2 of the measured enzyme complexes. In 15 patients the 
measured enzyme complexes were all normal despite decreased oxidation rates and ATP 
production. We named this subgroup non-identified.
3- Calculation of DS and comparison to traditional method of classification for group I and II 
The DS was calculated for each patient as described in table 1. For the development of the 
formula, the biochemistry results of the borderline patients were not considered.
All patients classified in group I (normal mitochondrial energy metabolism) had a DS > 0. All 
patients classified in group II (decreased mitochondrial energy metabolism) had DS < 0 (see 
Table 3).
In order to obtain a better fit to the model assumptions underlying discriminant analysis i.e. 
multivariate gaussian distribution and homogeneity of variances and covariances, the analysis
61
may be better performed on some mathematical transformation of the laboratory outcomes 
(often the logarithmic or square root transformation). However, for 8 of the 11 muscle 
biochemistry parameters there was a good fit to a univariate normal distribution (as measured 
by the Shapiro-Wilk statistic) and transformation did not result in a better fit. For the other 3 
parameters (oxidation rate from pyruvate plus malate minus ADP, ATP production from 
pyruvate plus malate and ADP stimulation) logarithmic transformation resulted in a 
substantial better fit, but logarithmic transformation of these 3 parameters in combination with 
the untransformed other 8 parameters did not result in a better discrimination (as measured by 
the Mahalanobis distance) between both groups (decreased vs normal). Besides, logarithmic 
or square root transformation of all 11 parameters resulted in a strongly reduced Mahalanobis 
distance. So, to obtain a summarizing score there will be no statistical loss and easiness of 
calculation will be served by using untransformed outcomes. The results of a standard linear 
discriminant analysis of the non-transformed outcomes of the muscle biochemistry variables 
were used in composing the scoring rule (analysis performed by means of SAS procedures, 
SAS version 6.12).
Inspection of the univariate sampling distributions for each of the 11 skeletal muscle 
parameters revealed strong differences (shift) between both groups: normal and decreased 
mitochondrial energy metabolism. E.g. for the variables 5, 6, 8 and 9 from table 1 the sample 
distributions were non-overlapping between both groups. This reflected the procedure used in 
the traditional method of classification based on deviant values for the individual parameters 
as compared to the reference ranges in table 1. This implies that selection of fewer parameters 
from the complete set of 11 parameters could easily be done by looking at the overlap in the 
univariate distributions and application of a stepwise selection procedure (e.g. within the 
regression procedure SAS-REG). It turned out that there was complete discrimination based 
on the variables 5 and 6 from table 1. The range and ordering of DS-values based only on 
these two parameters was very similar to the range and ordering based on all 11 parameters 
and the correlation between both summary scores was very high, r=0.93 for the group 
decreased and r=0.90 for the group normal. Besides, for the prospective study with 20 new 
patients complete discrimination was obtained when variables 5 and 6 from table 1 were used.
Table 3. Traditional classification of patients and DS for each patient (n=S6)
pat Group I: normal mitochondrial energy metabolism n=10 (18%) DS
19 0.9
24 19.4
42 8.8
60 12.4
61 9.1
62 7.8
63 10.9
64 4.3
65 10.2
66 18.4
Group II: decreased mitochondrial energy metabolism n—42
a) Single defects n—16 (28%) deficiency*
3 C V (60%) -8.9
7 C III (90%) -8.6
8 C III (90%) -2.0
9 C I (23%) -15.3
20 C I (75%) -2.9
23 C IV (60%) -14.6
25 SCC(75%)b -10.8
30 PDHC (40%) -8.0
32 C I (30%) -13.5
39 C III (85%) -2.2
41 C III (80%) -13.2
49 PDHC (55%) -9.2
50 C I (75%) -8.0
53 C III (80%) -15.5
54 C III (70%) -14.1
59
b) Combined defects n= ll (20%)
C I (75%) -15.8
2 C I (75%)+III (40%)+IV(70%) -9.5
6 C I (44%)+III (70%) -17.2
10 C III (60%)+lV (90%) -13.1
14 C III (60%)+IV (90%) -14.4
18 C I (90%)+ITI (60%) -8.2
27 C III (80%)+IV (50%) -8.3
28 PDHC (70%)+C III (50%) -12.0
29 C I (85%)+III (80%) -14.0
33 PDHC (70%)C I (10%)+SCC (10%)+III (20%)+IV (20%) -16.7
44 PDHC (70%)+C III (80%) -11.5
47
c) Non-identified n=15 (27%)
PDHC (44%)+C I (43%)+lII (30%)+IV (70%) -11.9
1 -13.1
5 -5.9
12 -8.5
15 -7.6
16 -7.7
21 -13.8
22 -11.6
26 -13.3
35 -5.6
36 -3.8
38 -1.8
52 -5.8
56 -10.6
57 -6.7
58 -14.1
Group III: borderline mitochondrial energy metabolism n=4 (7%)
13 -2.9
34 -0.6
48 -3.4
55 -4.5
a in parentheses % of lowest value of reference range;b C III is normal, it is assumed that C II or CoQ are deficient
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4- Calculation of DS for borderline patients
Thereafter using the developed formula, the DS was calculated for the borderline patients. 
They all had a DS <0. Measurement of the PDHC, C I, SCC, C III and C IV activity, revealed 
normal results for patients nos. 13, 34 and 48. Patient no. 55 had a C III enzyme activity of 
2.22 milliunits per milliunit citrate synthase (reference 2.50-6.61).
5- Validation of the method
To validate this scoring method we applied it to a prospective group of 20 patients. Seven 
patients had a DS > 0 and 13 patients had a DS < 0. It was concluded that 7 patients had a 
normal mitochondrial energy metabolism and 13 patients a decreased mitochondrial energy 
metabolism. This was in agreement with the interpretation performed afterwards by the 
biochemist and technical assistant (Table 4).
Table 4, Scoring method resulting in PS is validated by applying it to a prospective group of 20 patients
pat * p + m *p + 0 * p + m * p 4- m *m + p *m + ac *m + ac *su + ac ATPap ATP/p ADP DS traditional
ADP- ADP-
CCCP+
ma + ma + ar + ratio stim classification
3 4.95 5.61 0.73 5.20 6.30 4.54 2.76 3.19 76.60 15.50 6.80 14.0 normal
9 5.71 6.48 0.73 5.74 6.52 4.16 2.24 3.34 70.00 12.30 7,80 9.3 normal
11 5.35 5.35 0.69 5,57 7.27 4.60 2.27 3.61 46.09 8.60 7.80 7.8 normal
12 5.10 5.60 0.66 5.03 5.86 2.90 2.73 3.46 54,50 10.60 7.90 4.8 normal
13 4.88 6.01 0.84 5.04 6.37 5.43 3.11 4.09 52.00 10.70 5.80 8,9 normal
15 4.59 5.21 0.76 4.35 4.72 4.97 2.49 3.16 49.40 10.70 6.00 7.0 normal
19 3.93 6.40 1.21 5.59 6.15 5.97 3.22 3.49 44.43 11.30 3.20 4.1 normal
deficiencyb
1 2.87 2,77 0.70 2.76 2.70 1.90 1.20 1.47 26.50 9.20 4.00 -5.0 decreased non-identified
2 2.47 4.37 0.47 2.93 3.73 3.18 1.81 2.13 37.20 15.00 5.10 -7.2 decreased CI (85%)+C II (60%)
4 1.04 2.15 0.42 1.24 0.49 0.65 0.48 0.60 6 5.7 2.5 -18.5 decreased CI (30%)+C IV{20%)
5 3.17 4.28 0.53 3.60 3.72 3.41 1.69 2.16 31.17 9.80 6.00 -4.9 decreased non-identified
6 2.65 3.20 0.53 3.22 3.32 1.90 1.20 1.34 24.60 9.27 4.94 -8.2 decreased Cl (70%)
7 0.74 1.34 0.55 0.91 0.64 0.81 0.80 0.57 3.52 4.90 1.40 -14.7 decreased CI (7%)+C 111(80%)+ 
CIV (60%)
8 2.3 2.94 0.42 2.85 2.64 2.00 1.21 1.00 11.24 4.90 5.40 - 11.0 decreased non-identified
10 2.07 4.47 0,55 3.61 2.49 2.78 1.80 1.90 22.33 10.80 3.80 -13.8 decreased CIO (65%)
14 1.98 2.48 0.57 1.74 2.20 1.95 1.82 1.30 18.04 9.10 3.50 -7.3 decreased non-identified
16 0.59 0.70 0.12 0.94 0.75 0.73 0.47 0.48 4.68 7.90 5.00 -15.9 decreased PDHC (26%)+C 1 (29%)+
C III (25%)+C IV (25%)+ANT
17 2.31 3.65 0.63 2.92 2,46 2.51 1.58 1.54 21.70 9.40 3.70 -9.9 decreased PDHC (82%)+C 1(70%)+ 
C III (70%)+C IV (58%)
18 1.16 1.59 0.31 1.14 1.32 1.20 0.70 0.66 10,30 8.90 3.75 -13.8 decreased CIII (60%)
20 1.31 1.68 0.43 1.28 1.28 1.39 0.94 0.88 9.60 7.30 3.00 -12.1 decreased non-identified
* nanomoles substrate oxidized per hour per mU CS ananomoles product formed per hour per mU CS
b in parentheses % of lowest value of reference range
Abbreviations: p:pyruvate; m:malate; c:camitinc; ma:malonate; ac:acetylcamitine; ariarsenlte; su:succinate 
In one patient the ATP/Pyr ratio is >15, this is due to analytical errors in both assays
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Discussion
Mitochondriocytopathies can be due to single or combined deficiencies of the components of 
the mitochondrial energy generating system. Common to all the defects is that they lead to 
decreased oxidation rates of mitochondrial substrates and ATP production rate. Oxidation 
rates and ATP production can also be decreased due to denervation and disuse [8,9,13,17]. 
There are cases in which the biochemical results of the oxidation rates of mitochondrial 
substrates and ATP production are non-conclusive. The biochemist faces the dilemma 
whether to perform further investigations or not. At present this decision making process is 
not standardized and suffers from inter- and intra-individual variability.
Mainly in these cases, the use of the DS can facilitate and standardize this process. The DS 
discriminates between a normal and a deficient mitochondrial energy metabolism. A DS > 0 
points to a normal mitochondrial energy metabolism and based on the skeletal muscle 
biochemistry results no further investigations are necessary. Conversely, a DS < 0 points to a 
decreased mitochondrial energy metabolism and warrants further investigations.
Exceptionally, despite normal oxidation rates and ATP production rate in skeletal muscle, 
further investigations are performed because the clinical, biochemical or morphological 
findings are strongly suggestive of a mitochondriocytopathy.
Furthermore, the developed DS simplifies studies between oxidation rates and ATP 
production rate in skeletal muscle and other parameters (e.g. clinical, biochemical, 
radiological, morphological). It is easier to assess correlations with one summary result than 
with 11 different results.
For example, mitochondriocytopathies are diagnosed more often in young infants due to the 
more severe presentation at a younger age. We used the DS to assess whether there was a 
relationship between age at biopsy in the study group and oxidation rates of mitochondrial 
substrates and ATP production rate. We found indeed that the younger the age at biopsy the 
more disturbed mitochondrial energy metabolisms as illustrated in figure 1.
We also looked at the DS value and histological abnormalities in a subgroup of patients in 
which the skeletal biopsy specimen had been investigated by the same morphologist. Seven of 
the 20 patients had non-specific histological abnormalities. The mean DS in this group was 
-6.7 (median -7.3). The mean DS of the 13 patients with no histological abnormalities was 
-3.0 (median -5.0). We conclude that the DS can be useful for the interpretation of skeletal 
muscle biochemical results. It also facilitates studies between these results and other 
parameters (e.g. clinical, biochemical, radiological, morphological).
sa
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Figure 1. DS and age at biopsy
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Addendum: Assessment of mitochondrial substrates oxidation rates and ATP plus CrP 
production rate.
The assessment of the substrate oxidation rates of several mitochondrial substrates in fresh 
skeletal muscle is done by determining the 14CO2 production rate from [1-14C]-pyruvate, [U- 
14C]-malate or [1,4-14C] succinate. The 14CO2 production rate from [14C]-pyruvate in the 
presence of malate and ADP, gives an indication of the overall function of the mitochondrial 
energy generating system, from PDHC to transporters. If malate is replaced by carnitine the 
PDHC function is mainly measured. A lower 14CO2 production rate in the presence of malate 
than in the presence of carnitine points to a defect in the RC.
To assess the coupling state of mitochondria, the ADP stimulation is measured by dividing the 
14CO2 production rate from [14C]-pyruvate in the presence of malate plus ADP by the 14CO2 
production rate from [14C]-pyruvate in the presence of malate without ADP. To discriminate 
between defects of PDHC, CAC or RC and defects of complex V or ANT, 14CO2 production 
rate from [1-14C]-pyruvate plus malate without ADP is measured in the presence of CCCP (m- 
chlorocarbonyl cyanide phenylhydrazine), a strong uncoupler. If the 14CO2 production rate 
substantially increases as compared to [1-14C]-pyruvate plus malate and ADP, this strongly 
suggests a defect of complex V or ANT.
The overall activity: PDHC, CAC, RC, complex V and ANT, is also assessed by measuring 
the 14CO2 production rate from [U-14C]-malate in the presence of pyruvate and malonate 
(complex II inhibitor). If acetylcarnitine is added instead of pyruvate, and the 14CO2 
production rate significantly increases, this points to a PDHC defect. The 14CO2 production 
rate from [U-14C]-malate in the presence of acetylcarnitine and malonate is usually twice as 
much as in the presence of arsenite (an inhibitor of the E3 subunit, common to PDHC and 2- 
ketoglutaric acid dehydrogenase). If it is about equal, a 2-ketoglutaric acid dehydrogenase 
deficiency is likely. The 14CO2 production from succinate plus acetylcarnitine gives 
information about the functioning of CAC from succinate to malate, and the RC, complex V 
and ANT.
ATP plus CrP production rate from pyruvate plus malate in the presence of ADP is also 
measured. Normally when 1 mol pyruvate is fully oxidized, 15 mol of ATP are maximally 
formed. The ratio of ATP plus CrP production rate from pyruvate plus malate in the presence 
of ADP and the oxidation rate of [1-14C]-pyruvate in the presence of malate and ADP reflects 
the efficiency of the ATP generating system.
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Clinical differences in patients with mitochondriocytopathies due 
to nuclear versus mitochondrial DNA mutations
M.E. Rubio-Gozalbo, K.P. Dijkman, L.P. van den Heuvel, R.C.A. Sengers, U. Wendel, 
J.A.M. Smeitink
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Abstract
Defects in oxidative phosphorylation (OXPHOS) are genetically unique because the different 
components, respiratory chain enzyme complexes (I, III, and IV) and complex V, are encoded 
by nuclear and mitochondrial genome. The objective of the study was to assess whether there 
are clinical differences in patients suffering from OXPHOS defects caused by nuclear or 
mitochondrial DNA (mtDNA) mutations.
We studied 16 families with > 2 siblings with a genetically established OXPHOS deficiency,
4 due to a nuclear gene mutation and 12 due to a mtDNA mutation. Siblings with a nuclear 
gene mutation showed very similar clinical pictures that became manifest in the first years 
(ranging from first months to early childhood). There was a severe progressive course; 7 of 
the 8 children died in their first decade. Conversely, siblings with a mtDNA mutation had 
clinical pictures that varied from almost alike to very distinct. They became symptomatic at an 
older age (ranging from childhood to adulthood), with the exception of defects associated with 
Leigh or Leigh-like phenotype. The clinical course was more gradual and relatively less 
severe; 4 of the 26 patients died. There are differences in age at onset, severity of clinical 
course, outcome, and intrafamilial variability in patients affected of an OXPHOS defect due to 
nuclear or mtDNA mutations. Patients with nuclear mutations become symptomatic at a 
young age, and have a severe clinical course. Patients with mtDNA mutations show a wider 
clinical spectrum of age at onset and severity.
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Introduction
Mitochondriocytopathies are most frequently due to a defect in the oxidative phosphorylation 
(OXPHOS) system. This system consists of four multi-subunit enzyme complexes (I-IV) of 
the mitochondrial respiratory chain (RC) and ATP synthase (complex V). The RC, located in 
the inner mitochondrial membrane, transfers electrons from NADH and FADH2 to the final 
electron acceptor oxygen and at the same time translocates protons from the mitochondrial 
matrix across the inner mitochondrial membrane to the intermembrane space. Subsequently, 
protons are returned to the mitochondrial matrix by complex V, resulting in the generation of 
adenosine triphosphate (ATP), the main carrier of chemical energy.
ATP synthesis occurs in all cells except erythrocytes, and at least in theory, any organ or tissue 
can be affected whenever energy generation is disturbed. There is indeed an ever increasing 
variety of documented symptoms in OXPHOS deficiencies [40]. Skeletal muscle, central 
nervous system (CNS) and heart muscle are frequently involved. Age of onset ranges from 
neonatal to adulthood. Clinical course varies from complete recovery [23] to rapid 
deterioration and death in the neonatal period [22]. Biochemically patients with OXPHOS 
disorders often present with high lactate concentrations in body fluids, but normal lactate body 
fluid concentrations do not exclude an OXPHOS defect [35].
Genetically, the respiratory chain is unique, as it is encoded by the nuclear and mitochondrial 
genome. Human mitochondrial DNA (mtDNA), maternally transmitted, encodes 13 structural 
subunits of the RC enzyme complexes I, III, IV, and complex V [1]. In addition to structural 
genes, mtDNA also codes for 22 transfer RNAs and two ribosomal RNAs. The knowledge of 
human nuclear genes encoding RC enzyme complex subunits has increased exponentially 
over the last years [2,16,30,33]. Along with this, the first nuclear mutations causing RC 
defects have been elucidated [4,15,27,33,35,37,41]. OXPHOS defects caused by nuclear 
mutations usually show a recessive mode of inheritance whereas OXPHOS defects caused by 
mtDNA mutations are maternally transmitted. The purpose of this study was to assess whether 
there are clinical differences between OXPHOS defects originating from nuclear versus 
mitochondrial DNA mutations. Such differences could be of importance for parental 
counseling and diagnostic molecular genetic studies in patients affected by an OXPHOS 
deficiency.
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Materials and methods
This study included 16 families, 4 from our center and 12 described in the literature with at 
least two offspring affected by a genetically established OXPHOS defect. The study was 
performed in families with at least two affected offspring to be able to assess the intrafamilial 
variability in both groups. The patients described in the literature were acquired by a Medline 
search from 1966 until January 1999. To be included in the study, the genetic defect had to be 
established in at least two siblings and clinical features, histology of muscle tissue and/or RC 
enzyme complex activities and/or complex V activity studies had to be reported.
The siblings were divided into two groups, group I: siblings with a mutation in the nuclear 
DNA; group II: siblings with a mutation in the mtDNA.
Age at onset, presenting symptoms, clinical course, CNS involvement (assessed by CT-scan 
or MRI of the brain), histology of skeletal muscle tissue (light microscopy, histochemical and 
enzyme-histochemical stainings), RC enzyme complex activities and/ or complex V activity 
(expressed as percentage of the lowest control value), and genetic studies were compared in 
the affected siblings of each family, in both groups.
Results
Four families with two siblings suffering from an OXPHOS defect due to a mutation in the 
nuclear genome (group I), and twelve families with > 2 siblings (10 families with 2, and 2 
families with 3 siblings) suffering from an OXPHOS defect due to a mutation in the 
mitochondrial genome (group II) were included.
The clinical characteristics such as gender, age at onset, presenting symptoms and clinical 
course in the affected siblings of each family are listed in Table 1a (group I) and Table 1b 
(group II). The results of imaging of the brain (CT/MR), histology of the skeletal muscle, 
enzyme activity measurements and genetic studies in the affected siblings of each family are 
listed in Table 2a (group I) and Table 2b (group II).
Group 1. Siblings with a mutation in the nuclear DNA
Consanguinity was absent in 3 families (nos.1,2,3), and unknown in the other (no.4). Age at 
onset, presenting symptoms and clinical courses of both siblings were identical or very similar 
in all 4 families. All affected children became symptomatic in early childhood and at least 
seven of the 8 children died early in life. All of them suffered from a severe encephalopathy, 4 
of them suffered from Leigh syndrome (see Table 1a). Lactate in blood was either consistently
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elevated or normal in the siblings of group I (data not shown). Imaging of the brain showed 
very similar abnormalities in both siblings in 3 families; in one family only one child was 
investigated. Histological examination of skeletal muscle was very similar in both siblings in 
the families of this group. Two of the three histologically studied sibling-pairs showed no 
distinct abnormalities. The enzyme complex deficiency in skeletal muscle or fibroblasts was 
the same for all sibling-pairs, with slight differences in the measured residual enzyme activity 
(see Table 2a).
Group II. Siblings with a mutation in the mtDNA
Consanguinity was absent in 5 families, and unknown in the other 7. Age at onset in this 
group ranged from childhood to adulthood in all siblings with the exception of the siblings 
suffering from a mutation in the ATPase gene (family no. 14) and one of the siblings suffering 
from tRNATrp (T5537i) who had already become symptomatic in the first year of life. These 
three children had a Leigh or Leigh-like phenotype. Age at onset between affected siblings 
differed by more than 3 years in 8 families.
The presenting symptoms of the affected siblings were similar in 6 families, but variable in 
the other 6 . The clinical course was similar in 3 families but showed differences in the other 9. 
Only four patients in this group had a fatal outcome, one died aged 17 months, 2 siblings died 
in the sixth decade, and one died in the second decade (see Table 1b).
Lactate in blood was either consistently elevated or normal in the siblings of group II, except 
in one family (data not shown).
In 5 families data on imaging of the brain for two of more affected siblings were reported, 4 of 
them showed MRI or CT-scan abnormalities. Histological examination of muscle tissue was 
described for two or more of the affected siblings in 6 families. The histological findings were 
strikingly similar in all of them (see Table 2b). In four families muscle enzyme measurements 
were performed in more than one sibling. The siblings in 3 families had the same measured 
enzyme complex deficiency with slight differences in the residual activity. In family no. 8, 
siblings nos. 1 and 2 had a complex I deficiency with variable residual activity, whereas 
sibling no. 3 had a normal complex I activity. This was also the less severe affected sibling 
(see Table 2b).
The mother was affected in 5 families, asymptomatic in 5 families, and no data were available 
in the remaining 2 families.
Table 1a. Siblings with a mutation in the nuclear DNA: gender, age onset, presenting symptoms and clinical course
fam. pat. sex age
onset
presenting
symptoms
clinical course ref.
1 1 
2
m
m
5 mo. 
7 mo.
vomiting, generalized hypotonia, 
developmental arrest 
vomiting, generalized hypotonia, 
developmental arrest
progressive neurological deterioration, 
death at 14 mo. due to pneumonia 
progressive neurological deterioration, 
death at 14 mo. due to pneumonia
c,[22,27]
2 1 
2
m
m
26 mo. 
3 yr.
feeding problems, dysarthria,
ataxia after infection
walking difficulties after infection
generalized hypotonia, nystagmus, bilateral 
optic atrophy, death at ca. 4 yr. due to RI 
progressive left-sided hemiparesis, dysarthria, 
abnormal breathing,death at 5 yr. due to RI
c,[35,39]
3 1 
2
f
f
10 mo. 
10 mo.
loss of interest in surroundings, 
difficulty moving left-side 
regression
12 mo. rigidity, bilateral pyramidal tract signs, 
blindness, vegetative state, died at 19 mo.
13 mo. rigidity, bilateral pyramidal tract signs, 
blindness
[3,4]
4 1 f early
infancy
generalized hypotonia rapidly progressive encephalopathy, 
psychomotor regression, death from RI
[17,33]
2 f early
infancy
generalized hypotonia rapidly progressive encephalopathy, 
psychomotor regression, death from RI
Abbreviations: fam.: family number; ref.: reference number; c: our center; pat.: patient; RI: respiratory insufficiency
Table 1b. Siblings with a mutation in the mtDNA: gender, age onset, presenting symptoms and clinical course
fam. pat. sex age onset presenting symptoms clinical course ref.
5 1 m childhood anemia, fatigue progressive muscle weakness and PI from late second decade [5]
2 m childhood anemia requiring transfusions progressive muscle weakness and PI from late second decade
6 1 m 24 yr. bilateral blepharoptosis 39 yr. dysarthria, dysphagia, ataxia, muscle weakness and atrophy, [18]
ophthalmoplegia, gradually progressive, died at 56 yr. of pneumonia
2 f 35 yr. ataxia, muscle weakness lower 39 yr. bilateral blepharoptosis, muscle weakness, ophthalmoplegia,
extremities gradually progressive, died of pneumonia at age 50 yr.
7 1 f 17 yr. backache slowly progressive, at 26 yr. pain in arms and legs and fatigue c
2 f 14 yr. fatigue, pancreatitis progressive renal failure, and chronic fatigue at 25 yr.
8 1 f 18 yr. severe seizures drug-resistent seizures, bradyfrenia, dysarthria, ataxia [8]
2 f 7 yr. focal epileptic seizure 71/2 yr. vomiting, seizures, visual and sensory disturbances, hypotonia,
areflexia, ataxia, hepatomegaly, died at 14 yr. from cardiomyopathy
3 f 15 yr. sensorineural hearing loss stationary
9 1 m childhood attention deficit , poor growth seizures, stroke-like episodes, myopathy, cardiac abnormalities, dementia [11]
2 f childhood learning problems, poor growth seizures, myopathy, cardiac abnormalities, pancreatitis
10 1 f 17 yr. myoclonic epileptic seizures 26 yr. moderate mental retardation with lower limb weakness, deafness [7]
2 f 15 yr. myoclonic epileptic seizures 20 yr. moderate mental retardation, ataxia
11 1 f 37 yr. muscular involvement mild myoclonus, mild peripheral neuropathy [21]
2 m 27 yr. muscular involvement moderate myoclonus, seizures, ataxia, deafness, peripheral neuropathy
12 1 m 26 yr. involuntary muscle jerks progressive course, at 46 yr. slurred speech, generalized muscle weakness [12]
2 f 17 yr. involuntary muscle jerks progressive course, at 33 yr. generalized tonic-clonic seizures
13 1 m 13 yr. muscle weakness, tremor stationary at 15 yr. [28]
2 f 8 yr. cerebellar ataxia, epilepsy stationary at 10 yr.
14 1 m 4 mo. developmental delay oculomotor dyspraxia, hypotonia, dystonia, at 6 yr. walks with support [32]
2 m 1st yr. motor incoordination at 8 yr. altered mental state during infection, thereafter regression, at 11 yr.
learning disabled, poor coordination, motor tics
15 1 m 3 yr. spastic paraparesis during fever partial recovery, additional deteriorations with intercurrent illnesses, at 24 yr. c, [9,38]
tetraparesis, ataxia, dysarthria, moderately retarded
2 f 9 yr. walking difficulties during infection at 13 yr. paraparesis and difficult micturition following rubella inoculation,
pyramidal and cerebellar signs, wheelchair, at 23 yr. moderately retarded
3 f 4 yr. fatigue, impairment fine movement slowly progressive, at 20 yr. mentally normal, outdoors wheelchair,
16 1 m 4 yr. difficulty seeing objects 6 yr. impaired visual acuity, at 8 yr. optic atrophy, ataxia [25]
2 m 10 mo. regression 14 mo. blindness, died at 17 mo. of cardiorespiratory arrest
Abbreviations: fam.: family number; ref.: reference number; c: our center; pat.: patient, RI: respiratory insufficiency, PI: pancreatic insufficiency
Table 2a. Siblings with a mutation in nuclear DNA: imaging of the brain, histology, enzyme complex deficiency and genetics
fam. pat. imaging brain 
(CT/MR)
histological
abnormalities
enzyme
deficiency
genetics ref.
1 1 moderately dilated ventricles no *c I: 55% R59x/T423M mutation in NDUFV1 subunit c I c,[22,27]
2 nd no *c I: 70% R59x/T423M mutation in NDUFV1 subunit c I
2 1 hyperintensities: putamina no *c I: 26% G364A/G364A mutation in NDUFS7 subunit c I c,[35,39]
nucleus ruber, medulla oblongata
2 hyperintensities: globus pallidus, no *c I: 17% G364A/G364A mutation in NDUFS7 subunit c I
caudatus right
3 1 white matter hypodensity mainly nd #SCCR: 58% A554T/A554T mutation in Fp subunit c II [3,4]
frontal lobes and occipital horns
2 white matter hypodensity mainly nd #SCCR: 67% A554T/A554T mutation in Fp subunit c II
frontal lobes and occipital areas
4 1 symmetric lesions scattered from severely decreased *c IV: 5-10% 516+2T? G/550delAG SURF-1 gene [17,33]
basal ganglia to brain stem COX stain
2 symmetric lesions scattered from severely decreased *c IV: 5-10% 516+2T? G/550delAG SURF-1 gene
basal ganglia to brain stem COX stain
Abbreviations: fam.: family number; ref: reference number; c: our center; pat.: patient; nd: no data; 
SCCR: succinate cytochrome c oxidoreductase; * muscle; # fibroblasts; ** blood
Table 2b.Siblings with a mutation in the mtDNA: imaging of the brain, histology, enzyme complex deficiency and genetics
fam. pat. imaging brain (CT/MR) histological abnormalities enzyme deficiency genetics ref.
5 1 nd RRF, scattered negative COX stain *c I: 9%, c III: 20%, c IV: 13% mtDNA deletions, *29% deleted [5]
2 nd RRF, scattered negative COX stain *c I: 10%, c III: 20%, c IV: 14% mtDNA deletions, *22% deleted
6 1 cortical/cerebellar atrophy nd nd mtDNA deletions, *60.7% deleted [18]
2 nd nd nd mtDNA deletions, *55.8% deleted
7 1 nd nd nd MELAS A3243G, **23% mutated c
2 nd nd *c I: 11% MELAS A3243G, *40% mutated
8 1 low signal intensity fronto-temporal non-specific findings *c I: 57% MELAS A3243G, *90% mutated [8]
2 hypodensities: white/gray matter nd *c I: 21% MELAS A3243G, *60% mutated
3 nd nd *c I: normal MELAS A3243G, *50% mutated
9 1 left-sided occipital stroke RRF nd MELAS A3243G, #47% mutated [11]
2 nd nd nd MELAS A3243G, **36% mutated
10 1 nd RRF, decreased COX stain, *c I, c III: nm; c IV: low MERRF, A8344G, *80% mutated [7]
arterioles SDH-reactive/COX-negative
2 nd RRF, decreased COX stain, *c I: low, c I+III: low, c IV: low MERRF, A8344G, *93% mutated
arterioles SDH-reactive/COX-negative
11 1 nd RRF, SDH-stain increased *c I: 9%, c III: n.d., c IV: 1% MERRF, A8344G, **90% mutated [21]
COX-stain: mosaic pattern
2 nd RRF, SDH-stain increased *c I: 15%, c III: 35%, c IV: 11% MERRF, A8344G, **86% mutated
COX-stain: mosaic pattern
12 1 normal RRF nd MERRF A8344G [12]
2 normal RRF, abnormal mitochondria nd MERRF A8344G
13 1 nd RRF, COX-negative fibers nd MERRF A8344G, *84% mutated [28]
2 nd RRF, COX-negative fibers nd MERRF A8344G, *84% mutated
14 1 signal increase putamina/periaqueductal no #ATPase: normal T9176C ATPase 6 gene [32]
2 bilateral signal increase striatal nd nd T9176C ATPase 6 gene
15 1 putamen and cerebellar signal increase atrophic angulated fibers *SCC and c IV: normal **T8993C ATPase 6 gene c, [9,38]
cerebellar and brainstem atrophy
2 brainstem signal increase and atrophy nd nd **T8993C ATPase 6 gene
3 brainstem atrophy, cerebellar signal nd nd **T8993C ATPase 6 gene
increase and atrophy
16 1 bilateral hyperintensities periatrial white RRF, few COX-negative fibers and nd 5537 (T5537i), **92% [25]
matter and splenium corpus callosum abnormal mitochondrial proliferation
2 deep white matter abnormalities RRF, few COX-negative fibers and *c IV: 14%, cI in brain: 30-40% 5537 (T5537i), *95%
abnormal mitochondrial proliferation
Abbreviations: fam.: family number; ref: reference number; c: our center; pat.: patient; nd: no data; SCCR: succinate cytochrome c oxidoreductase; * muscle; # fibroblasts; ** blood
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Discussion
The patients with an OXPHOS defect due to a nuclear mutation became symptomatic in 
infancy or early childhood and showed a rapidly progressive, severe clinical phenotype. There 
was little variability between siblings.
In agreement with these findings, all other reported patients with nuclear mutations 
documented until now, became symptomatic at an early age and had a severe clinical course 
and poor outcome. Van den Heuvel et al., and Loeffen et al. [15,37] described two non-related 
patients with severe encephalopathy, (one of them with Leigh syndrome) associated with a 
complex I deficiency due to nuclear gene mutations. Both became symptomatic early in life, 
and had a rapidly progressive fatal course. Tiranti et al. [34] reported another 18 unrelated 
patients with Leigh syndrome associated with a complex IV deficiency due to mutations in the 
complex IV assembly gene SURF-1. All these patients became symptomatic before the second 
year of life and sixteen died in the first decade. Papadopoulou et al. [19] described 3 unrelated 
infants with a fatal cardioencephalomyopathy and complex IV deficiency due to mutations in 
the SCO2 gene, another complex IV assembly gene.
Most patients with an OXPHOS defect due to a mtDNA mutation became symptomatic at an 
older age, except three patients with a Leigh phenotype who presented in the first year of life. 
Age of onset and clinical picture between siblings was more heterogeneous. The clinical 
course was less rapid and the outcome relatively less severe than in the group with a nuclear 
gene defect. The involvement of other organs than the CNS, e.g. pancreas and kidney, 
dominated the clinical picture in several patients.
Brain imaging, as far as known, in the patients in both groups, showed a wide spectrum of 
abnormalities: cerebellar and cortical atrophy, basal ganglia and brainstem lesions as well as 
white matter abnormalities.
Histology abnormalities in the patients with a mutation in the nuclear DNA group were less 
frequently encountered and RRF were not present in any of the siblings in this group. This 
maybe due to the younger age at diagnosis and/or so far unknown pathophysiological 
mechanisms.
Many mtDNA related diseases are known, over 50 pathogenic point mutations have been 
documented [26] in association with a wide spectrum of clinical presentations, age of onset, 
disease progression and outcome [10,13]. Table 3 lists the common symptoms, age at onset, 
and clinical course and outcome of the most common clinical syndromes associated with 
mtDNA mutations. Most patients become symptomatic in childhood and adulthood, and show
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gradual disease progression, with the exception particularly of patients with MILS 
(maternally-inherited Leigh syndrome) and Pearson's syndrome who usually present in 
infancy and show rapidly progressive course with fatal outcome. Patients with KSS (Kearns- 
Sayres syndrome) also have a fatal outcome, death usually occurs before the third decade [14]. 
The phenotypic variation seen in siblings affected of a mtDNA mutation can be at least partly 
explained by heteroplasmy. In the formation of the zygote, mtDNA is contributed exclusively 
by the oocyte. A mutation affecting some mtDNA in the ovum or in the zygote may be passed 
on randomly to subsequent generations of cells, some of which receive few or no mutant 
genomes (wild-type homoplasmy), others receive predominantly or exclusively mutant 
genomes (mutant homoplasmy), and others receive a mixed population of mutant and wild­
type mtDNAs (heteroplasmy). Because there are multiple copies of mtDNA in each cell, the 
phenotypic expression of a mtDNA mutation depends on the relative proportions of mutant 
and wild-type genomes. The critical number of mutant mtDNAs needed to cause cell 
dysfunction varies from tissue to tissue depending on the vulnerability of a given tissue to 
impairments of oxidative metabolism. In family 8 with MELAS mutation A3243G, for 
example, of the two more affected siblings, the sister with lower proportion of mutated 
mtDNA in muscle was neurologically more severely affected and also suffered from 
cardiomyopathy. The percentage of mutated mtDNA in the CNS might be higher in this 
patient and so at least partly explain the difference in severity. The other sibling had only 
sensorineural hearing loss, the percentage of mutated mtDNA in muscle was 50%. An 
asymptomatic sibling had 0% mutated mtDNA in muscle. The asymptomatic mother had 35 
% of mutated mtDNA in muscle. In addition to heteroplasmy, probably other genetic or 
environmental mechanisms [36] are involved in defining the range of clinical phenotypes 
associated with the aberrant mitochondrial genome.
Family history can be very helpful in mitochondrial disorders. Affected maternal relatives are 
frequently encountered in mtDNA disorders. This is not the case in autosomal-recessive 
nuclear DNA disorders. Children affected of an OXPHOS defect have in most cases a 
pedigree indicating autosomal-recessive inheritance and family history does not reveal 
patients with similar phenotypes in the maternal lineage. Routine screening for common 
mtDNA point mutations and deletions in children at our center reveals abnormalities only in a 
low percentage. This observation is in agreement with Shoffner [29] who reported mutations 
in mtDNA in patients with OXPHOS defects to occur in 30% of the investigated adults and 
only in 4% of the children.
Table 3. Common clinical syndromes associated with mtDNA mutations
Disease common symptoms age onset
neonatal infancy childhood adulthood
clinical course
gradual rapid
fatal
outcome#
mtDNA
mutation
gene
location*
MELAS seizures
stroke-like episodes 
nausea,vomiting
x x x no A3243G* tRNA-Leu
MERFF myoclonus epilepsy 
cerebellar ataxia 
myopathy
x x x no A8344G tRNA-Lys
LHON loss of vision x x x no G3460A
G11778A
T14484C
ND1
ND4
ND6
NARP sensory neuropathy 
ataxia, seizures, dementia 
retinitis pigmentosa
x x x no T8993G ATPase 6
MILS Leigh syndrome x x yes T8993G ATPase 6
KSS PEO
retinitis pigmentosa 
heart block 
cerebellar syndrome
x x x yes single large deletion
PEO PEO
proximal limb weakness
x x x no single large deletion
Pearson's syndrome sideroblastic anemia 
exocrine pancreas 
dysfunction
x x yes single large deletion
Abbreviations: MELAS=mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes; MERRF=myoclonic epilepsy, ragged red fibres; 
LHON=Leber's hereditary optic neuropathy; NARP=neuropathy, ataxia, retinitis pigmentosa; MILS=maternally-inhereted Leigh syndrome; 
KSS=Kearns-Sayres syndrome; PEO=progressive external ophthalmoplegia; *most common mutation #likely
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Nuclear mutations in the present study were identified in four of the 11 patients with Leigh 
syndrome; they showed a rapidly progressive encephalopathy of early onset and fatal outcome. 
Patients with Leigh syndrome caused by mtDNA mutations in our study and previous reports 
[6,20,24,31] frequently show a milder and more variable disease course.
The results of this study suggest that patients with nuclear mutations become symptomatic at a 
young age and have a severe clinical course, whilst patients with mtDNA mutations show 
greater variability in the clinical spectrum and severity as well as age of onset.
Due to the limited number of patients with an established nuclear mutation at present, there 
might be an ascertainment bias in our study. Severely affected children are more likely to be 
diagnosed. There are many mildly affected patients with an OXPHOS defect in which the site 
of the mutation is unknown. The differences found are between the currently recognized 
nuclear and currently recognized mtDNA mutations causing OXPHOS defects. It remains to 
be seen whether OXPHOS defects due to nuclear mutations also have a wider spectrum of 
severity.
In recognized nuclear mutations, disease becomes manifest at an early age and shows little 
variability between siblings.
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Abstract
We report a child with spinal muscular atrophy (SMA)-like picture, cardiomyopathy and 
cytochrome c oxidase (COX) deficiency. EMG and muscle biopsy showed findings typical of 
SMA. However, COX staining of the muscle was negative. DNA analysis did not detect 
deletions in the survival motor neuron (SMN) gene. Lactate and lactate/pyruvate ratio were 
increased in blood and CSF. COX activity was decreased in muscle and fibroblasts. Western 
blotting showed reduced contents for all COX subunits. Patients with clinical features 
resembling SMA, but with intact SMN gene, should be screened for a mitochondrial disorder.
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Introduction
Mitochondrial respiratory chain (RC) deficiencies have heterogeneous clinical presentations. 
The nervous system and skeletal and heart muscle are frequently affected. Cytochrome c 
oxidase (COX), a RC enzyme, catalyzes the transfer of reducing equivalents from cytochrome 
c to molecular oxygen. Its deficiency is associated with two major phenotypes: 1) the 
myopathic form and 2) the systemic form, which affects many organs, mostly the central 
nervous system [5]. However, isolated COX deficiency with clinical symptoms and 
electrophysiological and histopathological findings resembling spinal muscular atrophy 
(SMA) has never been reported. In 1996 Pons et al. [9] reported a case of mitochondrial 
myopathy simulating SMA type III, with decreased COX and succinate: cytochrome c 
reductase activities in combination with mitochondrial DNA depletion. Recently Comi et al. 
[3] reported an adult patient with COX deficiency and the clinical phenotype of predominantly 
upper motor neuron degeneration due to a microdeletion in subunit I, one of the 
mitochondrially encoded subunits of COX.
SMA is an autosomal recessive disorder characterized by degeneration of the anterior horn 
cells of the spinal cord, resulting in progressive paralysis with muscular atrophy. Three 
clinical types have been described depending on the age of onset and the severity of the 
symptoms. The biochemical defect in SMA is unknown. Two genes mapped to chromosome 
5q13 have been associated with SMA: the survival motor neuron (SMN) gene and the 
neuronal apoptosis inhibitor protein (NAIP) gene. Both genes are frequently deleted in SMA 
patients. Homozygous deletions of exons 7 and 8 of SMN are found in approximately 95% of 
patients. A few point mutations and microdeletions have also been reported. Deletions in the 
NAIP gene are found almost exclusively in patients who also show deletion of the SMN gene 
[2].
Here we report a child with a SMA-like picture, hypertrophic cardiomyopathy, and COX 
deficiency.
Case history and results
This boy, the first child of non-consanguineous parents, was born after an uneventful full term 
pregnancy by cesarean section due to fetal distress. Apgar scores were normal. Birth weight, 
length and head circumference were at the 10th percentile. At four weeks of age hypotonia 
and inspiratory stridor were noted, the inspiratory stridor increasing in the following two
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weeks. A neuromuscular disorder was suspected and at four months of age he was referred to 
our hospital.
Physical examination revealed an infant with severe inspiratory stridor. Weight, length and 
head circumference were at the 10th percentile. There was marked hypotonia, severe limb and 
axial weakness, frog posture, and poor head control. Facial movements were normal. Deep 
tendon reflexes were markedly depressed; ophthalmological examination was normal; the 
electroencephalogram and CT-scan of the brain were normal.
Routine laboratory investigations (hemoglobin, hematocrit, white cell count, differential white 
cell count, platelet count, plasma sodium, potassium, chloride, calcium, albumin, glucose, 
creatine kinase activity, ammonia, liver and kidney function) were normal.
Electromyography (EMG) revealed normal motor nerve conduction velocity although the 
amplitude of the compound muscle action potential was very low. Needle EMG showed a 
reduced insertional activity, consistent with fatty degeneration of large parts of the muscle. 
Fibrillation potentials and positive sharp waves were seen in abundance although with patchy 
distribution. There was also a patchy distribution of rare motor unit potentials. At maximal 
voluntary effort there was neither a single unit pattern nor any motor unit potentials.
A needle biopsy specimen of skeletal muscle for light microscopy, histochemical and enzyme- 
histochemical staining showed a clear bimodal fiber diameter distribution in some fascicles 
and there were different mean fiber sizes in the other fascicles. The biopsy specimen was 
dominated by type I fibers (80%). The hypertrophic fibers belonged exclusively to type I; 
atrophic fibers belonged to both type I and type II. There was a slight increase in fat cells. 
Increase of collagen was found between fascicles but not between muscle fibers. There were 
neither internal nuclei in muscle fibers nor atrophic fibers with pyknotic nuclei. Succinate 
dehydrogenase (SDH) staining was normal and ragged red fibers were not observed. However, 
the total biopsy was COX negative except for intrafusal fibers of some spindles and the 
smooth muscle fibers of arterioles (figure 1). Some small motor nerve bundles showed a 
decreased presence of myelinated nerves. Ultrastructural examination showed redundant basal 
membrane loops suggestive of volume decrease of muscle fibers (normally present in type I 
SMA), but no evident mitochondrial abnormalities.
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Figure 1. Quadriceps muscle
Cytochrome oxidase stain, original amplification x 250 before 24.1% reduction. (A) There is 
no cytochrome oxidase activity in the small and large muscle fibers. (B) The only positive 
fibers represent intrafusal spindle fibers. Bar = 50 |im.
Deletion screening of exons 7 and 8 of the SMN gene as described elsewhere [10] revealed no 
abnormalities. EMG and histopathological findings were consistent with SMA. However, 
because the COX staining of the muscle specimen was negative and given the fact that no 
deletions of exons 7 and 8 of the SMN gene had been found, a mitochondrial disorder was 
suspected.
Echocardiography revealed an asymptomatic hypertrophic cardiomyopathy. Lactic acid 
concentration was repeatedly increased in blood and CSF (3.0 and 4.9 mmol/L, respectively; 
normal < 2.1 mmol/L) with an increased lactate to pyruvate ratio in blood and CSF (21 and 24 
respectively; normal 12-15). Amino acid analysis revealed an alanine concentration of 596 
^mol/L in blood (normal 150-600 ^mol/L), 90 ^mol/L in CSF (normal 17-41 ^mol/L) and 
204 ^mol/mmol creatinine in urine (normal 72-206 ^mol/mmol creatinine), and no other 
abnormalities. Organic acid analysis in urine revealed normal concentrations of organic acids 
including lactic acid.
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Mitochondrial RC enzyme activities, measured in frozen skeletal muscle as previously 
described [6], showed a COX activity of 25% of the lowest control value, the other measured 
enzyme activities were normal. Measurement of mitochondrial RC enzyme activities in 
cultured skin fibroblasts as described elsewhere [1] revealed a diminished COX activity of 
58% of the lowest control value. Succinate: cytochrome c oxidoreductase activity was 
completely normal in skeletal muscle but slightly decreased in fibroblasts (Table ). 
One-dimensional western blotting experiments using a polyclonal antibody against human 
COX complex (kindly provided by Kadenbach) revealed severely reduced signals for all 
detected subunits (II,III,IV,Vab,VIa,VIbc,VIIa,VIIbc), when equal amounts of samples (on 
protein level) were loaded (figure. 2).
DNA analysis in skeletal muscle as previously described [4] revealed no deletion in 
mitochondrial DNA. None of the tested pathogenic mutations: A3243G (MELAS), T3271C 
(MELAS), A4317G (MELAS), A8344G (MERRF), were detected. Sequencing both strands 
of all 3 mitochondrial COX genes revealed only a homoplasmic A ^  T change at nucleotide 
7930.
The inspiratory stridor became so severe that a tracheostomy was performed. He died at the 
age of five months from progressive respiratory failure due to a respiratory infection. Autopsy 
was refused by his parents.
1 2 3 4 5 6 7
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Figure 2. Western blot analysis of muscle mitochondria
Subunits of the cytochrome c oxidase complex run on a 16.5% total, 3% cross-linking, tricine 
sodium dodecyl sulfate-polyacrylamide gel and immunostained with a rabbit polyclonal 
antibody against human COX complex.
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Lanes 1, 2, 4, 5, 6 = control muscles; lane 3 = index patient; lane 7 = molecular weight 
marker.
Discussion
This patient presented with clinical, morphological and neurophysiological features of SMA. 
However, the atypical features such as inspiratory stridor, markedly depressed instead of 
absent deep tendon reflexes, and the fact that no deletions in exons 7 and 8 of the SMN gene 
were found, cast doubt on this diagnosis. The negative COX staining of the muscle specimen 
was the first clue suggesting a mitochondriopathy. Further evaluation revealed a hypertrophic 
non-obstructive cardiomyopathy, and an increased lactic acid concentration and lactate to 
pyruvate ratio in blood and CSF, suggesting a mitochondrial disorder. This was confirmed by 
biochemical investigations in skeletal muscle and cultured skin fibroblasts which showed a 
COX deficiency.
The co-existence of SMA and congenital heart defects is well documented [8]. This patient 
however suffered from hypertrophic cardiomyopathy as is often observed in mitochondrial 
disease.
SMA features in combination with a mitochondrial disorder have to our knowledge only been 
described once before, by Pons et al. [9] The authors report on a case of a mitochondrial 
myopathy simulating SMA type III with a progressive decrease in COX and succinate: 
cytochrome c reductase activities measured in muscle homogenate associated with reduction 
of the mitochondrial DNA content shown immunochemically. Mitochondrial DNA depletion 
is a quantitative abnormality of mitochondrial DNA. Biochemically, patients show a 
deficiency of COX and other enzyme complexes containing mitochondrial DNA encoded 
subunits. We found an isolated COX deficiency in skeletal muscle and in cultured skin 
fibroblasts which makes a depletion of mitochondrial DNA very unlikely. Moreover, low 
levels of mitochondrial DNA have been found in muscle from patients with different 
myopathies, suggesting that it might be a relatively non-specific response of muscle to various 
pathological insults.
Due to denervation and disuse of skeletal muscle oxidative phosphorylation capacity may be 
altered. Mostly, combined deficiencies, (i.e. deficiency of more than one enzym complex) are 
observed. In the described patient we found an isolated COX deficiency in skeletal muscle. 
The fact that the COX activity was also diminished in cultured skin fibroblasts suggests that 
the diminished COX activity in muscle was not secondary to the denervation and supports a 
primary nature of the COX deficiency. Furthermore, the heart was also involved, pointing to
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multi-organ COX deficiency. Western blotting showed pronounced decreased signals for all 
detected COX subunits. Generally, decreased levels of most subunits are observed in COX 
deficiencies. Likely, the diminished availability or altered structure of a primarily affected 
subunit results in an inadequate assembly of the COX complex or a faster degradation. Comi 
et al [3] found a 5 bp deletion in COX subunit I in their patient with COX deficiency and 
upper motor neuron disease. They used monoclonal antibodies against COX subunits I to IV 
and found a pronounced decrease of COX I-specific signal but also a milder decrease of COX 
III and IV immunoreactivity.
The 5 bp deletion found by Comi et al [3] was excluded in our patient. The 7930 A ^  T 
exchange is most probably only a benign polymorphism, since it does not cause an exchange 
of amino acid. The medical history of the maternal lineage revealed no oligosymptomatic 
relatives as is commonly found in families with mtDNA mutations. In this patient there was 
no evidence of mitochondrial DNA disease.
The variability of neurological manifestations in mitochondrial disease is difficult to 
understand. Kaido et al. [7] reported a case of focal COX deficiency in the brain and dorsal 
root ganglia probably due to a point mutation in mitochondrial tRNAIle (nt 4269). COX 
deficiency of the nervous system manifesting as SMA could be due to focal deficiency in the 
lower motor neurons. However, this has not been proven since neither morphological nor 
biochemical studies have been performed in motor neurons.
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Abstract
The purpose of this study was the non-invasive quantitative determination by proton MR 
Spectroscopy (1H MRS) of alterations in cerebral metabolism in a 19-month-old male infant 
with severe global developmental delay caused by a Pyruvate Dehydrogenase Complex 
(PDHC) deficiency due to a mutation at the thiamine binding site. To assess the effect of 
thiamine supplementation two investigations were performed at different CSF thiamine 
concentrations. 1H MR spectra were collected at different echo times (20-270 ms) from a 
voxel located in the striatum; spectroscopic imaging was done on a larger region including 
occipital white matter. The tissue levels of N-acetylaspartate and choline were in the normal 
range, while creatine appeared elevated. Abnormally high lactate and alanine signals were 
observed both in and outside the striatum; the levels of these metabolites were higher during 
the second measurement at a lower thiamine concentration. Abnormal cerebral levels of 
alanine have only been described once before in PDHC deficiency. The 1H MRS profile of 
this patient reflects the diversity of brain metabolite alterations in patients with this genetically 
heterogeneous disease.
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Introduction
Pyruvate dehydrogenase complex (PDHC) is an intramitochondrial multi-enzyme complex 
responsible for the oxidative decarboxylation of pyruvate to acetyl-CoA which then enters the 
Krebs cycle. It consists of three catalytic enzymes: E 1 (pyruvate decarboxylase), E2 
(dihydrolipoamide transacetylase), and E3 (dihydrolipoamide dehydrogenase); two regulatory 
enzymes: PDH kinase and PDH phosphate phosphatase, and E3BP (dihydrolipoamide 
dehydrogenase-binding protein), a binding protein required for anchoring E3 to the E2 core of 
the PDHC [8,18]. Thiamine and lipoic acids serve as cofactors. Thiamine-responsive PDHC 
deficiency has been reported [14]. The majority of patients with a deficiency of PDHC activity 
have a mutation in the PDH-E1a gene, located on the X chromosome [2] and encoding for the 
E1a subunit. Biochemically, PDHC deficiency is associated with elevated concentrations of 
lactate, pyruvate and alanine in tissues and body fluids. The lactate to pyruvate ratio is normal 
in contrast to respiratory chain deficiencies. PDHC deficiency has a diverse clinical 
presentation^ 17] reflecting genetic heterogeneity. 1H MRS makes the in vivo monitoring of 
some relevant brain metabolites possible and can be used for the diagnosis and therapy 
follow-up of PDHC deficiency in the brain [3,6,7,9,10,19]. A common finding in these studies 
is an elevation of brain tissue lactate, of which the extent however may vary for different 
brain locations and disease states. Occasionally a relatively lower N-acetylaspartate signal in 
the 1H MR spectra is observed [3,6,19]. In this study quantitative determination of the brain 
levels of metabolites visible by 1H MRS was performed in detail for the basal ganglia in a boy 
with PDHC deficiency.
Case report
This boy was born after 40 weeks gestation; the parents were healthy and non-consangui- 
neous. Pregnancy was complicated by hypertension (no medication required) and premature 
contractions, successfully treated with beta mimetics. Apgar scores were 9 and 10 after 1 and
5 minutes respectively. Birth weight and length were at the 2.3 centile. There were no 
dysmorphic features. In the first months of life developmental delay was noted. At 7 months 
of age there was generalized hypotonia and strabismus.
Blood chemistry showed metabolic acidosis (pH 7.31, pCO2 3.8 kPa, HCO3- 15 mmol/l, BE - 
9.5 mmol/l) and normal creatinine, urea and transaminases. Further metabolic screening 
revealed increased concentrations of lactate and pyruvate in blood and CSF with a normal
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lactate to pyruvate ratio (Table 1). Alanine was elevated in blood, CSF and urine. Organic 
acid urine analysis revealed increased excretion of lactate and pyruvate.
Table 1. Metabolic investigations
Blood CSF Urine
Lactate 10.3
(<2 .1)
10.2
(<2 1 )
17,315
(<200)
Pyruvate 0.644
(<0.08)
1.2
(<0.08)
1,704
(<50)
Lactate/pyruvate ratio 16
(10-20)
8.5
(10-20)
Alanine 812 73 451
(144-500) (14-34) (<50)
values expressed in mmoles/l; values expressed in |imoles/l 
*** values expressed in ^moles/mmole creatinine 
Reference values in parenthesis
Cardiac evaluation (ECG and echocardiography) was normal. Electroencephalography (EEG) 
was normal. Cranial MRI revealed hyperintensity of the globus pallidus. The elevated lactate 
and pyruvate concentrations with a normal lactate to pyruvate ratio in body fluids suggested a 
defect in the PDHC. PDHC activity, measured as described by Sperl et al. [20], was normal in 
skeletal muscle (93 mU/mU citrate synthase; control range 33.6-122) and decreased in 
cultured skin fibroblasts (2.7 nmol/hour-mg protein; control range 21-87). Molecular analysis 
of the PDH-E1a gene as previously described [12] revealed a point mutation in exon 7 
(W214R).
Thiamine supplementation was started (25 mg/kg-day); however, no clinical improvement was 
noted. Biochemically, the patient responded to thiamine supplementation with reduction in the 
concentrations of lactate in the blood (1.8 mmol/l, after six days supplementation). Three
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weeks later lactate concentration in blood was elevated again. An increase in doses of 
thiamine (maximum 200 mg/kg-day) led only to temporary reduction of blood lactate. At 19 
months of age the child had severe global developmental delay.
Two MR examinations were performed, one week apart, at two different CSF thiamine 
concentrations, at the age of 19 months. The investigations were carried out on a 1.5 T MR 
system (Siemens SP) employing the standard circular polarized headcoil. SE -T1 weighted 
MR images were obtained in the coronal and sagittal and SE -T 2 weighted images in the 
transverse direction. Single volume MR spectra were obtained by PRESS [15] and STEAM
[5] pulse sequences. In the PRESS sequence the delay between the 90° and first 180° pulse 
was 11 ms; in the STEAM sequence the Tm period was 30 ms. Field homogeneity was 
optimized for the selected volume using the H2O signal. Spectral width was 1 KHz and 2 K 
data points were acquired. Nominal voxel size was 2 x 2 x 2 cm. For eddy current correction 
and referencing purposes a H2O signal was also measured from all voxels. A 2D 1H MR 
spectroscopic imaging dataset was acquired from a transversal slab preselected by a PRESS 
pulse sequence. The slab was 15 mm thick and extended 60 mm in the left-right and 90 mm in 
the anterior-posterior direction. Tr was 1600 ms and Te 135 ms. The field-of-view was 240 
mm and the matrix size 16 x 16.
Post-processing of MR spectra consisted of zero-filling to 4K, filtering and eddy current 
correction. Chemical shifts are given in parts per million with the methyl signal of N- 
acetylaspartate at 2.03 ppm. Quantitative evaluation of metabolite signals and tissue levels 
was performed by 2 methods: fitting to Gaussian line-shapes in the time-domain (VARPRO
[1]) or by frequency domain fitting of model compound spectra (LCModel [16]). The T1 of 
H2O proton spins was estimated from the water signals of the VOI obtained at 2 or 3 different 
scan repetition times (2, 5 and/or 6 sec). For this purpose 4 measurements were performed 
with STEAM localization at Te of 20 or 30 ms. This was used for the calculation of 
metabolite levels as previously described [11]. Figure 1a shows a transverse MR image of the 
brain of the child; the position of the voxel selected for 1H MRS at the basal ganglia is 
indicated. The main part of this voxel arises from the globus pallidus, including a 
hyperintense lesion, and some tissue content of the caudate nucleus and internal capsule. MR 
spectra obtained from this voxel (see Figure 1b) show dominating signals for the methyl 
groups of N-acetylaspartate (NAA), creatine (Cr) and choline compounds (Cho) and some 
additional resonances: e.g. for protons of myo-inositol (Ins) at 3.55 ppm. In the spectra signals 
between 1.2 and 1.6 ppm are also visible.
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Figure 1. A. T2 spin-echo MR image of a transverse plane in the brain of the patient. The box 
indicates the location and size of the voxel (8 cm ) from which MR spectra were obtained. 
B .1H MR spectrum obtained by STEAM localization from the voxel shown. At Te = 20 ms 
and Tr = 2500 ms. Signals from myo-inositol (Ins), choline compounds (Cho), creatine 
compounds (Cr), N-acetylaspartate (NAA), alanine (Ala) and lactate (Lac) are indicated.
In figure 2 this part of the spectrum is displayed in more detail. While these signals are in 
phase with other (methyl) signals at Te = 20 ms, they are in antiphase at 135 ms and again in 
phase at an echo-time of 270 ms, indicating J-modulation. Futhermore, this spectral complex 
consists of two doublets with splittings of 7-8 Hz. The central position of the larger doublet is 
at 1.34 ppm and that of the smaller doublet is at 1.48 ppm. Based on these findings we assign 
the low field doublet to the methyl group of alanine and the high field doublet to that of 
lactate.
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Metabolite signal ratios and metabolite tissue levels were derived from the spectra obtained in 
the striatum at a Te of 20 and/or 30 ms (see Table 2).
2.2 2.0 1.8 1.6 1.4 1.2 1.0 
Frequency (ppm)
1 3Figure 2. Selected spectral region of H MR spectra of an 8 cm voxel focussed on the 
striatum of the patient (see Fig 1)obtained at 2 different echo times showing inversion of the 
methyl signals for alanine and lactate.
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I. First measurement, thiamine level CSF 784 nmol/l II. Second measurement, thiamine level CSF 392 nmol/l
Table 2. M etabolite signal ratios and tissue levels
Te (ms) Signal ratio Tissue level (mmol/l)
NAA/Cho NAA/Cr Cho/Cr Ins/Cr Cho Cr NAA ** Ala Lac
I. 20 1.9 8.8 10.4 1.0 1.3
I. 30 1.92 1.25 0.65 0.28 1.9 / 2.1* 9.5 / 10.1 11.1 / 10.2 0.8 / 1.3 1.5 / 2.0
II. 20 1.9 9.5 11.5 2.3 2.8
II. 30 1.94 1.19 0.61 0.31 1.9 / 2.1 9.6 / 10.3 10.7 / 9.8 2.3 / 2.9 2.5 / 2.9
Note: Spectra were obtained at Te=20 ms / Tr = 2500 ms or Te = 30 ms / Tr = 6000 ms. Metabolite signals were fitted to Gaussian line-shapes in 
the time-domain [1]. As prior knowledge the doublet amplitude equivalence of lactate and alanine methyl signals was used. Quantification of 
tissue metabolite levels was performed using the water signal of the corresponding VOI as a reference [11]. It was arbitrarily assumed that 3% of 
the water signal was from CSF and that 10% was not recovered due to short T2 and other factors such as eddy currents. For the calculation of 
metabolite levels, T1 and T2 relaxation times as obtained from gray matter [11] were used, except for the T1 of water, which was estimated for 
the VOI itself (see text). *) Tissue metabolite levels shown after the slash have been obtained by data processing with the LCModel software 
package [16] applying an appropiate basis set of model compound spectra obtained at Te = 30 ms / Tr = 6000 ms.
**) NAA includes NAAG (N-acetylaspartylglutamate) in the same way that Cho denotes total choline compounds and Cr total creatine. 
compounds.
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The T1 relaxation time of water spins in the VOI location at the striatum was found to be 
1289 ± 122 ms (n=4). Values obtained from the first and second measurement session were 
very similar except for those of lactate and alanine. Evaluation of tissue metabolite levels by 
the two different spectral analysis approaches, VARPRO [1] and frequency domain fitting by 
LCModel [16], gave comparable results. Data processing by LCModel also provided tissue 
levels for other compounds. Myo-inositol levels were 3.9 mmol/l at the first and 3.5 mmol/l at 
the second measurement session (with estimated standard deviations of 9 % and 13 %). The 
total glutamine and glutamate pool was 11.5 and 13.1 mmol/l at these sessions respectively 
(with estimated standard deviations of 20 % or more).
Figure 3 shows a spectral map, displayed over a transverse MR image, obtained from the 
spectroscopic imaging experiment. Essentially the spectra of all voxels, which are from gray 
matter or from white and gray matter mixtures, show inverted signals at 1.2 -  1.6 ppm for 
lactate and alanine. Compared to the intensity of the NAA peak at 2.03 ppm the total intensity 
in this area varies between 0.25 and 0.46 for different locations, but precise metabolite 
quantitation at the applied echo and repetition time is hampered by unacquaintedness with 
precise local relaxation times.
Discussion
PDHC deficiency is associated with a heterogeneous clinical presentation including severe 
neonatal encephalopathy, Leigh encephalopathy and episodic ataxia. The diagnosis can be 
difficult [4]. Structural defects in the central nervous system such as agenesis of the corpus 
callosum, dysplasia of the inferior olivary nuclei and dentate nuclei, absence of hypoplasia of 
the medullary pyramids, periventricular neuronal heterotopias and delayed or deficient 
myelinisation, are common findings in this entity in cases of neonatal presentation, in contrast 
to many other inborn errors of metabolism that also affect the brain [13]. This patient’s 
clinical picture was dominated by a severe encephalopathy with decreased frontal and 
occipital myelinisation and hyperintensity of the globus pallidus on MRI.
1H MRS of the brain in this child provides noninvasive evidence of a cerebral PDHC 
deficiency. Although brain maturation in terms of changing tissue levels of MRS visible 
metabolites has only crudely been assessed up to now, it appears that at 19 months of age
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Figure 3. Metabolite map from a spectroscopic imaging experiment at Te = 135 ms overlaid 
on a part of a T2 weighted transversal MR image. On the right an enlarged spectrum is shown 
from a voxel including a hyperintense region in the globus pallidus.
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tissue levels of the most prominent MRS metabolites approach adult values in gray matter
[11]. The estimated tissue level of NAA in the striatum is comparable to data reported from 
,gray matter in general and from basal ganglia [6, 11] indicating near normal neuronal density 
in this area. The level of choline compounds appears to fall in the high range of normal 
values reported for gray matter [6,11] while the level of creatine compounds is higher than the 
normal range reported for the basal ganglia [6]. Increased choline and creatine levels have 
been associated with glial involvement in metabolic brain disease [6], but the simultaneous 
increase of myo-inositol often seen for these cases, was not observed in our patient.
There are several reports of 1H MRS studies in children with PDHC deficiency. However, 
only in one case absolute quantification of metabolite levels is reported [6]. Cross et al. [3] 
studied 6 patients, all of them with lactate increase, but no alanine signal was reported. 
Krägeloh-Mann et al.[10] reported on 3 patients with Leigh disease due to a PDHC 
deficiency, all of them with a lactate increase; no alanine was found. Shevell et al. [19] 
investigated 3 patients with increased lactate and decreased NAA/Cr and Chol/Cr ratios. 
Alanine was not found. Harada et al.[7] reported on a patient in which lactate was seen, but no 
alanine. The authors mentioned that the pyruvate concentration was under the limit of 
sensitivity. Frahm et al. [6] described a 5-year-old boy with increased lactate and alanine and 
decreased NAA in gray matter. The common finding is the pathological signal of lactate, 
however, an elevated alanine signal, as observed in the present study, has only been reported 
in one other case [6]. The alanine concentration is often elevated in body fluids of patients 
with PDHC deficiency. This increase is caused by transamination of accumulated pyruvate to 
alanine. The concentrations found are far less than for lactate (e.g. see table 1). Alanine 
concentration can be below the level of detection, that probably being the reason why in some 
reports alanine is not seen. In a number of studies signal-to-noise may have been insufficient 
for the detection of alanine signals. The question remains why some patients with PDHC 
deficiency seem to accumulate more alanine than others. Spectroscopic imaging results in our 
patient revealed that significant lactate and alanine signals are present over a widespread area, 
pointing to a generalized brain involvement. The tissue levels of these compounds were 
higher during the second measurement possibly due to the lower CSF thiamine concentration. 
Shevell et al. [19] reported on 3 patients with decreased NAA/Cr and Cho/Cr ratios. Our 
findings seem to be comparable, with NAA and Cho levels near normal and Cr elevated.
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However, Frahm et al. [6] described a 5-year-old boy with decreased NAA in gray matter, 
which would fit to a lower NAA/Cr.
In summary, this report presents the most detailed study of absolute metabolite levels in a 
patient with PDHC deficiency up till now, showing normal NAA levels in basal ganglia gray 
matter and elevated Cr, lactate and alanine levels. Clearly, more studies on absolute 
metabolite levels from various brain areas in patients with PDHC deficiency are needed to 
understand how the brain is involved as far as observable by 1H MRS.
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Chapter 7
Favourable Clinical Course in an Infant with Severe Deficiency of Complex III of the 
Respiratory Chain Combined with Less Severe Deficiency of Complexes I, II and IV
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J.M.F. Trijbels, H.J. ter Laak, E.C.M. Mariman, M.M. Bakker, J. de Jager, J.A.M. Smeitink
Eur J Pediatr 1997;156:931-934
Abstract
An infant with severe deficiency of complex III combined with less severe deficiency of 
complexes I, II and IV of the mitochondrial respiratory chain in skeletal muscle tissue
presented with intrauterine growth retardation, generalized hypotonia and motor development
1/2delay. In the following 3 years muscle tone and motor development gradually normalized 
whereas the lactic acidosis and enzyme activities did not improve.
This report documents a favourable clinical course in a child with combined respiratory chain 
deficiency despite persistent biochemical abnormalities.
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Introduction
The clinical presentation of patients with isolated or combined defects in the mitochondrial 
respiratory chain (RC) is very heterogeneous. Neonatal or early infancy manifestations usually 
predict a severe clinical course. The last years several cases of isolated mitochondrial 
disorders in the neonatal period or early infancy with a benign course have been reported. Five 
reports describe a benign complex IV deficiency, in all of them, the enzyme activity 
normalized at the time of clinical improvement [2,6,7,10,11]. One report describes a benign 
complex I deficiency, but there are no data available about enzyme activity after clinical 
improvement [9]. Here we describe an infant with persistent severe deficiency of complex III 
combined with less severe deficiencies of complexes I, II and IV and a favourable clinical 
course.
Case report
This 1.7 kg (<3rd percentile) infant was born after 38 weeks gestation and had Apgar scores 
of 9 and 10 at 1 and 5 minutes, respectively. Length was 41 cm (<3rd percentile). The 
umbilical pH was 7.34. She was the third child of unrelated healthy parents. The two other 
siblings are healthy. The mother had two miscarriages.
The intrauterine growth retardation could not be explained by maternal causes or placental 
insufficiency. Evaluation of blood IgM levels for infectious causes of fetal growth retardation 
was unremarkable. Physical examination at birth revealed no abnormalities except generalized 
hypotonia. During the first five weeks tube feeding was necessary because of diminished 
sucking.
At four months of age she was readmitted to the hospital because of failure to thrive. Physical 
examination showed a lively infant, weight 3,840 gram (P<10), length 54 cm (P<10), head 
circumference 39.8 cm (P10). Axial hypotonia, mild hypertonia of the limbs, and atrophy of 
shoulder, arm and leg muscles was observed. The sucking reflex was moderately active and 
there were generalized stretch responses. No other abnormalities were noted.
Repeated blood analysis showed increased lactate concentrations (3-10 mmol/L; N < 2.1), 
increased lactate to pyruvate ratios (40-60; N 10-15), elevated concentrations of 3-OH- 
butyrate (0.18-1.60 mmol/L; N 0.02-0.09) and acetoacetate (0.06-0.34 mmol/L; N 0.016­
0.040) and elevated 3-OH-butyrate to acetoacetate ratios (2.8-4.7; N < 2). Postprandial ketosis 
was present. Lactate concentrations in urine and cerebrospinal fluid were 3.0 mmol/mmol 
creatinine (N<0.1) and 5.3 mmol/L (N<2.1), respectively. Creatinine, urea and transaminases
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were normal. Plasma alpha-tocopherol (9.5 p,mol/L; N 15.6-43.8) and beta-carotene (<0.01 
p,mol/L; N 0.10-0.80) concentrations at the age of 3 months were reduced but normalized after 
supplementation. Electroencephalography and magnetic resonance imaging of the brain 
revealed no abnormalities.
A defect in the mitochondrial respiratory chain was suspected and a biopsy of the vastus
1/2lateralis muscle was performed at the age of 4 months.
The clinical course was characterized by refusal to eat which made tube feeding necessary. 
After her third birthday eating progressively improved and tube feeding could be stopped. Her 
growth remained below but paralleled the 10th percentile curve despite adequate caloric 
intake and no signs of malabsorption. Despite persistence of increased lactate concentrations 
in blood, the axial hypotonia and mild hypertonia of the limbs progressively normalized in the 
first year. Her motor development was initially delayed (she could sit unaided at the age of 
one year and walked at the age of 22 months) but normalized hereafter. Her motor 
development according to the Hoskins-Squires scale [4] at 3.8 years was 3 years. The quality
of the movements at this age was appropiate. Trunk tone was lower than normal. Assessment
1/2of motor development at 4 years was age adequate. There was never exercise intolerance. 
Psychological assessment according to the McCarthy Scale of Children Abilities [5] at age of 
3.9 years revealed a score of 68 (2 SD under average), at age 4.6 years the score had improved 
to 80 (more than 1 SD under average) with a homogeneous test profile on both occasions.
Methods
Surgical biopsies of the vastus lateralis muscle were performed, with informed parental
8/12consent, at age 4 months and age 3 years, for morphological, biochemical and molecular 
biological investigations. Light microscopy, histochemical and enzyme-histochemical 
stainings were performed according to conventional procedures. Substrate oxidation rates, 
ATP production rates and mitochondrial enzyme activities in fresh muscle were measured in 
600g supernatants of muscle homogenates as described by Fischer et al. [3] and Sperl et al. 
[8]. Complex III was measured using decylubiquinol and horse cytochrome c as electron 
donor and acceptor, respectively. Tween 20 (0.04%) was added to abolish the non-enzymatic 
reaction and to break the mitochondria (Bentlage, unpublished results).
In order to search for the molecular cause of the disorder, total cellular DNA was isolated 
from muscle tissue as previously described by De Vries et al. [1]. Using restriction digestion 
of PCR-generated fragments of mitochondrial DNA, the DNA of the patient was tested for a
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number of pathogenic mutations. Southern blot analysis was used to search for mitochondrial 
DNA deletions. PvuII-digested DNA was separated on a 0.8% agarose gel and subsequently
32blotted to a nylon membrane. Hybridisation with P-labeled complete human mitochondrial 
DNA followed. Next, the gene for cytochrome b was sequenced using the dyeterminator cycle 
sequencing kit and the ABI A370 automated sequencer (Perkin Elmer).
Results
Examination of the first vastus lateralis muscle specimen showed normally distributed type I 
and type II fibres. Histochemical staining for oxidative enzymes and glycogen revealed 
normal results, but there were large fat depositions in the fibres. Electron microscopy showed 
enlarged abnormal mitochondria with concentric cristae. Examination of the second vastus 
lateralis muscle specimen revealed a high percentage of unequally distributed type I fibres (70 
versus 50 normally). Muscle fibres still showed signs of delayed maturation at this age, but 
diameters were normal. There were no fibres with internal nuclei and SDH- and COX- stain 
were normal. Electron microscopy revealed abnormal mitochondria with too few cristae, 
degenerating mitochondria, and mitochondria with dense deposits suggestive for early 
crystalloid formation (Figure 1).
The oxidation rates with pyruvate and malate as substrates and ATP+creatine phosphate 
production rates from these substrates were severely decreased (Table 1). The activity of 
rotenone-sensitive NADH:ubiquinone oxidoreductase (complex I) was diminished (52% and 
18% of the lowest control value in the first and second biopsy respectively). Succinate 
dehydrogenase (complex II) activity was 75% and 84% of the lowest control value 
respectively in the first and second biopsy. Succinate:cytochrome c oxidoreductase (complex 
II+CoQ+complex III) activity was diminished (37% of the lowest control value in both 
biopsies). The decylubiquinol:cytochrome c oxidoreductase (complex III) activity was 
undetectably low in the first biopsy and 11% of the lowest control value in the second biopsy. 
Cytochrome c oxidase (complex IV) activity was diminished (91% and 65% of the lowest 
control value in the first and second biopsy respectively).
None of the tested pathogenic mutations: A3243G (MELAS), T3271C (MELAS), A4317G 
(MELAS), A8344G (MERRF), T8993G/C (NARP/Leigh syndrome), were detected. A
32deletion in the mitochondrial DNA of the patient was excluded. Hybridisation with P- 
labeled complete human mitochondrial DNA revealed a single band of 16.5 kb representing 
the full-length linearized mitochondrial DNA. Cytochrome b sequencing showed one base
substitution, G15043A, which does not change the aminoacid composition of the cytochrome 
b polypeptide.
119
Table 1. Biochemical parameters of vastus lateralis muscle tissue
1st
biopsy 
age 4 
months
(%)e 2nd
biopsy
08/12age 3 
years
(%)e Control
range
N
Oxidation ratesa for
[1 -  14C]Pyruvate + malate 0.57 (16) 0.47 (13) 3.61-7.48 14
[U -  14C]Malate + pyruvate 0.45 (13) 0.52 (15) 3.43-7.30 14
+ malonate 
ATP + creatine phosphate 
production rateb from 
Pyruvate + malate 4.25 (10) 4.76 (11) 42.1-81.2 14
NADH: Q1 oxidoreductased 0.050 (52) 0.017 (18) 0.096- 13
Succinate dehydrogenased 0.050 (75) 0.056 (84)
0.197
0.067- 11
Succinate: cyt c oxidoreductased 0.11 (37) 0.11 (37)
0.177
0.30-0.97 38
Decylubiquinol: cyt c n.d. 0.31 (11) 2.85-6.71 22
oxidoreductased 
Cytochrome c oxidased 0.74 (91) 0.53 (65) 0.81-3.12 21
Citrate synthasec 124 (258) 78 (162) 48-162 32
a nmol substrate oxidized per hour per mU citrate synthase, b nmol product formed per hour 
per mU citrate synthase
c mU per mg protein, d mU per mU citrate synthase 
e (%) of lowest control, n.d.=not detectable
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Figure 1. Abnormal mitochondria in vastus lateralis muscle.
(A) Many mitochondria with dense deposits. (B) Magnification of a mitochondrion in A.
(C) Mitochondria with too few cristae. (D) A degenerating mitochondrion. Arrows in A,B, 
and D point to dense deposits representing early crystalloid formation.
Bars: 0.5 p,m (black) and 0.1 p,m (white).
Discussion
This girl presented in the neonatal period with intrauterine growth retardation, generalized 
hypotonia and diminished sucking. There were neither signs nor symptoms of central nervous 
system involvement. As an infant she was flaccid but alert and responsive, in contrast to the 
lethargy associated with encephalopathy. Her motor development was delayed at first but 
normalized, other developmental aspects were adequate. There were no clinical signs of 
encephalopathy. MRI of the brain and electroencephalography at the age of 4.5 months, 2 and 
4 years, showed no abnormalities. The lactate concentration in cerebrospinal fluid was 
elevated but possibly this only reflected the high concentration in blood rather than
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involvement of CNS. Biochemical studies in skeletal muscle revealed indeed a severe 
complex III deficiency combined with a less severe deficiencies of complexes I, II and IV. A 
second biopsy specimen taken at the time when she was free of symptoms showed identical 
abnormalities.
Molecular biological investigations showed one base substitution in cytochrome b, which 
does not change the aminoacid composition of the cytochrome b polypeptide and therefore 
reflects a silent polymorphism.
This case illustrates that a severe deficiency of enzyme complexes of the respiratory chain in 
muscle, with significantly impaired overall substrate oxidation and ATP production rates, can 
have a benign course. Furthermore, the fact that biochemical abnormalities persist suggests 
that there are unknown adaptation mechanisms in skeletal muscle. Whether or not alpha- 
tocopherol and beta-carotene supplementation contributed to the favourable outcome remains 
unknown.
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Systemic infantile complex I deficiency with fatal outcome in two 
brothers
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Abstract
A male infant presented at 5 months of age with vomiting, developmental stagnation and 
convulsions. Complex I activity was in skeletal muscle 0.025 mU/mU citrate synthase (N 
0.044-0.265) and in fibroblasts 0.046 mU/mU citrate synthase (N 0.100-0.307). Despite 
riboflavine supplementation progressive neurological deterioration occurred and he died at 14 
months of age. During the mother's following pregnancy complex I activity was measured in 
chorionic villi and found mildly reduced, pregnancy was continued. A male infant was born 
who presented at 7 months of age with vomiting, developmental stagnation and hypotonia. 
Complex I activity was in skeletal muscle 0.031 mU/mU CS and in fibroblasts 0.100 mU/mU 
CS. There was progressive neurological deterioration and he died at 17 months of age. 
Complex I activity in autopsy liver of both patients was normal. Apparently, complex I 
deficiency presenting in infancy can have a fatal outcome despite only mild reduction of 
enzyme activity in skeletal muscle and/or fibroblasts, and normal activity in liver.
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Introduction
Mitochondrial respiratory chain enzyme deficiencies have an ever increasing variety of 
clinical presentations [5,8]. There is ample evidence that a defect in the same enzyme 
complex of the respiratory chain may give rise to different clinical phenotypes, suggesting 
different genetic defects, that the severity of the clinical picture may not correlate with the 
extent of the in vitro measured biochemical defect in skeletal muscle, and that tissue specific 
expression of a defective respiratory chain enzyme because of mitochondrial heteroplasmy 
and different energetic thresholds of tissues has to be taken into account during the diagnostic 
process [7].
Here we describe two offsprings in a family with fatal infantile multisystemic complex I 
deficiency including prenatal diagnosis by means of chorionic villi investigations for complex 
I activity.
Case reports
A male infant was born at term as the first child of healthy nonrelated parents after an 
uneventful pregnancy and delivery. Birth weight was 3,320 g (P 50), and length was 51 cm (P 
50). At the age of 5 months he began to vomit; generalized hypotonia, developmental arrest, 
strabismus, and convulsions were noted. Laboratory investigations revealed moderately 
increased lactic acid concentrations in blood and CSF (2.3 and 3.1 mM, respectively; normal 
< 2.1). Aminoacid analysis revealed an elevated alanine concentration in blood and urine: 673 
[xM (normal 144-378) and 256 ^moles/mmole creatinine (normal 36-162), respectively. 
Organic acid analysis in urine revealed a lactic acid concentration of 184 ^moles/mmole 
creatinine (normal 0-200) and no other abnormalities. CT-scan of the brain showed 
moderately dilated ventricles. A deficiency of complex I of the mitochondrial respiratory 
chain was found in a quadriceps muscle specimen, obtained by biopsy at the age of 8 months. 
The patient showed progressive neurological deterioration in the following months despite 
riboflavin supplementation (10 mg/kg per day). He died at 14 months of age because of severe 
metabolic derangement caused by an aspiration pneumonia.
During the mother's second pregnancy complex I activity was measured in chorionic villi and 
found mildly reduced. Despite these findings the pregnancy was continued and a male infant 
was born after an uneventful pregnancy and delivery. Birth weight was 3,500 g (P 50), length 
was 53 cm (P 50-90), and head circumference was 35 cm (P 50). At the age of 7 months he 
started vomiting and refused to eat. Generalized hypotonia was noted and his developmental
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status deteriorated (he could not sit up without support or crawl anymore). Laboratory 
investigations revealed increased lactic acid concentrations in blood and CSF (3.4 and 3.0 
mM, respectively). Aminoacid analysis revealed an elevated alanine concentration in blood 
but a normal concentration in urine (565 ^M and 137 ^moles/mmole creatinine, respectively). 
Organic acid analysis in urine revealed a lactic acid concentration of 60 ^moles/mmole 
creatinine, and no other abnormalities. Complex I activity was found to be reduced in a 
quadriceps muscle specimen, obtained by biopsy at the age of 9 months. He showed 
progressive neurological deterioration and died at 17 months of age because of severe 
metabolic derangement elicited by a pneumonia.
Materials and methods
The quadriceps muscle specimens were processed for morphological, histochemical and 
biochemical investigations. Light microscopy, histochemical and enzyme-histochemical 
stainings were performed according to conventional procedures. The oxidation rates for 
pyruvate and malate, the ATP plus creatine phosphate production rates, and activities of 
enzyme complexes of the respiratory chain and the pyruvate dehydrogenase complex were 
measured in 600g- supernatant from fresh skeletal muscle as described by Fischer et al 1986
[6], and Sperl et al 1990 [11].
Complex I activity was measured in chorionic villi as described by Ruitenbeek et al 1992 [10], 
and in fibroblasts as described by Bentlage et al 1996 [1]. Complex I activity was measured in 
a liver specimen, obtained by autopsy within one hour after death, in a 10% homogenate in 
SEF (250 mM sucrose, 2 mM EDTA, 10 mM K phosphate) as described by Fischer et al 
1986. Citrate synthase was used as reference enzyme.
In order to search for the molecular cause of the disorder, total cellular DNA was isolated 
from muscle tissue as previously described by De Vries et al 1992 [4]. Using restriction 
digestion of PCR-generated fragments of mitochondrial DNA, the DNA of the patients was 
tested for a number of pathogenic mutations. Southern blot analysis was used to search for 
mitochondrial DNA deletions.
Results
Histopathological findings in skeletal muscle of both patients revealed no distinct 
abnormalities. Ragged-red fibres were not seen. Biochemical investigations in fresh skeletal 
muscle supernatants from both patients revealed that oxidation rates with pyruvate and malate
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as substrates, and ATP plus creatine phosphate production rates from pyruvate plus malate 
and from succinate plus acetylcarnitine as substrates, were clearly diminished. The activity of 
complex I (NADH:Q1 oxidoreductase) of the respiratory chain (patient 1 55% and patient 2 
70% of the lowest control value) and of NADH:02 oxidoreductase activity (25% of the lowest 
control value in both patients) were also decreased. The other measured enzyme activities 
were in the normal range (Table 1).
Table 1. Biochemical investigations in skeletal muscle
patient 1 patient 2 control range
Oxidation ratesa
[1 - 14C]Pyruvate + malate 1.59 0.90 3.61-7.48 (n=14)
[U - 14C]Malate + pyruvate + malonate 1.54 0.87 4.68-9.62 (n=14)
ATP + creatine phosphate production rateb
from Pyruvate + malate 14 8.2 42-82 (n=14)
Activity of
Citrate synthasec 146 117 48-162 (n=32)
Cytochrome c oxidased 1.48 1.27 0.81-3.12 (n=21)
Succinate: cyt c oxidoreductased 0.42 - 0.30-0.97 (n=38)
NADH: Q1 oxidoreductased 0.024 0.031 0.044-0.26 (n=30)
NADH: O2 oxidoreductased 0.07 0.07 0.28-0.84 (n=12)
a nmol substrate oxidized per hour per mU citrate synthase 
b nmol product formed per hour per mU citrate synthase 
c mU per mg protein d mU per mU citrate synthase
Measurement of complex I activity in skin fibroblasts showed diminished activity in patient 1 
(62% of lowest control value) and low normal activity in patient 2 (Table 2).
Complex I activity in liver tissue was normal in both patients.
A chorionic villus sample obtained during the mother's second pregnancy demonstrated a 
mildly decreased complex I activity (74% of the lowest control value).
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Table 2. Complex I activity in skin fibroblasts, autopsy liver and chorionic villi
NADH:Q1 oxidoreductase activity 
patient 1 patient 2 control range
Skin fibroblasts 
mU/U citrate synthase 62 101 100-307 (n=13)
Autopsy liver 
mU/U citrate synthase 51 110 32-364 (n=10)
Chorionic villi 
mU/U citrate synthase - 62 84-238 (n=19)
None of the tested pathogenic mutations: A3243G (MELAS), T3271C (MELAS), A4317G 
(MELAS), A8344G (MERRF), T8993G/C (NARP/Leigh syndrome), were detected. A 
deletion in the mitochondrial DNA of the patients was excluded.
Discussion
These two infant brothers presented with vomiting, developmental arrest and subsequent 
neurological deterioration after a symptom free period of 5 - 7 months. Lactic acid 
concentration was increased in blood and CSF. Despite treatment with riboflavin patients 
deteriorated. Responsiveness to riboflavin has only been reported in individuals with the 
myopathic form of complex I deficiency [2,9]. Both patients showed a moderate complex I 
deficiency in skeletal muscle which resulted in reduced oxidation rates of different substrates. 
From the clinical course -neurological deterioration with early death- and increased lactate 
concentration in CSF, one might infer that the complex I deficiency was disproportionately 
more severe in brain tissue. Enzyme activity was not measured in post-mortem brain tissue.
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The data presented illustrate that a moderate deficient complex I activity in skeletal muscle, 
skin fibroblasts and chorionic villus, and normal complex I activity in liver, can yet have a 
lethal outcome.
In the fetus affected with complex I deficiency, the residual activity in the chorionic villus 
sample was 25% below the lowest control value. Such a difference between a normal and an 
affected fetus appears to be sufficient in order to arrive at the correct diagnosis.
This case corroborates our experience and reports in the literature [3,12] that offsprings 
affected with a respiratory chain disorder in a family have an overwhelmingly identical 
clinical course. This is of tremendous importance for parental information about prognosis 
and counseling.
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Chapter 9
General discussion and future perspectives
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9.1 Mitochondriocytopathies in children: past
The association of mitochondrial abnormalities and disease in humans has only been 
recognized since 1962. In that year Luft et al. [16] described an adult patient with non- 
thyroidal hypermetabolism due to loose-coupling of mitochondria. Many years later pediatric 
patients were described [24,31].
During the decade that followed, the attention was confined to pure myopathic 
mitochondriocytopathies and muscle morphology. Numerous clinical descriptions were 
reported [5,9,11,17, 26]. The main clinical symptoms in these patients were muscle weakness 
and exercise intolerance. In 1963, Engel and Cunningham [7] introduced a modification of the 
Gomori trichome stain that allowed the identification of abnormal deposits of mitochondria as 
purplish irregular patches in what they called ragged red fibers (RRF). These RRF became the 
morphological hallmark of mitochondrial disorders. However, it is nowadays known that RRF 
are, in contrast to adults, rarely seen in children with a mitochondrial cytopathy. Moreover, 
RRF are also seen in disorders of non-mitochondrial etiology, such as muscular dystrophies, 
polymyositis, dermatomyositis, and some glycogenoses, in which they probably represent 
secondary changes.
In the 1970s the multisystem nature of mitochondrial disorders became clear; symptoms and 
biochemical defects not only involved skeletal muscle but could affect multiple tissues.
It became known that these disorders were associated with elevated lactic acid concentrations 
in body fluids. A disturbance in the PDHC, citric acid cycle or OXPHOS results in an 
impaired pyruvate metabolism. In that case, pyruvate is mostly converted to lactate by the 
cytosolic lactate dehydrogenase, or transaminated to alanine.
Furthermore, biochemical studies in muscle specimens were performed systematically and 
specific biochemical defects, including defects of the pyruvate dehydrogenase complex and 
the individual complexes of the respiratory chain, were described [26]. Tissue specificity was 
first described by Willems et al. [35] in a patient with Leigh syndrome associated with 
cytochrome c oxidase deficiency in skeletal and heart muscle, and normal cytochrome c 
oxidase in liver. Isolated as well as combined defects of the respiratory chain complexes were 
documented.
In the 1980s, the biochemical knowledge improved making a rational biochemical 
classification into five groups possible [6,18]: 
a- defects of transport 
b- defects of substrate utilization
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c- defects of the Krebs cycle
d- defects of the respiratory chain
e- defects of oxidation/phosphorylation coupling.
The unique fact that mitochondria contain their own DNA, mitochondrial DNA (mtDNA), 
maternally transmitted, which sequence and organization had been elucidated by Anderson et 
al. in 1981 [1], directed the attention to mtDNA abnormalities and maternal inheritance. 
Human mtDNA encodes 13 structural subunits of the respiratory chain complexes I, III, IV, 
and complex V. In addition to structural genes, mtDNA also codes for 22 transfer RNAs and 
two ribosomal RNAs. Molecular biology studies led to the identification of the first mutations 
in mtDNA associated with mitochondrial disease [10,14,34].
In the 1990s, the knowledge of human nuclear genes encoding mitochondrial enzyme 
complexes increased exponentially [2,19,25,28].
Despite all the progress in this field, one of the main problems remained the clinical 
recognition of patients affected by a mitochondrial cytopathy.
9.2 Mitochondriocytopathies in children: present
9.2.1 Wide clinical range and non-specificity of signs and symptoms
The wide clinical range and non-specificity of signs and symptoms associated with 
mitochondriocytopathies make it rarely possible to clinically recognize pediatric patients 
suffering from a mitochondrial cytopathy on clinical grounds. Children very often come to the 
attention because of more or less severe encephalopathy. Valuable clues from additional 
investigations, like elevated concentrations of lactate, pyruvate and alanine in body fluids, and 
neuroradiological abnormalities such as symmetric lesions of the basal ganglia, are not 
invariably present and are also common to other entities. Nowadays, the diagnosis 
mitochondrial cytopathy is assessed in most cases by biochemical investigation of a skeletal 
muscle specimen. Based on clinical findings and results of additional investigations it is 
usually difficult for the clinician to decide whether the suspicion of a mitochondrial cytopathy 
is strong enough to justify a muscle biopsy. A muscle biopsy in children is an invasive 
procedure because to obtain enough muscle to warrant optimal investigation (mitochondrial 
substrates oxidation rates and ATP plus creatine phosphate production, as well as activity of 
the individual enzymatic complexes) a surgical biopsy is needed. Accordingly, a reliable 
selection procedure of patients who should undergo a muscle biopsy is necessary. If the
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selection criteria are too narrow patients remain undiagnosed. If they are too wide, 
unnecessary muscle biopsies are performed.
The study presented in this thesis was initiated as an attempt to optimize the clinical selection 
of patients affected by a mitochondrial cytopathy. In a prospective study in pediatric patients 
with a standardized investigation protocol (chapter 2), we were able to assess an optimal 
screening procedure in pediatric patients and selected 5 parameters with significant 
relationship with the result of the biopsy examinations (normal or deficient). These five 
parameters were: age < 4 years, elevated fasting lactate to pyruvate ratio, elevated thrombocyte 
count, elevated lactate, and elevated alanine. From these selected parameters a prognostic 
index to calculate the chance of a normal biopsy in an individual patient could be constructed. 
Each parameter is scored 0 (not present) or 1 (present). The chance of a normal biopsy with a 
given value of this index (sum of the scores) can be calculated: logit (Pr) = a  + P x index; a: -
0.8167 and P: 0.8331. (Pr: probability of normal biopsy). The chance of a normal biopsy with 
an index value of 5 is 0.03, 4 is 0.07, 3 is 0.16, 2 is 0.30, 1 is 0.50 and 0 is 0.69. Patients in 
whom none of the selected parameters are present, still have a 31% chance of a mitochondrial 
cytopathy. In patients in whom the selected parameters are absent, the presence of additional 
findings without prognostic value, but associated with mitochondrial disorders (ptosis, 
cataract, cardiomyopathy, multiple symmetric lesions in the basal ganglia, mesencephalon and 
brainstem, as seen in Leigh disease), usually lead the clinician to perform the muscle biopsy. 
This was the case in two brothers with a Leigh syndrome, known at our center. They had a 
prognostic index value of 1 (age < 4); all other parameters with prognostic value were absent. 
In these children, the findings on the imaging of the brain compatible with Leigh syndrome 
were decisive enough to perform the muscle biopsy. The skeletal muscle investigations 
showed an isolated complex I deficiency. Molecular biology studies revealed a nuclear 
mutation in the NDUFS7 subunit of complex I.
The clinician willing to calculate the chance of an abnormal biopsy result in an individual 
patient can use as laboratory screening: lactate and pyruvate in blood, aminoacids in blood and 
urine, lactate and aminoacids in CSF (if neurological manifestations are present), urine 
organic acids and thrombocytes. The urine portion for aminoacid and organic acid analysis 
should be collected in the fed state. If no lactate increase is found in body fluids, an oral 
glucose loading test should be performed to test the capacity of the biochemical pathway 
under maximal load. With the results of these investigations the prognostic index for an 
individual patient can be calculated. The use of this prognostic index will help clinicians to
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decide in which patients a muscle biopsy should be performed in order to prove a 
mitochondrial cytopathy.
Future studies using techniques such as proton MR spectroscopy of the brain as illustrated in 
chapter 6, and near infrared spectroscopy [30], might help to make this prognostic index 
more accurate. The patients with a high prognostic index are the ones who will more often 
undergo a muscle biopsy with a low risk of finding a normal mitochondrial energy 
metabolism.
Denervation and disuse among others can result in secondary mitochondrial dysfunction 
[3,12,20,23]. At present, based on the results of biochemical investigations in skeletal muscle, 
it is very difficult to distinguish primary and secondary mitochondrial dysfunction.
The association of a slightly elevated thrombocyte count with oxidative phosphorylation 
defects has not previously been reported and requires further study. This finding could not be 
explained by other causes known to be associated with an elevated thrombocyte count such as 
infections, exercise, surgery, iron-deficiency, or other chronic anemias [27,33]. It remains to 
be seen whether this finding is reproducible in future studies, and whether it is a general 
finding or confined to a subgroup of patients with mitochondriocytopathies.
9.2.2 Skeletal muscle investigations
The establishment of a mitochondrial energy metabolism disturbance in tissue, preferably 
skeletal muscle because it expresses the defect in the majority of cases, is still the golden 
standard in diagnosis of a mitochondrial cytopathy.
Biochemical investigations of skeletal muscle specimens at our center are performed 
according to a stepwise procedure. First, oxidation rates of mitochondrial substrates and ATP 
plus creatine phosphate (CrP) production rate are measured in the intact mitochondria of a 
fresh muscle specimen. If these investigations yield normal results, no further enzymatic 
studies are performed. If the outcome of these investigations points to a defect in the 
mitochondrial energy metabolism, depending on the abnormalities established, the activities 
of PDHC (pyruvate dehydrogenase complex), RC complexes and complex V are measured, 
and the content of VDAC (voltage dependent anion-channel) and ANT (adenine nucleotide 
translocator) are determined immunochemically. In exceptional cases, despite normal 
oxidation rates and ATP production, further studies are performed. This was the case in a 
patient with the clinical triad of cataract, cardiomyopathy and lactic acidosis (Sengers 
syndrome). Biochemical investigations in fresh skeletal muscle (substrate oxidation rates and
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ATP production) were normal. However the clinical, clinical chemical and morphological 
findings were so strongly suggestive of a defect in the mitochondrial energy metabolism that 
extensive investigations were performed. A decreased level of ANT was found in this patient. 
In 40% of the patients, no specific deficiency is found despite clearly reduced substrate 
oxidation rates in vitro. These patients possibly suffer from a hitherto unknown defect. If no 
fresh muscle specimen is available, and only the individual enzyme complexes can be 
measured and are found to be normal, the wrong conclusion might be drawn that there is no 
evidence of mitochondrial cytopathy. We therefore strongly recommend biochemical 
investigations in a fresh muscle specimen in patients suspected of a mitochondrial cytopathy.
9.2.3 Molecular biology
Due to the different characteristics of inheritance of nuclear and mitochondrial DNA, 
autosomal recessive (mainly) versus maternal, clinical differences in these genetically 
different groups of defects could be expected. Mitochondrial DNA mutations have been 
known for many years. The first nuclear mutations causing mitochondrial disease have been 
elucidated during the last few years [4,15,22,27-29,32,36]. This makes it possible to study 
genotype-phenotype relationship. In chapter 4, a clinical study in patients with an established 
genetic defect in nuclear versus mtDNA is described. Major clinical differences between both 
groups are age at onset, severity of clinical course, outcome, and intrafamilial variability. 
Patients with nuclear mutations become symptomatic at a young age, and have a severe 
clinical course. Affected sibilings have a very similar clinical picture. Patients with mtDNA 
mutations show a wider clinical spectrum of age of onset and severity.
This difference is important for molecular genetic studies and parental counseling. The 
definition of the molecular defect is crucial for genetic counseling. However, at present, the 
molecular defect is unknown in most cases. Families with a young child affected by an 
OXPHOS defect, and no family history suggesting maternal inheritance, are very likely to 
harbor an autosomal recessive inherited nuclear mutation, with a 25% recurrence risk for the 
parents. The child is likely to have a rapidly progressive course with a poor outcome. 
Molecular biology studies in these patients should be directed to the nuclear genome. 
Mitochondrial DNA studies of common point mutations, and deletions of mtDNA in blood 
and/or skeletal muscle routinely performed at our center reveal a very low percentage of 
mtDNA abnormalities in pediatric patients. For the pediatric population, it seems more 
meaningful to screen for mtDNA in those cases with a clinical constellation suggestive of a
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known mtDNA mutation (e.g. MELAS), or in diseases with genetic heterogeneity (e.g. Leigh 
disease) and/or family history suggesting maternal inheritance.
9.3 Mitochondriocytopathies in children: future
The work presented in this thesis can help the clinician to better recognize patients affected by 
a mitochondrial cytopathy. However, other diagnostic tools are needed to achieve a more 
accurate prognostic index. Exercise testing on a bicycle ergometer with concomitant 
measurement of lactate in blood has proved to be helpful in discriminating mitochondrial 
from non-mitochondrial myopathies [8]. However, the use of this test is limited in pediatric 
patients because they are either too young to exercise on a bicycle or suffer from a severe 
encephalopathy. In pediatric patients, especially, it is important to use diagnostic tools which 
do not require the patient’s co-operation. Furthermore, the diagnostic tool should preferably 
be non-invasive. Proton MR spectroscopy of the brain which makes in vivo measurement of 
some relevant brain metabolites possible has been used in single cases as a diagnostic tool in 
mitochondriocytopathies affecting the brain. Prospective studies to assess the additional 
prognostic value of this method are necessary.
Parents of children affected by a mitochondrial disorder will increasingly ask for prenatal 
diagnosis and genetic counseling. In the case of nuclear gen defects, the elucidation of the 
defects underlying mitochondriocytopathies will make reliable prenatal diagnosis and parental 
counseling possible on a large scale. Today, this is only possible in a few families with known 
nuclear genetic defects. In the case of mtDNA mutations, genetics is complicated by 
heteroplasmy. Prenatal diagnosis for mtDNA mutations is hindered by the inability to predict 
the clinical severity expected from the mutant DNA measured in fetal tissue. Recent data 
derived from a mouse model and direct evidence from human oocytes [21] point to 
segregation during oogenesis. If segregation indeed occurs during oogenesis, then sampling 
either products of conception or oocytes will be representative of the dose of mutant mtDNA 
to be transmitted. The treatment of patients with mitochondriocytopathies is still very 
inadequate. Gene therapy for defects of the respiratory chain due to nuclear DNA mutations 
holds the same promise and faces the same obstacles as gene therapy for other inborn errors of 
metabolism [13]. Mutations of mtDNA genes pose an especially difficult problem because of 
the high number of mtDNA copies and the lack of effective mitochondrial transfection 
vectors. Research in this area to solve these problems is warranted.
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Chapter 10 
Summary
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Mitochondriocytopathies are a group o f disorders caused by a disturbed mitochondrial energy 
metabolism due to defects in the pyruvate dehydrogenase complex (PDHC), citric acid cycle, 
OXPHOS system (respiratory chain and complex V), and transporters such as the adenine 
nucleotide translocator (ANT). The main causes o f mitochondriocytopathies are respiratory 
chain deficiencies.
Clinically, biochemically and genetically, the mitochondriocytopathies form a very 
heterogeneous group o f diseases. Although no single manifestation is specific, several 
circumscript syndromes due to mitochondrial DNA (mtDNA) mutations are recognized. 
However, pediatric patients rarely fit into one o f these syndromes and mtDNA mutations are 
not frequently found
The clinical presentation and physical examination o f affected patients is common to many 
other pediatric diseases, and the clinician needs useful clues from other investigations (e.g. 
detection o f a high concentration o f lactate in body fluids) to suspect a mitochondrial 
cytopathy. To obtain the correct diagnosis histopathological, biochemical and genetic 
investigations in tissue are necessary. Skeletal muscle is the preferred tissue because it 
expresses the defect in the majority o f patients.
The aim of this thesis has been to gather more knowledge about mainly clinical aspects of 
mitochondriocytopathies in pediatric patients.
Chapter 1 gives a general survey on mitochondriocytopathies in pediatric patients. First, the 
most frequently encountered phenotypes in pediatric patients: fatal infantile lactic acidosis, 
Leigh syndrome, unspecified encephalopathy, cardiomyopathy, and myopathy, as well as 
important age-related presenting symptoms are described. Next, the metabolic screening 
(measurement o f lactate and pyruvate in blood, aminoacids in blood and urine, lactate and 
aminoacids in CSF, urine organic acids) and additional investigations (cardiac evaluation, 
imaging o f the brain, electromyography) that can be relevant in this group o f disorders are 
summarized. Finally, the diagnostic procedure based mainly on morphological and 
biochemical studies on the muscle specimen, and the current therapeutic strategies are shortly 
discussed.
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Chapter 2 describes a study to assess an optimal screening for pediatric patients suspected of 
a mitochondriocytopathy to justify a muscle biopsy. A muscle biopsy in pediatric patients is 
an invasive procedure. To obtain enough material to optimally assess the diagnosis, a surgical 
biopsy under general anesthesia is needed.
In this study, forty-five patients suspected o f a mitochondrial cytopathy were investigated 
following a standard protocol. This protocol included: medical history, physical examination, 
cardiac and ophthalmologic evaluation, biochemical investigations, in vivo function tests, 
neuroimaging and a skeletal muscle specimen for morphological and biochemical 
investigations.
The results o f the biochemical investigations in the muscle specimen were compared with the 
results o f the other investigations included in the screening protocol. Of all measured 
parameters, five showed a statistical relationship with the result (normal or deficient) o f the 
biochemical investigations in the muscle specimen. These five parameters were: age<4 years, 
elevated fasting lactate to pyruvate ratio, elevated thrombocyte count, elevated lactate, and 
elevated alanine.
Using these parameters, a prognostic index was constructed. Each parameter was scored 0 
(not present) or 1 (present). The chance o f a normal biopsy with a given value of this index 
(sum of the scores) was calculated: logit (Pr) = a  + P x index; a: -0.8167 and P: 0.8331. (Pr: 
probability o f normal biopsy). The chance o f a normal biopsy with an index value o f 5 is 0.03, 
4 is 0.07, 3 is 0.16, 2 is 0.30, 1 is 0.50 and 0 is 0.69.
Therefore, the optimal screening for pediatric patients suspected o f a mitochondriocytopathy 
includes the following laboratory screening: lactate and pyruvate in blood, aminoacids in 
blood and urine, lactate and aminoacids in CSF (if neurological manifestations are present), 
urine organic acids and thrombocytes. The urine portion for aminoacid and organic acid 
analysis should be collected in the fed state. If no lactate increase is found in body fluids, an 
oral glucose loading test should be performed. Using the results o f these investigations the 
chance of a normal biopsy in an individual patient can be calculated. Further studies are 
needed to make the prognostic index more accurate. The association o f a slightly elevated 
thrombocyte count with oxidative phosphorylation defects has not previously been reported 
and requires further study.
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Chapter 3 presents a method to summarize the results of biochemical investigations in 
muscle. The diagnostic approach of patients suspected of a mitochondriocytopathy includes 
biochemical investigation of skeletal muscle. First oxidation rates of mitochondrial substrates 
and ATP plus CrP production are measured which brings up eleven different results. If these 
measurements are abnormal, enzymatic studies (pyruvate dehydrogenase complex, complex I­
V) are performed depending on the pattern of abnormalities. In some cases it is difficult to 
conclude from these 11 results whether the patient has a disturbed mitochondrial energy 
metabolism or not, because the different results do not unanimously point to normal or 
deficient.
To facilitate and standardize the interpretation of mainly these difficult cases, we tested a 
scoring method based upon linear discriminant analysis to summarize these eleven different 
results in one: the discriminant score (DS). This DS perfectly discriminates between patients 
with normal and defective mitochondrial energy metabolism. DS > 0 indicates a normal 
mitochondrial energy metabolism and based on the skeletal muscle biochemistry results no 
further investigations are necessary. Conversely, a DS < 0 indicates a decreased mitochondrial 
energy metabolism and warrants further investigations.
It is concluded that the DS can be used for the interpretation of the biochemical results 
(oxidation rates and ATP production rate) in the skeletal muscle specimen. Furthermore, the 
use of a summary score simplifies correlation studies between these results and other 
parameters (e.g. clinical, biochemical, radiological, morphological).
Chapter 4 describes a study on clinical differences in patients with an oxidative 
phosphorylation (OXPHOS) defect due to nuclear versus mtDNA mutations. Defects in 
OXPHOS are genetically unique because the different components, respiratory chain enzyme 
complexes (I, III, and IV) and complex V, are encoded by nuclear and mitochondrial genome. 
Clinical differences may be of importance regarding genetic counseling and molecular biology 
studies.
We studied 16 families with > 2 siblings with a genetically established OXPHOS deficiency, 
4 due to a nuclear gene mutation and 12 due to a mtDNA mutation. The study was performed 
in families with at least two affected offspring to be able to assess the intrafamilial variability 
in both groups.
Patients with nuclear mutations became symptomatic at a young age, and had a severe clinical 
course. Affected siblings had a very similar clinical picture. Patients with mtDNA mutations
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showed a wider clinical spectrum of age at onset and severity. Siblings with a mtDNA 
mutation had clinical pictures that varied from almost alike to very distinct.
It is concluded that there are differences in age at onset, severity of clinical course, outcome, 
and intrafamilial variability in patients affected of an OXPHOS defect due to nuclear or 
mtDNA mutations.
Chapter 5 reports a new phenotype in a child -  spinal muscular atrophy (SMA)-like picture, 
cardiomyopathy and cytochrome c oxidase (COX) deficiency.
This patient presented with clinical, morphological and neurophysiological features of SMA. 
However, there were some atypical features such as inspiratory stridor, markedly depressed 
instead of absent deep tendon reflexes, and no deletions in exons 7 and 8 of the survival motor 
neuron gene, which casted doubt on this diagnosis. The negative COX staining of the muscle 
specimen was the first clue suggesting a mitochondriopathy. Further evaluation revealed a 
hypertrophic non-obstructive cardiomyopathy, and an increased lactic acid concentration and 
lactate to pyruvate ratio in blood and CSF, suggesting a mitochondrial disorder. This was 
confirmed by biochemical investigations in skeletal muscle and cultured skin fibroblasts 
which showed a COX deficiency
It is suggested that patients with clinical features resembling SMA, but with intact survival 
motor neuron gene, are screened for a mitochondrial disorder.
Chapter 6 illustrates non-invasive quantitative determination by proton MR Spectroscopy (1H 
MRS) of alterations in cerebral metabolism. 1H MRS of the brain can be used as non-invasive 
diagnostic tool in patients affected of a mitochondrial disorder to investigate whether 
metabolites such as alanine and lactate in brain tissue are elevated. A 19-month-old male 
infant with severe global developmental delay caused by a Pyruvate Dehydrogenase Complex 
(PDHC) deficiency due to a mutation at the thiamine binding site was investigated. To assess 
the effect of thiamine supplementation two investigations were performed at different CSF 
thiamine concentrations. Abnormally high lactate and alanine signals were observed both in 
and outside the striatum; the levels of these metabolites were higher during the second 
measurement at a lower thiamine concentration.
In summary, this report presents the most detailed study of absolute metabolite levels in a 
patient with PDHC deficiency up till now, showing normal N-acetylaspartate levels in basal 
ganglia gray matter and elevated Cr, lactate and alanine levels.
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Chapter 7 reports on a child with a severe deficiency of complex III and less severe 
deficiencies of complex I, II and IV of the respiratory chain with a favourable clinical course 
despite the persistence of severe biochemical abnormalities in skeletal muscle.
The child presented with intrauterine growth retardation, generalized hypotonia and motor
1/2development delay. In the following 3 years muscle tone and motor development gradually 
normalized whereas the lactic acidosis and enzyme activities did not improve.This is a very 
unique finding. The reported benign mitochondriocytopathies in the literature are 
characterized by a recovery in enzyme complex activity. In this patient however, there was 
clinical improvement whereas the enzyme complex activity did not recover. The fact that 
biochemical abnormalities persist suggests that there are unknown adaptation mechanisms in 
skeletal muscle.
Chapter 8 describes 2 siblings with an isolated complex I deficiency with severe 
encephalopathy. Both siblings had an identical clinical picture that became manifest in the 
first year of life. There was a severe progressive course with fatal outcome. A mutation in one 
of the nuclear encoded subunits of complex I - NDUFV1 -  was recently found in these 
siblings.
In Chapter 9, considerations about the work performed in this thesis and recommendations 
for future investigations are given.
In summary, it is recommended to widely screen for mitochondriocytopathies in pediatric 
patients, because of the broad variety of clinical phenotypes and non-specificity of symptoms. 
Laboratory screening should include lactate and pyruvate in blood, aminoacids in blood and 
urine, lactate and aminoacids in CSF (if neurological manifestations are present), urine 
organic acids and thrombocytes. The urine portion for aminoacid and organic acid analysis 
should be collected in the fed state. If no lactate increase is found in body fluids, an oral 
glucose loading test should be performed.
For an optimal diagnostic approach, mitochondrial substrate oxidation rates and ATP 
production rate are measured in a fresh muscle specimen. To avoid inter- and intra-individual 
variation in the interpretation of these biochemical results in the muscle specimen in non-
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conclusive cases, the DS can be used. A DS >0 suggests a normal mitochondrial energy 
metabolism based on the biochemistry results of skeletal muscle.
Pediatric patients affected of an oxidative phosphorylation defect are likely to have a mutation 
in nuclear DNA if the disorder becomes manifest at a young age with a rapidly progressive 
clinical course.
153
Samenvatting
Mitochondriocytopathieën zijn een groep van ziektes, veroorzaakt door een stoornis in het 
mitochondrieel energie-metabolisme als gevolg van defecten in het pyruvaat dehydrogenase 
complex (PDHC), de citroenzuur cyclus, het OXPHOS systeem (ademhalingsketen en 
complex V), en in mitochondriële transmembraan-carriers. De belangrijkste oorzaken van 
mitochondriocytopathieën zijn ademhalingsketen defecten.
Klinisch, biochemisch en genetisch vormen de mitochondriocytopathieën een zeer heterogene 
groep van ziektes. Hoewel geen enkele manifestatie specifiek is, worden verschillende goed 
gedefinieerde syndromen door mutaties in het mitochondrieel DNA (mtDNA) erkend. Echter, 
pediatrische patiënten passen zelden in een van deze syndromen en mtDNA mutaties worden 
niet vaak gevonden.
De klinische presentatie van aangedane patiënten lijkt op vele andere pediatrische ziektes en 
de klinicus heeft aanwijzigen nodig uit andere onderzoeken (zoals het vinden van hoge 
concentraties van lactaat in lichaamsvloeistoffen) om een mitochondriële ziekte te 
veronderstellen. Om de juiste diagnose te kunnen stellen zijn histopathologische, 
biochemische en genetische onderzoeken nodig. Skeletspier is het geprefereerde materiaal 
omdat het defect in de meeste gevallen hierin tot uiting komt.
Hoofdstuk 1 geeft algemene informatie over mitochondriocytopathieën in pediatrische 
patiënten. Ten eerste worden de meest frequente fenotypes in pediatrische patiënten 
beschreven: fatale infantiele lactaatacidose, Leigh syndroom, niet-gespecificeerde 
encefalopathie, cardiomyopathie en myopathie, evenals leeftijd-gerelateerde symptomen. 
Daarna worden de metabole screening (meting van lactaat en pyruvaat in bloed, aminozuren 
in bloed en urine, lactaat en aminozuren in liquor, organische zuren in urine) en additionele 
onderzoeken (cardiale evaluatie, beeldvormend onderzoek van de hersenen, electromyografie) 
die relevant kunnen zijn in deze groep van ziektes opgesomd. Als laatste worden de 
diagnostische procedure, gebaseerd met name op morfologische en biochemische studies van 
de spier en de therapeutische strategieën kort bediscussieerd.
Hoofdstuk 2 beschrijft een studie om te komen tot een optimale screening van pediatrische 
patiënten verdacht van een mitochondriocytopathie ten einde zo min mogelijk onnodige
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spierbiopsieën te verrichten. Een spierbiopsie in pediatrische patiënten is een invasieve 
procedure. Om genoeg materiaal te verkrijgen om de diagnose te stellen is een chirurgische 
biopsie nodig.
In deze studie werden vijf en veertig patiënten verdacht van een mitochondriocytopathie 
onderzocht volgens een standaard protocol. Dit protocol omvatte: anamnese, lichamelijk 
onderzoek, cardiale en ophthalmologische evaluatie, biochemische onderzoeken, functie 
testen in vivo, beeldvormende diagnostiek van de hersenen, en morfologisch en biochemisch 
onderzoek in een skeletspier specimen.
De resultaten van de biochemische onderzoeken in de skeletspier werden vergeleken met de 
resultaten van de andere onderzoeken van het screeningsprotocol. Van alle gemeten 
parameters, hadden er vijf een statistische relatie met het resultaat (normaal of deficiënt) van 
de biochemische onderzoeken in het spier specimen. Deze vijf parameters waren: leeftijd < 4 
jaar, verhoogde nuchter lactaat-pyruvaat ratio, verhoogd aantal thrombocyten, verhoogd 
lactaat en verhoogd alanine.
Gebruik makend van deze parameters, werd een prognostische index gemaakt. Voor elke 
parameter werd een 0 (niet aanwezig) of een 1 (wel aanwezig) gescoord. De kans op een 
“normale” biopsie met een gegeven waarde van deze index (som van de scores) werd 
gecalculeerd: logit (Pr) = a + ß x index; a: -0.8167 en ß: 0.8331. (Pr: probabiliteit van een 
normale biopsie). De kans op een normale biopsie met een index waarde van 5 is 0.03, 4 is
0.07, 3 is 0.16, 2 is 0.30, 1 is 0.50 en 0 is 0.69.
Een optimale screening voor pediatrische patiënten verdacht van een mitochondriocytopathie 
houdt de volgende laboratorium screening in: lactaat en pyruvaat in bloed, aminozuren in 
bloed en urine, lactaat en aminozuren in liquor (indien er neurologische manifestaties 
aanwezig zijn), organische zuren in urine en thrombocyten. De urine portie voor aminozuren 
en organische zuren analyse kan het beste in niet-nuchtere toestand verzameld worden. Indien 
geen lactaat verhoging wordt gevonden in lichaamsvloeistoffen, zou een (orale) 
glucosebelasting test gedaan moeten worden. Gebruik makend van de resultaten van deze 
onderzoeken, kan de kans op een normale biopsie in een individuele patiënt berekend worden. 
Andere studies zijn nodig om de prognostische index nog verder te ontwikkelen. De 
associatie van een licht verhoogd aantal thrombocyten met oxidatieve phosphorylerings- 
defecten is niet eerder gerapporteerd en vraagt verdere studie.
Hoofdstuk 3 presenteert een methode om de resultaten van de biochemische onderzoeken in
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de spier samen te vatten. De diagnostische benadering van patiënten verdacht van een 
mitochondriocytopathie omvat het biochemisch onderzoek van het skeletspier specimen. Eerst 
worden mitochondriële substraat-oxidatiesnelheden en ATP plus creatine fosfaat productie­
snelheid gemeten, hetgeen elf verschillende resultaten oplevert. Indien deze metingen 
afwijkend zijn, worden enzymatische studies (pyruvaat dehydrogenase complex, complex I-V) 
gedaan afhankelijk van de gevonden afwijkingen. In sommige gevallen is het moeilijk om op 
basis van deze elf resultaten vast te stellen of de patiënt een verstoord mitochondrieel energie- 
metabolisme heeft of niet, omdat de verschillende resultaten niet unaniem wijzen in de 
richting normaal of deficiënt.
Om de interpretatie van met name deze moeilijke gevallen te vergemakkelijken en te 
standaardiseren, toetsten we een scoringsmethode gebaseerd op lineaire discriminant analyse 
om deze elf verschillende resultaten samen te vatten in één uitkomst: de discriminant score 
(DS). Deze DS discrimineert perfect tussen patiënten met een normaal en een deficiënt 
mitochondrieel energie-metabolisme. DS > 0 indiceert een normaal mitochondrieel energie 
metabolisme en gebaseerd op de biochemische resultaten van de skeletspier zijn geen verdere 
onderzoeken nodig. Daartegenover staat dat een DS < 0 een verlaagd mitochondrieel energie- 
metabolisme veronderstelt, en er verder onderzoek nodig is.
De DS kan gebruikt worden voor de interpretatie van de biochemische resultaten (oxidatie 
snelheden en ATP productie snelheid) in het skeletspier specimen. Verder, vereenvoudigt de 
DS correlatie studies tussen deze resultaten en andere parameters (zoals klinische, 
biochemische, radiologische, morfologische).
Hoofdstuk 4 beschrijft een studie over klinische verschillen bij patiënten met een oxidatief 
phosphorylerings defect (OXPHOS) veroorzaakt door een nucleaire of mtDNA mutatie. 
OXPHOS defecten zijn genetisch uniek omdat de verschillende componenten, 
ademhalingsketen enzymcomplexen (I, III, and IV) en complex V, gecodeerd worden door 
nucleair en mitochondrieel DNA. Klinische verschillen kunnen van belang zijn voor 
genetische counseling en moleculair-biologische studies.
Er werden 16 gezinnen met > 2 kinderen met een genetisch opgehelderde OXPHOS- 
deficiëntie, 4 door een mutatie in nucleair DNA en 12 door een mutatie in mtDNA, 
bestudeerd. De studie werd gedaan in gezinnen met > 2 kinderen om de intrafamiliaire 
variabiliteit in beide groepen te kunnen vaststellen.
Patiënten met nucleaire mutaties werden symptomatisch op jonge leeftijd, met een ernstig
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klinisch beloop. Aangedane broers of zussen lieten een zeer vergelijkbaar klinisch beeld zien. 
Patiënten met mtDNA mutaties lieten een breder klinisch spectrum zien zowel qua leeftijd 
van presentatie als qua ernst. Aangedane broers of zussen met een mtDNA mutatie hadden 
een klinisch beeld dat varieerde van zeer vergelijkbaar tot zeer verschillend.
Voor zover nu bekend blijken er verschillen te zijn tussen deze twee groepen qua leeftijd van 
presentatie, ernst van het klinisch beeld, beloop en intrafamiliaire variabiliteit.
Hoofdstuk 5 beschrijft een nieuw fenotype bij één kind, namelijk een beeld dat lijkt op een 
spinale spieratrophie alsmede cardiomyopathie en cytochroom c oxidase deficiëntie.
Deze patiënt presenteerde zich met klinische, morfologische en neurofysiologische kenmerken 
van spinale spieratrofie. Echter, er werden enkele atypische kenmerken geconstateerd zoals 
inspiratoire stridor en zeer moeilijk op te wekken i.p.v. afwezige reflexen. Tevens werd geen 
deletie in exon 7 en 8 van het “survival motor neuron” gen gevonden. Er werd aan de 
oorspronkelijke diagnose nl. spinale spieratrofie getwijfeld. De negatieve COX-kleuring van 
het skeletspier specimen was de eerste aanwijzing richting mitochondriocytopathie. Verder 
onderzoek liet een hypertrofische niet-obstructieve cardiomyopathie met een verhoogde 
lactaat concentratie en verhoogde lactaat-pyruvaat ratio in bloed en liquor zien, wat een 
mitochondriële ziekte suggereerde. Dit werd bevestigd door biochemisch onderzoek in de 
skeletspier en gekweekte huidfibroblasten waarbij een COX deficiëntie werd gevonden.
Het wordt aanbevolen dat patiënten met klinische kenmerken gelijkend op spinale 
spieratrofie, en een intact “survival motor neuron” gen, worden gescreend op een 
mitochondriële ziekte.
Hoofdstuk 6 illustreert niet-invasieve kwantitatieve determinatie met proton MR- 
Spectroscopie (1H MRS) van afwijkingen in het cerebrale metabolisme. 1H MRS van de 
hersenen kan worden gebuikt in de diagnostiek bij patiënten met een mitochondriële ziekte 
om te onderzoeken of metabolieten zoals alanine en lactaat verhoogd zijn in het 
hersenweefsel. Een 19-maanden oude jongen met een ernstige algehele 
ontwikkelingsachterstand die veroorzaakt werd door een pyruvaat dehydrogenase complex 
(PDHC) deficiëntie als gevolg van een mutatie in de thiamine-binding site werd onderzocht. 
Om het effect van thiamine suppletie vast te stellen werden twee onderzoeken gedaan bij 
verschillende liquor thiamine concentraties. Abnormaal hoge lactaat en alanine signalen 
werden geobserveerd zowel in als buiten het striatum; de concentraties van deze metabolieten
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waren hoger gedurende de tweede meting bij een lagere thiamine concentratie.
Samenvattend, presenteert dit rapport de meest gedetailleerde studie van metabolieten 
concentraties in een patiënt met PDHC deficiëntie tot op heden.
Hoofdstuk 7 rapporteert een kind met een ernstige deficiëntie van complex III en minder 
ernstige deficiënties van complex I, II and IV met een gunstig klinisch beeld ondanks het 
persisteren van de ernstige biochemische afwijkingen in de skeletspier. Het kind presenteerde 
zich met intrauteriene groeiachterstand, gegeneraliseerde hypotonie en motorische 
achterstand. In de navolgende 3,5 jaar, normaliseerde de spiertonus en motore ontwikkeling 
gestaag, terwijl de lactaatacidose en enzymactiviteiten niet verbeterden. Dit is een unieke 
waarneming. De in de literatuur beschreven benigne mitochondriocytopathieën worden 
gekarakteriseerd door een herstel in enzymcomplex activiteit. Bij deze patiënt echter, was er 
klinische verbetering terwijl de enzymcomplex activiteiten niet verbeterden. Het feit dat 
biochemische abnormaliteiten persisteren suggereert dat er andere, niet bekende, adaptatie- 
mechanismen in skeletspier aanwezig zijn.
Hoofdstuk 8 beschrijft 2 broers met een geïsoleerd complex I defect met ernstige 
encefalopathie. Beide broers hadden een identiek klinisch beeld dat manifest werd in het 
eerste jaar van hun leven. Er was een ernstig progressief beeld met fatale afloop. Een mutatie 
in een van de nucleair gecodeerde sub-eenheden van complex I -NDUFV1- werd gevonden in 
deze broers (zie hoofdstuk 3).
In hoofdstuk 9 worden beschouwingen gegeven omtrent het in dit proefschrift beschreven 
onderzoek en worden aanbevelingen gedaan voor verder onderzoek.
Samenvattend wordt het aanbevolen om breed te screenen op mitochondriocytopathieën in 
pediatrische patiënten, gezien de grote variëteit aan klinische fenotypes en niet-specifieke 
symptomen. Laboratorium screening moet gericht zijn op onderzoek naar lactaat en pyruvaat 
in bloed, aminozuren in bloed en urine, lactaat en aminozuren in liquor (als er neurologische 
verschijnselen zijn), organische zuren in urine en thrombocyten. De urine portie moet worden 
verzameld in niet-nuchtere toestand. Als er geen lactaat verhoging wordt gevonden in 
lichaamsvloeistoffen, moet een (orale) glucose belastingtest overwogen worden.
Voor een optimale diagnostische benadering worden mitochondriële substraat-oxidatie
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snelheden en ATP productie-snelheid gemeten in verse spier specimina. Om inter- en intra- 
individuele verschillen in de interpretatie van moeilijke biochemische resultaten in het spier 
specimen te beperken, kan de DS worden gebruikt. Een DS > 0 suggereert een normaal 
mitochondrieel energie metabolisme gebaseerd op de biochemische resultaten van onderzoek 
van de skeletspier.
Pediatrische patientën met een oxidatief fosforylerings-defect die jong symptomatisch worden 
met een snel progressief beeld hebben waarschijnlijk een mutatie in nucleair DNA.
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De schrijfster van dit proefschrift is geboren en getogen in Castellon, Spanje. Het laatste jaar 
van de middelbare school volgde zij in de Verenigde Staten. Terug in Spanje, is zij 
geneeskunde gaan studeren aan de Universiteit van Valencia. Tijdens haar studie aldaar, 
leerde zij haar echtgenoot, een Nederlander, kennen. Dit was reden om naar Nederland te 
verhuizen en hier haar studie af te ronden. Zij heeft aan de Universiteit van Amsterdam haar 
doctoraal behaald in 1986 en in 1989 het artsexamen (cum laude) afgelegd. In aansluiting op 
het artsexamen werkte zij in het Emma Kinderziekenhuis AMC te Amsterdam, aanvankelijk 
als arts assistent niet in opleiding, later als arts assistent in opleiding tot kinderarts. Op 1 
november 1995 werd zij als kinderarts ingeschreven in het specialisten-register.
In januari 1996 is zij begonnen met haar fellowship kindergeneeskunde metabole ziekten op 
de afdeling Kindergeneeskunde, subafdeling metabole ziekten in het Universitair Medisch 
Centrum St. Radboud te Nijmegen en in februari 1998 is zij als kinderarts-metabole ziekten 
geregistreerd. Tot januari 2000 is zij werkzaam geweest als tijdelijk staflid op deze afdeling. 
In de periode 1996-2000 is het in dit proefschrift beschreven onderzoek verricht.
Vanaf februari 2000 werkt zij als kinderarts metabole ziekten in het Academisch Ziekenhuis 
Maastricht.
Zij is getrouwd met Henk J.D. Fritscheck en zij hebben twee geweldige zonen: Robert en 
Arthur.
Stellingen 
behorend bij het proefschrift 
“Clinical aspects of mitochondriocytopathies in childhood”
M. E. Rubio-Gozalbo 
Nijmegen, 20 juni 2000
1. De kans, dat een patiënt een verlaagd mitochondrieel energie-metabolisme in spier heeft, 
kan met behulp van de prognostische index berekend worden (ditproefschrift).
2. De discriminant score kan de interpretatie van de resultaten van het biochemisch 
onderzoek in spier (oxidatie snelheden en ATP productie) vergemakkelijken (dit 
proefschrift).
3. OXPHOS defecten veroorzaakt door een gekende mutatie in een van de nucleair 
gecodeerde genen, worden gekenmerkt door een ernstig, snel progressief ziektebeeld dat 
zich in de eerste levensjaren manifesteert (ditproefschrift).
4. Een spinale spieratrofie-achtig fenotype kan met complex IV deficiëntie geassocieerd 
voorkomen (ditproefschrift).
5. Broers en/of zussen van een patiënt met een OXPHOS defect door een zelfde mutatie in 
een nucleair gecodeerd gen hebben een vergelijkbaar klinisch beeld en verloop (dit 
proefschrift).
6. Biochemisch onderzoek in een spier specimen, waarin oxidatie snelheden van 
mitochondriële substraten en ATP productie snelheid gemeten kunnen worden, is 
essentieel om de diagnose mitochondriocytopathie te kunnen stellen (ditproefschrift).
7. Rampen dreigen als overvloed geen afvoer heeft (anoniem).
8. Arbeidsduurverkorting in de zorg ten tijde van een krappe arbeidsmarkt draagt wezenlijk 
bij aan toename van de wachtlijst.
9. Financiering van academische ziekenhuizen op basis van productie cijfers doet ernstig 
tekort aan de zwaarte van de academische patiëntenzorg.
10. Langdurig en veelvuldig vergaderen is een typisch Nederlandse gewoonte die voor niet 
Nederlanders, zelfs na de meest intensieve inbureerinccursus niet volledig te beffriinen is.
